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Abstract
Metastatic disease, or the migration of cancer cells from the primary tumor to distant 
locations in the body, contributes to over 90% of cancer mortalities. Migration is a 
requirement of metastasis and involves the detachment of cancer cells from the primary 
tumour in vivo, followed by invasion of the cell into the surrounding stromal tissue. 
Tumour cells that are migration-deficient are incapable of detaching from the primary 
tumour and exhibit compact phenotypes in the chicken embryo model. Based on these 
findings, it was hypothesized that mediators of migration could be identified using an 
RNAi genomic library and screening for compact tumour phenotypes in the chicken 
embryo model. It was also postulated that knockdown of two proteins known to be 
involved in migration, rhoA and cortactin, would prevent migration of human epidermoid 
carcinoma (HEp3) cells in vivo, serving as a positive control and proof-of-principle for the 
RNAi screen. Results of this study identify rhoA and cortactin as positive regulators of 
migration, both in vitro and in vivo, and demonstrate the feasibility of the RNAi screen. 
Furthermore, execution of an RNAi screen, covering 5000 human genes, identified three 
novel mediators of tumour cell migration: MESCD1, KIF3B and ARHGAP12.
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1.1 Cell Migration in the Human Body
Cell migration is necessary for a diverse range of biological processes in the human body. 
The body’s defense system relies on the ability of immune cells to migrate throughout the 
tissues in the body, in the event an immune response is warranted. Part of the body’s front 
line response to pathogens, such as viruses and bacteria, are natural killer cells, an 
especially motile immune cell that circulates the body in search of pathogens to ‘kill’ using 
specialized enzymes (Walzer and Vivier 2011). Natural killer cells can also participate in 
extravasation, or movement out of blood vessels, into the site of infection (Walzer and 
Vivier 2011). Hematopoietic stem cell migration into recipient bone marrow space is 
required for a successful bone marrow transplantation, and the mechanisms of stem cell 
migration have implied roles for a number of migratory mediators such as the Rho- 
GTPase, RhoA and its effector ROCK (Fonseca and Corbeil 2011). Endothelial cell 
migration is well documented and the ability of endothelial cell movement is highly 
influenced by endothelial growth factor (VEGF) and mitrochondrial reactive oxygen 
species (Wang 2011). Endothelial cell migration, mediated by these factors, can assist in 
the repair of damaged tissues such as blood vessels that become injured from high blood 
pressure in atherosclerosis (Wang 2011). In reproduction, the movement of germ cells and 
spermatocytes across the seminiferous epithelium is important to the process of 
spermatogenesis and germ cells employ mediators such as matrix metalloproteases to assist 
in their migration through dense tissue (Chen 2011). The process of cell migration is 
clearly an important underlying feature of many biological processes, even processes that 
are completely unrelated, such as reproduction and wound healing. In cancer, many of the 
cell migration strategies used in normal physiological processes such as extravasation, 
RhoA/ROCK signaling pathways, migration in response to growth factor stimulation, and 
release of matrix metalloproteases, are executed to assist in migration and metastasis 
(Hanahan and Weinberg 2000; Wyckoff 2006; Lai 200; Mader 2011 and Boire 2005).
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1.2 Cell Migration and Metastasis in Cancer
Metastasis, or the capacity of tumour cells to colonize secondary organs distant from the 
primary tumour, contributes to 90% of cancer related mortalities (Hanahan and Weinberg 
2000). Cancer cell metastasis is regarded as the sixth hallmark of cancer because it relies 
on previous events to establish the primary tumour, yet the cellular modifications that 
promote metastasis are required for further cancer progression (Hanahan and Weinberg 
2000). The process of metastasis is often defined as the ‘invasion-metastasis cascade’ 
because it consists of consecutive, rate-limiting steps and the entire process can be 
prevented by blocking a requirement of any one step (Talmadge and Fidler 2010). Briefly, 
the steps in the invasion-metastasis cascade involve: the migration and invasion of cancer 
cells from the primary tumour into surrounding tissue, intravasation into the blood or 
lymph, survival in the circulation, and extravasation out of vessels at the secondary site 
using invasion and migration programs, followed by ‘colonization’ or growth at the 
secondary site (Figure 1.2.1) (Talmadge and Fidler 2010). One of the early steps in 
metastasis requires cells to migrate away from the primary tumor and blocking this step 
has been demonstrated to prevent the remainder of the metastatic cascade (Zijlstra 2008). 
This observation made by Zijlstra et al supports the body of evidence that implicate tumour 
cell migration as a prerequisite for metastasis (Palmer 2011; Yansong 2001 and Shieh 
1999).
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Adapted from: Steeg, P.S., Nature Reviews Cancer 3, 3 (2003)
Figure 1.2.1: Steps in metastasis
The steps in the 4invasion-metastasis-cascade ’ are initiated following the migration and invasion of cancer 
cells (green) from the primary tumour into surrounding extracellular matrix, composed of stromal cells 
(orange), and matrix proteins such as collagen and fibronectin (black). Intravasation into the bloodstream 
through endothelial cells (red) or at their junctions and/or into the lymphatics, provides a route for cancer cell 
dissemination throughout the body. Cells that survive in the circulation can extravásate, or move out of the 
vasculature at secondary sites. The invasion and migration programs used to move into the vasculature are 
also required to move out of these vessels and into the surrounding stroma at the secondary site. Proliferative 
cells at the secondary sites progress to form micrometastases that can progress into clinically relevant 
metastases.
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1.2.1 Requirements of Cancer Cell Migration
There are a plethora of molecules involved in enabling cancer cell migration, from cell 
surface receptors that receive external cues to structural components that physically 
generate cell movement (Jones and Ehrlich 2001 and Olsen and Sahai 2009). Although 
components of the migratory machinery seem all encompassing, many of these molecules 
work in concert to drive select functions of cancer cell migration (Tomar and Schlaepfer 
2009). On the basis of certain characteristic molecules used in cancer cell migration 
strategies, cancer cell migration has even been loosely described as belonging to one of 
two main arms: protease-dependent, mesenchymal migration and protease-independent, 
amoeboid migration (Rowe and Weiss 2008 and Hanahan and Weinberg 2011). Together, 
these two forms of migration cover the three fundamental requirements of cancer cell 
migration in a 3D environment: cytoskeletal reorganization, protease matrix degradation 
and recognition of the matrix by cellular adhesion molecules (CAMs). This section focuses 
on the three requirements of cell migration, highlighting many of the key players and 
regulators involved in each requirement, and emphasizes the role of these migratory 
mediators in potentiating metastasis.
1.2.1.1 Cytoskeletal Reorganization
Cell motility is propagated through cytoskeletal reorganization events such as the 
polymerization of actin monomers (G-actin) into filaments (F-actin). There is tight control 
over actin polymerization rates by proteins that directly bind actin and signaling molecules 
that orchestrate these binding events. To coordinate with cell migration, the ‘barbed’ or 
‘plus’ ends of actin filaments are facing the plasma membrane and it is at these ends that 
new actin monomers are added to advance the cell toward the stimulus (Olsen and Sahai 
2009). There are many important regulators of actin polymerization to keep cell migration 
in check, and often the aberrant behavior of these regulators can promote cancer 
progression. Proteins involved in the polymerization of actin include: formin homology 
(FH), members of the Ena/VASP family, Cofilin, Arp2/3 complex, WASP, WAVE, 
cortactin, and Rho family of GTPases (Olsen and Sahai 2009; Loureiro 2002; Miki, 
Suetsugu and Takenawa 1998; Artym 2006 and Tomar and Schlaepfer 2009).
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P r o t e in s  In v o l v e d  in  A c tin  P o ly m e r iz a t io n  
Formin Homology (FH) Proteins
The FH proteins contain three important domains, FH1, FH2 and CRIB, important in both 
nucleating actin filaments and regulating polymerization (Olsen and Sahai 2009). The FH1 
and FH2 domains work together to build actin, with profilin binding to the FH1 domain, 
and bringing a G-actin monomer with it, and the FH2 domain binding to F-actin to bring 
the FHl-profilin-G-actin-monomer in association with the F-actin filament (Olsen and 
Sahai 2009). The CRIB domain is bound by many GTPases, which will be discussed in 
more detail in the next section, including Cdc42, RhoA, RhoB and Rif (Olsen and Sahai 
2009). Binding of these regulatory GTPases to CRIB allows FH to be in an active ‘open’ 
conformation so that actin polymerization can proceed (Olsen and Sahai 2009).
The Enabled/Vasodilator-Stimulated Phosphoprotein (Ena/VASP)
The Ena/VASP family of proteins have the same function as FH proteins, and interact with 
the barbed end to recruit monomeric actin, but in addition, these proteins influence the 
branching density of F-actin within lamellipodia (Breitsprecher 2011). Lamellipodia are a 
fan-like cell protrusions that are often seen at the front of migrating cells in 2D cultures 
and are related to the metastatic potential of cancer cells (Olsen and Sahai 2009 and Kim 
2011). Ena/VASP proteins have three functionally conserved domains: c-terminal 
Ena/VASP homology 1, (EVH1), a proline-rich domain, and a N-terminal EVH2. EVH1 
is required for cellular targeting, the proline rich domain, like the FH1 domain in FH 
proteins, binds profilin-monomeric-actin complexes, and the EVH2 domain, similar to the 
FH2 domain of FH, binds filamentous actin (Breitsprecher 2011). The difference between 
FH and Ena/VASP proteins is that FH proteins remain associated with the actin filament, 
simultaneously protecting it from capping proteins that hinder actin elongation, and rely on 
the recruitment of profilin to bring in monomeric actin (Breitsprecher 2011). Conversely, 
profilin is dispensable to Ena/VASP for actin chain elongation, and is not needed to protect 
the growing chain from capping proteins in vitro, however, profilin does appear to enhance 
Ena/WASP protection of the actin chain from capping proteins in a dose dependent manner 
(Breitsprecher 2011; Pula and Krause 2008). Phosphorylation negatively regulates
Ena/VASP-mediated actin elongation by decreasing its ability to protect the growing actin 
chain from capping proteins (Pula and Krause 2008). More importantly, the 
phosphorylation state of Ena/VASP appears to play a role in the regulation of cell motility 
as seen by the decrease in fibroblast migration upon phosphorylation of mammalian Ena 
(Mena) (Loureiro 2002).
Cofilin
Cofilin, unlike FH and Ena/VASP proteins, severs filamentous actin, rather than elongating 
it, but can still contribute to the overall actin polymerization by creating more available 
barbed ends for actin propagation (Olsen and Sahai 2009). Cofilin can be modulated by 
capping proteins, which sterically hinder the interaction of cofilin with the filamentous 
chain, and by LIM kinase, which decreases the activity of cofilin (Olsen and Sahai 2009).
Actin Related Proteins 2 and 3 (Arp2/3 complex)
Arp2/3 are two components of an actin-nucleating complex that aid in the polymerization 
of branched actin filaments by associating with the side of a pre-existing actin filament 
(Olsen and Sahai 2009). Apr2/3 is regulated by the WASP (Wiskott- Aldrich syndrome 
protein) and WAVE (WASP family Verprolin-homologous protein) proteins that, like FH 
or Ena/VASP actin nucleating proteins, can bind to actin monomers but in this case allow 
G-actin to.come into close contact with the Arp2/3 complex and increase the rate of actin 
polymerization (Olsen and Sahai 2009). WAVE and WASP are folded into an auto- 
inhibited conformation and upon the binding of a GTPase (Cdc42 or racl) the 
conformation changes to an open active form (Miki, Suetsugu and Takenawa 1998 and 
Olsen and Sahai 2009). Thus, Arp2/3 complex is under at least three layers of regulation:
1) the binding of GTPases to WASP and WAVE conferring an active status to these 
proteins, 2) the binding of monomeric actin to WAVE/WASP and 3) the binding of active 
WASP and WAVE to the Arp2/3 complex. Arp2/3 complexes are also associated with 
invasive cell structures called invadopodia that often accumulate in regions of matrix 
degradation and are implicated in invasion, migration and metastasis in vivo (Artym 2006 
and Yansong 2001). Cortactin, a protein required for the maturation of invadopodia, binds
Arp2/3 complex, locating it to regions of cell invasion to form these invasive cell 
protrusions by actin polymerization (Artym 2006 and Olsen and Sahai 2009).
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RhoGTPases
Rho-family of GTPases (Ras-homology-family of guanine triphosphates) are regulatory 
proteins that act as switches to activate many proteins involved in cell migration. The 
prototypical Rho-GTPases involved in actin polymerization are: Rho, Racl and Cdc42. 
These molecular switches are ‘turned on’ by the Rho-GEFs (guanine exchange factors) that 
exchange a GDP for a GTP, rendering the Rho-GTPase in the active form and are ‘turned 
off by Rho-GAPs (GTPase activating proteins) that, counterintuitive to their name, 
inactivate Rho-GTPases (Tomar and Schlaepfer 2009). Activation of Rho-GTPases by 
GEFs can be initiated upon adhesion of cells to the extracellular matrix (ECM) to initiate 
cell migration (Tomar and Schlaepfer 2009). In response to such extracellular signals, 
cdc42 binds to the CRIB domain on FH and activates barbed end (180°) actin 
polymerization, which produces actin-rich spikes called filopodia (Olsen and Sahai 2009). 
Filopodia structures are used by the cell for directional cell migration on a 2D substratum, 
and the occurrence of filopodia are associated with cell invasion (Olsen and Sahai 2009 
and Pan 2011). Cdc42 can also bind WASP, however this initiates Arp2/3 mediated 
branched actin (70°) and would form lamellipodia in 2D matrices (Olsen and Sahai 2009). 
Lamellipodia may correspond to invadopodia seen in 3D matrices since both lamellipodia 
and invadopodia rely on Arp2/3 mediated actin polymerization (Olsen and Sahai 2009). 
Rac-1 is also activated upon cell adhesion and like cdc42, can bind to WAVE to induce 
Arp2/3 mediated formation lamellipodia-at the leading edge of migrating cells in 2D, often 
referred to as a pseudopod in 3D matrices (Olsen and Sahai 2009). RhoA has at least two 
different functions in cell migration upon activation: 1) form stress fibers to aid in cell 
adhesion during the initial events of cell migration 2) induce cell contractility during the 
late phase of cell migration (Tomar and Schlaepfer 2009). Although cell contractility itself 
is unrelated to actin polymerization, the inhibition of cofilin severing through downstream 
effectors of RhoA (ROCK and LIM-Kinase) during contraction decreases the availability 
of barbed ends for actin nucleation. This second function, therefore, may act to halt
polymerization in the event of actomyosin-contraction mediated by RhoA-ROCK (Tomar 
and Schlaepfer 2009 and Maekawa 1999).
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Pr o tein s  In v o l v e d  in A ctin  Po l y m e r iz a t io n  a n d  th e ir  C o n n ec t io n  to  C a n c e r
Mediators of actin polymerization can facilitate cell migration through the formation of 
cell protrusions and invasive structures and have been associated with increased tumour 
invasion and metastasis, predicting poor patient outcome. These findings emphasize the 
importance of actin cytoskeletal reorganization in human cancer progression and identify a 
strong association between the mediators of cancer cell migration and metastasis. Recently, 
the actin polymerizing proteins, FH and Ena/VASP, have been shown to increase invasion 
and motility in human cancer cells and more importantly an increased expression of an 
Ena/VASP family protein, hMena, confers poor prognosis in a variety of cancers (Kitzing 
2010; Di Modugno 2006 and Toyoda 2009).
Increases in cofilin activity have been found in rat mammary carcinoma cells and, in 
concert with Arp2/3, caused enhanced lamellipodia formation, which is a critical step in 
the initiation of migration and indicative of the potential for metastasis (DesMarais 2004 
and Kim 2011). In human gastric carcinoma Arp2 and 3 are overexpressed compared to 
adjacent gastritis tissue and positively correlate with tumor size, depth of invasion and 
venous invasion, however, a survival disadvantage in Arp2/3 overexpressing cancer was 
not found (Zheng 2008). This study suggests that Arp 2/3 complex is important in the 
progression of gastric cancer to a metastatic phenotype. As for cofilin, expression of wild- 
type, or non phosphorylatable (constitutively active) mutant cofilin increases the migration 
and invasion of melanoma cells (Dang, Bamburg and Ramos 2006). Furthermore, 
increasing positive regulators of cofilin, such as Aur-A, induces mammary cell migration 
and breast cancer metastasis, and vice versa, an increase in negative regulators of cofilin, 
such as LIM kinase, abolishes lamellipodia formation and polarized cell migration (Wang 
2010 and Zebda 2000).
RhoGTPases are important regulators of cytoskeletal reorganization, both promoting and 
inhibiting actin polymerization to suit the migratory needs of the cell. Recently, RhoA was 
identified as one of the most significantly upregulated plasma membrane-associated
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proteins in hepatocellular carcinoma (HCC) as determined by highly purified plasma 
membrane proteins from clinical tissue samples followed by proteomics identification. In 
the same study, immunohistochemistry on clinical samples for HCC confirmed RhoA 
expression and suggested that RhoA may contribute to poor differentiation and increased 
cancer stage (Gou 2011). L. Gou et al. also demonstrated that RhoA was required for cell 
migration of hepatocellular carcinoma cell lines since RNA interference of RhoA led to a 
significant decrease in cell migration of these cells through a transwell membrane, 
emphasizing the migratory role of RhoA and making a connection between the migratory 
capacity RhoA confers and the poor patient outcome (Gou 2011). Racl expression is also 
increased in human gastric cancer and not only does expression increase in higher grade 
tumors, but Rac 1-positive, high grade tumors also correlated with decreased survival 
(Walch 2008). Racl-GTP (active Racl) expression is also associated with increased grade 
of upper urinary tract cancers and contributes to lymph node invasion and metastasis 
(Kamai 2010).
Taken together, these findings indicate a clear association between the mechanistic role of 
actin-polymerizing proteins in cell migration and their enhanced metastatic potential upon 
expression of these proteins. In this respect, cytoskeletal reorganization is not only a 
requirement of cell migration, but is necessary for the progression of human cancers. 
Identification of novel actin nucleating proteins that assist in the formation of invasive 
structures such as filopodia, lamellipodia and invadopodia could potentially provide new 
targets for metastasis.
1.2.1.2 Protease Degradation
Proteases are one of the largest groups of enzymes in the human genome as there are 570 
known proteases that are also tightly regulated, in part, by a smaller group of protease 
inhibitors (Mason and Joyce 2011). There are five human protease classes grouped by 
catalytic mechanism (matrix, cysteine, metallo, serine, and threonine) however, the matrix 
metalloproteases (MMPs) are the most heavily involved in cancer progression 
(Kessenbrock, Plaks and Werb 2010). MMPs are initially expressed in an enzymatically 
inactive state and must be modified, sometimes by enzymatic cleavage by another 
protease, to become proteolytically active. MMPs can be divided into two general classes:
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the secreted MMPs (MMP-1, -2, -3, -7, -8, -9, -10, -11, -12, -13, -19, -20, -21, -22, -27, - 
28) and the membrane-type MMPs (MT-MMPs), (MMP-14, -15,-16, -17, -23, -24, -25), 
the latter using a transmembrane domain with a cytoplasmic domain attached, a 
glycosylphosphatidylinositol anchor, or an amino-terminal signal anchor, in order to 
remain bound to the cell surface. MMPs, in the context of aggressive cancer, function to 
disrupt cell-cell adhesion and mediate cell migration away from the tumour, degrade the 
ECM to permit tumour cell migration and invasion into the stroma, and mediate signaling 
cascades that ultimately lead to the metastatic capacity of tumour cells. The numerous 
publications detailing the suppression of MMPs, followed by decreases in tumour 
invasiveness, led to clinical trials for MMP inhibitors, however, these trials failed to 
increase survival rates in patients (Kessenbrock, Plaks and Werb 2010). This recent twist 
in events has led to the accepted conclusion that although MMPs do degrade physical 
barriers of tumour cells, they also have more complex functions in the human body. The 
focus of this section will be to explore the three main roles of MMPs that make them a 
requirement of migration and invasion for most cells, whether by their ECM degradative 
function, or by their more complex signaling roles recently postulated.
D isr u ptio n  o f  C ell  A d h e sio n s  by  M m ps En h a n c e s  C ell  M ig r a tio n  a n d  In v a sio n
There are several mechanisms that MMPs can employ to facilitate invasion and tumour 
cell migration. One way is by disruption of cell-cell adhesion molecules, permitting cells to 
migrate away from each other. One example of MMP-mediated cell de-adhesion and tumor 
progression is the cleavage of the cell adhesion molecule epithelial (E)-cadherin by MMP- 
3,-9,-7, and MT1-MMP (MMP-14) (Van Roy and Berx 2008). E-cadherin is a 
transmembrane, cell adhesion molecule (CAM) that maintains tissue organization and 
forms adherent junctions between cells tightly holding them together in a ‘sheet’ (Aplin 
1998). Loss or disruption of this CAM is associated with many malignancies, contributing 
to a disorganized tissue phenotype and transitioning cells from an ‘epithelial’ phenotype, to 
that of a more motile ‘mesenchymal’ state (Hanahan and Weinberg 2000). In addition to 
the disruption of cell junctions, cleavage of E-cadherin can result in a soluble fragmented 
form that can act as a signaling molecule to further increase aggressiveness of cancer cells. 
The appearance of this soluble fragment of E-cadherin was concurrently observed with
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MMP-9 expression, increased cell migration and invasion and transition to a more 
aggressive mesenchymal phenotype in stimulated head and neck small cell carcinoma 
cells. In the same study, the direct role of MMP-9 on E-cadherin disruption was confirmed 
by knockdown of MMP-9 using siRNA, which inhibited the production of soluble E- 
cadherin during EGF-stimulated cell migration and invasion (Zuo 2011). Although not 
directly tested in the study, this soluble form of E-cadherin has been shown in other studies 
to work in a paracrine manner to increase cell invasion further potentiating the effect of E- 
cadherin disruption of cell migration and invasion (Lynch 2010).
The findings from in vitro studies regarding E-cadherin cleavage by MMPs have also 
correlated to what is found in the clinic. In a study where EGFR, MMP-9 and E-cadherin 
expression levels in ovarian epithelial cancer tissues were examined, it was observed that 
both EGFR and MMP-9 were overexpressed in high grade and advanced stages of the 
disease, however E-cadherin expression was inversely proportional to cancer progression 
(Alshenawy 2010). Patient tissue samples of esophageal squamous cell carcinoma have 
also been shown to possess high expression of MMP-2 and a low expression of E-cadherin. 
Furthermore, silencing a common upstream mediator of MMP-2 and E-cadherin, in an 
esophageal cell line (EC-1), mimicked this expression pattern and decreased the migration 
of these cells through a transwell membrane (Zhang 2011). Although MMP-2 does not 
directly cleave E-Cadherin, this study emphasizes the necessary coordination of cell-cell 
contact loss and MMP function in the invasion and progression of human malignancies.
D e g r a d a tio n  o f  th e  E x t r a c e l l u l a r  M a tr ix  (ECM) a n d  B a se m e n t  M em b ra n e  (BM) 
by  M m ps  E n h a n c e s  C e ll  M ig r a t io n  a nd  In v a sio n
While the loosening of cell contacts allows cancer cells to detach, protease degradation of 
the ECM and basement membrane (BM) enables these invasive cells to migrate into the 
surrounding tissue and vasculature. In this manner, MMPs ‘clear the way’ for migrating 
cells by expanding the pore size through the basement membrane to which cells must move 
through. The BM itself is an extensively complex barrier, made up of more than 50 distinct 
molecules to form a 100-300nm-thick lamina that is laid down under all epithelia and 
endothelium and structurally supports these cells (Rowe and Weiss 2008). The BM is 
composed of both polymerized laminin and type IV collagen that are crosslinked to
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provide a dynamic, mesh-like framework and the BM pore size is determined by both the 
amount of cross-linking as well as the quantity of ECM (Rowe and Weiss 2008). BM pore 
sizes are in the neighborhood of 50nm and since cells can only efficiently move through 
pores of more than 2mm, there is a spatial conundrum of how the cell can get through the 
BM (Rowe and Weiss 2008). Surprisingly, the cell employs invasive machinery that can 
either be of the proteolytic or non-proteolytic variety, in order to traverse the membrane. 
While the proteolytic mechanisms used to remodel the BM and ECM are discussed in 
detail in this section, non-proteolytic methods of cell invasion are discussed in ‘Types of 
Migration Machinery’.
Upon adhesion of a cell to the ECM, proteases are recruited to the location of the cell that 
makes contact with the ECM (called a focal contact or focal adhesion site). At the focal 
contact site, the membrane bound proteases, such as MT1-MMP, are in the perfect position 
to cleave ECM components such as collagen, fibronectin and laminins, as well as pro- 
MMPs, to create active soluble MMPs such MMP-2,-9 and -7 (Friedl and Wolf 2003). 
MMP-2 (aka gelatinase A) and MMP-9 (gelatinase B) are also type IV collagenases and, in 
addition, can degrade the BM. For example, overexpression of MTl-MMP-tagged with 
green fluorescent protein (GFP) in HT1080 fibrosarcoma cells, embedded in a collagen 3D 
matrix, resulted in a simultaneous increase of MT1-MMP-GFP at the surface of the cell 
and accumulation of cleaved collagen product (Wolf 2007). Furthermore, knockdown of 
MT1-MMP by RNAi, decreased the rate at which collagen was cleaved, as monitored by 
fluorescein isothiocyanate (FITC) release from cleaved collagen lattices (Wolf 2007).
More importantly, the overexpression of MT1-MMP in HT1080 cells caused an increase in 
cell migration, that was reverted upon treatment with an MMP inhibitor (Wolf 2007). This 
study by K. Wolf et al. demonstrates the functional role of MMPs, in particular MT1- 
MMP, in the degradation of BM matrices for enhanced cell migration through these 
matrices.
M m p-M e d ia t e d  S ig n a l  T r a n sd u c tio n  En h a n c e s  C ell  M ig ra tio n  a n d  In v a sio n
A third way to increase invasion through MMPs is by MMP-mediated signal transduction. 
Recent findings are emerging that suggest a role for MMPs, not only in the degradation of 
ECM, but in the modulation of signaling cascades that result in increased migration and
13
invasion. An example of a signal-altering MMP that results in increased metastasis is 
MMP-1. MMP-1 can be released into the tumour microenvironment by fibroblasts and has 
been found to activate a G- protein coupled receptor through proteolytic cleavage of its 
extracellular domain (Boire 2005). G-protein coupled receptors are membrane bound and 
associate with many cytoplasmic proteins that engage in signal transduction. To prove the 
hypothesis that MMP-1 cleaves a receptor responsible for signaling to downstream cell 
migration events, A. Boire et al added exogenous MMP-1 to media of breast carcinoma 
cells that do not express MMP-1. They observed that addition of MMP-1, but not other 
soluble MMPs (-2,-3 -7,-9), caused the number of cells that migrated through a transwell 
membrane to double (Boire 2005). Furthermore, this cell migration could be inhibited 
through knockdown of the receptor or by addition of MMP inhibitors clarifying the 
importance of both MMP1 and the signaling receptor in transducing cell migration.
1.2.1.3 Cellular Adhesion through Cell Adhesion Molecules
Cell-adhesion molecules (CAMs) have many important functions in the human body 
including the control of migration, maintenance of tissue integrity and adhesion of cells, 
such as immune mediators, to endothelial cells prior to transendothelial migration. In 
addition to their structural functions, CAMs also modulate signal-transduction pathways by 
interacting with molecules such as receptor tyrosine kinases, components of the Rho- 
family of GTPases, and molecules that upregulate MMPs. CAMs can also incur 
posttranslational modifications, adding another layer of cell adhesion regulation. Recent 
experimental evidence indicates that such processes have a crucial role in tumour 
progression, in particular during invasion and metastasis.
In t e g r in s
Integrins are single membrane spanning cell surface glycoproteins composed of 
heterodimers, a and p. They engage with the ECM, as well as counter receptors on 
neighboring cells, and transduce signals regarding the cell surroundings into the cell via 
their cytoplasmic tails. Integrins engage with the cytoskeleton of the cell as well as matrix 
degradation enzymes and these relationships allow integrins to have a hand in cell 
adhesion, motility and invasion. In particular, integrins can change their subtype to
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recognize different tissues the cell may encounter, in order to facilitate invasion in concert 
with MMPs. One of the most important roles of integrins in cell migration is the assembly 
of focal adhesions by stimulation of focal adhesion kinase.
lntegrin subtype expression and tissue recognition
There are more than 22 integrin subtypes formed by the various permutations between 
more than 16 a subunits and 8 P subunits (Hanahan and Weinberg 2000). As cells change 
environments throughout the process of metastasis and invasion, they can change the 
expression of their integrin subtypes in order to recognize and bind the various ECM they 
will encounter, from blood vessel endothelial cells to protease degraded ECM to intact 
stroma.
Under physiological conditions, cells can adapt to their surroundings in order to activate 
necessary responses through integrin signaling. Normal dermal fibroblasts play a role in 
tissue remodeling in response to changes in tissue rigidity in wound healing. When 
fibroblasts are plated on collagen, which is then overlaid onto substrata with varying 
rigidity, the cells change their expression of integrins as well as a smooth muscle actin 
(aSMA) to accommodate for the changes in surface structure (Jones and Ehrlich 2011). 
The fibroblasts, when plated onto a high rigidity surface, had increased expression of avP3 
integrin and aSMA and enhanced stress fibers whereas on low rigidity surfaces, the cells 
expressed a2pi integrin and had finer cytoskeletal microfilaments with less aSMA (Jones 
and Ehrlich 2011). These findings suggest that cells can change integrin expression 
patterns in response to their environment, influencing the actin cytoskeleton, and possibly 
affecting cell motility.
Interestingly, avp3 is one of the most versatile integrins, allowing adhesion to many 
different ECM components, and its expression allows for cells to migrate on almost any 
matrix protein it encounters (Johnson 1991). Additionally, expression of avP3 protein has 
been shown to coincide with the tumorigenicity of melanoma cells in murine models, 
which may be attributed to the P3 subunit because cells that have a mutated form of this 
subunit are unable to metastasize in comparison to cells with an intact P3 subunit (Jones 
and Ehrlich 2011 and Johnson 1991). The finding that increased expression of P3 integrin
is found in late stage and metastatic melanoma patient samples, in comparison to 
melanocytes and non-tumorigenic, microinvasive lesions, supports the notion that the 03 
subunit imparts aggressive attributes to cancer cells (Van Belle 1999).
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lntegrin association with MMPs and invasion
Preferential expression of integrins facilitates migration and invasion through the 
recognition of surrounding matrices and can further potentiate invasion by localizing 
matrix metalloproteases (MMPs) to these sites. The first study to solidify the interaction 
between a particular active MMP and an integrin was performed by P. Brooks et al. in 
1996. In the study, secreted, active MMP2 and the av03 integrin were co-localized on the 
surface of both melanoma cells and angiogenic blood vessels in vivo. In culture, melanoma 
cells expressing av03 bound directly to soluble MMP-2, but not a C-terminally truncated 
form, on the surface of invasive tumor cells (Aplin 1998).
More recently, it was demonstrated that the interaction between MMP-2 and av03 is 
critical for the promotion of endothelial ECM degradation when in association with the 
membrane type 1 MMP (MT1-MMP) (Leroy-Dudal 2005). In this study, MT1-MMP 
cleaved pro-MMP-2, and in this active form, interacted with av03 integrins on the cell 
surface, localizing the proteolytic activity to the invasive front of tumor cells (Leroy-Dudal 
2005). More importantly, pharmacological inhibition of the MMP2- av03 interaction 
decreased the transmigration of ovarian carcinoma cells through human umbilical vein 
endotheial cells (HUVECs) (Leroy-Dudal 2005). This study highlights a role for integrins, 
in concert with active MMP-2, in the migration of cancer cells through endothelial ECM 
that surrounds the vasculature. The evidence reported in these elegant studies combines the 
knowledge that integrins facilitate cell movement, and provide a mechanism by which 
integrins aid in invasion.
Integrins can facilitate migration by adjusting their subtype to accommodate their 
surroundings, and by expressing subtypes that participate in matrix degradation to clear a 
path for invasion. Integrins also have an important role to play in cell migration by 
regulating the assembly and disassembly of adhesion complexes to meet the migratory 
requirements of the cell. Integrin-mediated cell adhesion events rely on many effectors to
deliver external signals into the cell, interact with the cytoskeleton, and regulate 
adhesion/de-adhesion events to ultimately orchestrate motility.
Integrin mediated cell adhesion
There are a number of intracellular proteins that bind directly to the cytoplasmic domain of 
integrin receptors and link outside integrin signaling to inside cytoskeletal interactions. In 
this manner, integrins and their effectors work on the cytoskeleton to assist in the assembly 
of focal contacts. Focal contacts are specialized structures that allow the cell to connect 
with the ECM. Within focal contacts are sites of adhesion where clusters of integrins bind 
not only to the ECM proteins outside the cell but also to distinct cytoplasmic proteins that 
interface with actin filaments inside the cell. The cytoplasmic proteins that directly bind to 
integrins at focal contacts include talin and a-actinin (Aplin 1998). Talin and a-actinin 
connect the actin cytoskeleton to focal adhesions through their actin-binding partner, 
vinculin, and are necessary to form nascent focal adhesions (Aplin 1998). Vinculin, in 
addition to binding actin, also binds to paxillin. Paxillin and talin can both bind to focal 
adhesion kinase (FAK), which serves as a switch to potentiate, as well as shut down, focal 
adhesion (Figure 1.2.2).
Integrin-mediated assembly of Focal Adhesions (FAs) through Focal Adhesion Kinase 
(FAK) activation in cell migration
FAK is a cytoplasmic, non-receptor, protein tyrosine kinase and upon integrin clustering at 
focal adhesions, FAK has been shown to experience enhanced tyrosine phosphorylation, 
rendering it 2-3 fold active upon adhesion in fibroblasts (Aplin 1998). Overexpression of 
FAK has been shown to increase the migration of Chinese hamster ovary cells across 
fibronectin and the expression levels of FAK promote the progression of aggressive 
melanoma phenotype (Cary 1996 and Hess 2005). FAK knockout cells, conversely, have 
reduced cell migration and decreased tyrosine phosphorylation of FA-associated proteins, 
but the number of stable FAs is increased (Ilic 1995). These counterintuitive results from 
work done with FAK -/- cells can be taken together to imply a role for FAK in the turnover 
rather than creation of FAs, to induce cell motility.
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But how does FAK mediate FA assembly/disassembly and, consequently, cell migration? 
In a study performed earlier this year, it was demonstrated that by altering the ability to 
phosphorylate the Tyr-925 residue of FAK, focal adhesion turnover is altered along with 
migration rates (Deramaudt 2011). In more detail, this study used FAK-/- embryonic 
fibroblast cells to introduce one of two constructs, a non-phosorylatable form of FAK and 
a constitutively phosphorylated type of FAK (Deramaudt 2011). The differences found 
between these two forms was that unphosphorylated-FAK led to FA stabilization, 
decreased FA disassembly and reduced cell migration, similar to previous findings with 
FAK -/- cells, while conversely, phosphorylated-FAK did not experience any reduction in 
FA disassembly, had increased FAs at cell leading edge, more cell protrusions and higher 
migration speeds, similar to results seen previously in FAK over-expressing cells 
(Deramaudt 2011). Taken together, these results show that FAK phosphorylation acts as a 
switch that coordinates either FA disassembly when phosphorylated, or stabilizes FAs 
when dephosphorylated. These findings offer an explanation for how FAK works as a 
regulator to increase FAs at the leading edge for initiation of protrusion formation, yet 
disassembles these focal adhesions during cell movement and contractility.
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Adapted from Tomar, A. and Schlaepfer, D.D. Curr. Opin. Cell Biol 5 (2009)
Figure 1.2.2: Integrin-mediated focal adhesion formation
A. Upon binding to the fibronectin-rich ECM, integrins signal as heterodimers (a and P) to transduce the 
outside-signal-in to intracellular binding partners of the P-subunit for formation of focal adhesion contacts. B. 
Focal adhesions are formed along the outside of the cell where it makes contact with the ECM. The 
intracellular integrin binding partners, Talin and a-actinin, link the signal to the actin cytoskeleton through 
their common binding partner Vinculin. Paxillin (PAX) is also recruited to the site of focal adhesion 
formation and both PAX and Talin bind Focal Adhesion Kinase (FAK). C. FAK serves as a switch to 
potentiate, as well as shut down, focal adhesion. In the inactive form (dcphosphorylated), FAK can increase 
focal adhesion and bind the Arp3 complex to initiate the recruitment of Arp2/3 complex. At the early stages 
of cell migration, activation of FAK (phosphorylated) leads to disassembly of focal adhesions and 
phosphorylation of pl90RhoGAP, a RhoA inactivating protein. FAK phosphorylation thus allows for the 
formation of Rac 1 - mediated, Arp2/3 branched actin nucléation, resulting in lamellipodia. D.
Phosphorylation of RhoGEF, a RhoA activating protein, by active FAK, allows for RhoA/ROCK mediated 
actomyosin contraction in the later stages of cell migration.
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FAK-mediated regulation of cell migration through GTPases
Another model of FAK-mediated regulation of FAs and migration, suggests that FAK 
regulates guanine nucleotide exchange factors (GEFs) and GTPases-activating proteins 
(GAPs) to control the temporal activation of Rho and Rac GTPases (Tomar and Schlaepfer 
2009). GEFs work to activate GTPases by increasing the release of GDP and allowing 
GTP to bind, and GAPs work in the opposite manner by increasing the hydrolysis of GTP 
and promoting the inactivation of GTPases (Aplin 1998). Evidence to support this model 
comes from the fact that FAs at the leading edge mature under high contractility, through 
GEF-mediated activation of RhoA, a contractility molecule, and that FA disassembly 
occurs upon loss of this contractility through inactivation of RhoA (Gupton and Waterman- 
Storer 2006).
FAK mediated cell migration through GAPs and GEFs functions at both the beginning and 
end of the migration cycle (Figure 1.2.3). At the onset of cell migration, RhoA is in the 
leading edge of the cell and it is here that it will be activated by GEFs to induce actin stress 
fibers (Olsen and Sahai 2009). Stress fiber formation is a form of actomyosin contraction 
and thus, favors the assembly of FAs at the front of the cell whereas RhoA inhibition, 
through GAPs, decreases contractility, leading to FA turnover. In fact, this exact scenario 
is seen in the early stages of lamellipodia formation (15-45 minutes) whereby FAK inhibits 
RhoA by regulating pl90RhoGAP, a GAP specific for RhoA, and at the same time FAK 
enhances Rac activation by phosphorylation of pl30Cas or PIX (Tomar and Schlaepfer 
2009). RhoA is also inhibited by Racl, but not vice versa, and so RhoA will not be active 
at the same time as Racl (Tomar and Schlaepfer 2009). Focal contacts are initially formed 
to give the cell some traction, however when FAK and Racl inactivate RhoA, FAs are 
disassembled at the front of the cell and Rac-mediated lamellipodia formation, which 
would not favor focal contacts of the cell to the ECM, can occur. (Tomar and Schlaepfer 
2009). This model also corroborates with what is seen in FAK-null fibroblasts because it 
makes sense that without FAK to inhibit RhoA, there would be a high incidence of FAs in 
these cells. In fact, in the literature, FAK-/- or FAK mutant cells have high RhoA activity 
and FA turnover defects, leading to many FAs (Tomar and Schlaepfer 2009 and Ilic 1995).
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If these mechanisms occur at the leading edge of the cell, what happens in the rear? At 
about +60 minutes post fibronectin induced lamellipodia formation, FAK has been shown 
to phosphorylate Rgnef, a RhoGEF at the rear, resulting in high Rho activity and increased 
actomyosin contraction, and, in a completely opposite manner to the front, contraction 
promotes the trailing edge disassembly of weaker FAs at the back by pulling on stronger 
FAs at the front (Tomar and Schlaepfer 2009 and Gupton and Waterman-Storer 2006). To 
achieve contractility. RhoA signals to its effector, ROCK (Rho-Kinase), which can directly 
bind myosin light chain II (MLCII) (Narumiya, Tanji and Ishizaki 2009). ROCK-mediated 
phosphorylation of MLCII forces myosin to take on an active conformation, resulting in 
the binding of MLC II to actin filaments and gliding them against one another to create cell 
contraction (Olsen and Sahai 2009). Actomyosin contraction allows the cell to pull apart 
from the ECM and advance in the location of the stimulus (Tomar and Schlaepfer 2009). 
This conclusion is supported by the reduced motility and tail retraction defects, however no 
effect on cell spreading, seen in fibroblasts when RhoGEF is knocked down and RhoA 
activation is reduced (Lim 2008).
In summary, many studies are in support of the temporal model of FA regulation by FAK 
and GEFs/GAPs where upon fibronectin-Integrin stimulated cell spreading, RhoA is first 
activated, then inactivated, followed by final RhoA activation. Put simply in a review by 
A. Tomar and D. Schlaepfer, FAK ‘pushes’ the cell forward by Rac-mediated lamellipodia 
formation in early cell spreading by activating pl90RhoGAP to inhibit RhoA and by 
phosphorylation of pl30Cas or PIX to activate Rac (Johnson 1991). FAK then follows up 
the push by ‘pulling up the rear’ of the cell late in cell spreading by activating RhoGEF 
and subsequent activation of RhoA (Tomar and Schlaepfer 2009).
In summary, integrins play a role in cancer migration and invasion by altering their 
subtype to better interact with surrounding extracellular matrices as well as degrade them. 
In addition to the preferential expression of integrins to promote matrix degradation and 
migration, cancer cells can also regulate assembly and disassembly of adhesion complexes 
to adapt to the migratory requirements of the cell through the actions of FAK.
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Adapted from Tomar, A. and Schlaepfer, D.D. Curr. Opin. Cell. Biol. 5 (2009)
Figure 1.2.3: Focal Adhesion Kinase regulation of cell motility
FAK regulates guanine nucleotide exchange factors (GEFs) and GTPases-activating proteins (GAPs) to 
control the temporal activation of Rho and Rac GTPases. At the early stages of cell migration (15-45 
minutes) active FAK inhibits RhoA by regulating pl90RhoGAP, a GAP specific for RhoA, and at the same 
time, FAK enhances Racl. Racl also inhibits RhoA to further potentiate Rac 1-mediated lamellipodia 
formation (PUSH). In the later stages of migration (+60 minutes) FAK phosphorylâtes Rgnef, a RhoGEF at 
the rear, resulting in high RhoA activity and increased actomyosin contraction. Contraction promotes the rear 
disassembly of weak F As at the back by pulling on stronger F As at the front. To achieve contractility, RhoA 
signals to its effector, ROCK, which can directly bind myosin light chain II (MLCII) for actomyosin 
contraction (PULL).
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C a d h er in s
Classical cadherins are single spanning transmembrane proteins and are comprised of more 
than 5 subtypes, with E- and N- subtypes most often implicated in cancer (Cavallaro and 
Christofori 2004). One specific subtype of cadherin binds exclusively to the same subtype 
on the surface of another cell, unlike the integrins, which bind to many different ligands. 
Cadherins localize to adherence junctions, or sites of cell-cell contact, and it is here that 
they mediate cell-cell adhesion by transduction of signals to the actin-cytoskeleton. 
Cadherins mediate cell signaling through the interaction of their cytoplasmic tails with a 
family of intracellular proteins called catenins. Briefly stated, the cytoplasmic tail of the 
cadherin molecule binds to P-catenin and this process is essential to the function of 
cadherins because truncating the cytoplasmic domain also deletes catenin binding sites, 
abolishing cadherin-mediated adhesion (Aplin 1998). The a-catenin protein serves to bind 
both p-catenin and the actin cytoskeleton by direct binding to a-actinin (actin bundling 
protein), which is a similar downstream effector of integrin-mediated adhesion (Figure 
1.2.4). Disruption of this cadherin-catenin- complex is detrimental to establishing cell-cell 
contacts and is a common mechanism used during the progression to tumour malignancy 
(Cavallaro and Christofori 2004). For example, epithelial (E)-cadherin is altered in most 
epithelial tumours and its loss supports tumour cell migration, invasion and metastatic 
dissemination (Cavallaro and Christofori 2004). Likewise, transformation of normal 
epithelial cells with v-Src, phosphorylâtes P-catenin, leading to loss of cytoskeletal 
interactions and adherence junctions (Aplin 1998).
Loss o f E-Cadherin and tumor cell migration and invasion
The first group to show a causal link between the loss of Epithelial (E)-cadherin and tumor 
cell invasion and metastasis in vivo was Christofori’s group in 1998. Using a Rip 1 Tag 
mouse model of pancreatic P-cell carcinoma in comparison to Rip 1 Tag mice crossed with 
a dominant negative form of E-cadherin, this group demonstrated that mice with normal E- 
cadherin arrested their tumour development at the adenoma stage while mice that were 
dominant negative for E-cadherin developed carcinoma with early invasion and metastasis 
(Perl 1998). More recently, a model for non-small cell lung carcinoma (C-Raf x 
conditional knock out of E-cadherin gene) was used to demonstrate effects of E-cadherin
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loss in vivo. Upon E-cadherin ablation in this model, normally benign lesions gave rise to 
micrometastasis (Ceteci 2007). The elegant work that has been done in vivo to date, 
demonstrates the importance of E-cadherin in suppressing invasion and metastasis.
E-Cadherin loss promotes the Epithelial-Mesenchymal Transition (EMT) and promotes 
cell migration and invasion
The loss of E-cadherin has been associated with the onset of a developmental regulatory 
program, called the ‘epithelial-mesenchymal transition’ (EMT). EMT defines a 
characteristic change in phenotype of transformed epithelial cells as they transition from 
what Hanahan and Weinberg describe as: a ‘polarized, polygonal/epithelial morphology to 
that of a more spindly/fibroblastic morphology’. In addition to morphological changes, 
cells that undergo EMT are associated with an increase in matrix-degrading enzymes and 
cell motility increasing their ability to metastasize (Hanahan and Weinberg 2011).
Loss in the expression of epithelial cell markers, such as E-cadherin and cytokeratin, and 
gain in expression of mesenchymal markers, such as Neural (N)-cadherin, cadherin-11, 
(expressed by osteoblasts), Vimentin intermediate filament protein, and distinct 
transcriptional factors, accompany the EMT process (Kallergi 2011). The process of 
exchanging expression of E-cadherin to N-cadherin and cadherin-11, in particular, is called 
the ‘cadherin switch' and is associated with increases in invasion and migration (Cavallaro 
and Christofori 2004).
The invasive qualities that N-cadherin and cadherin-11 impart upon the cell post-EMT 
have been theorized to allow the tumour cell to move into its surroundings. This theory 
rests upon the fact that epithelial cells express E-cadherins, however the ‘mesenchymal’- 
like cells express N-cadherin and caderin-11, which are cadherins often found in stromal 
cells (Cavallaro and Christofori 2004). It is thought that the loss of E-cadherin not only 
prevents adherence between adjacent tumour cells, but also entices the tumour cell to 
engage with stroma cells and invade, since cadherins interact with the exact same cadherin 
receptor on neighboring cells. Evidence for this theory can be gleamed from a clinical 
study where the gain of N-cadherin/loss of E-cadherin expression is seen in high-grade 
human prostate cancer tissue, but no N-cadherin expression was found in the surrounding
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normal prostatic tissue, and less N-cadherin was seen in lower grade prostatic tissue 
(Tomita 2000). Furthermore, when immunofluorescence analysis of cadherin-11 was 
performed on prostate tissue, all of the prostate cancer specimens showed expression of 
cadherin-11 at the interface of the stroma and tumor cells, whereas no expression of 
cadherin-11 was found in nonmalignant prostate tissue (Tomita 2000). This study indicates 
that the cadherin switching in high-grade prostate cancer is related to the interaction 
between cancer cells and the stroma and could contribute to the invasiveness of these 
tumours.
Disruption of E-cadherin promotes Actin cytoskeletal reorganization and cell migration 
through Rho GTPases
Another role that cadherins play in the migration of cancer cells is through their association 
with Rho GTPases. As mentioned previously, disassembly of the cadherin-catenin- 
complex leads to the disruption of E-cadherin, which results in a loss of association with 
the actin cytoskeleton through the impedance of actin binding to a-catenin. This implies 
that the loss of E-cadherin could also play a role in forcing the actin cytoskeleton to 
reorganize itself. Rho GTPases play a key role in the organization of the actin cytoskeleton 
and thus, Rho GTPases can also modulate cell-cell adhesion by their association with 
cadherins (Cavallaro and Christofori 2004).
Rho GTPases and adhesion junctions have been shown to participate with one another 
through the association of E-cadherin and pl90GAP, the Rho A inhibitory molecule. For 
example, L. Asnaghi and colleges have shown that E-cadherin inhibits RhoA activation 
through pl90GAP to suppress cell migration and proliferation by demonstrating that the 
suppressive affects of E-cadherin can be alleviated through the siRNA inhibition of all 
three molecules (RhoA, pl90GAP or E-cadherin) (Figure 1.2.4) (Asnaghi 2010).
In summary, cadherins participate in the progression of tumours and their invasive capacity 
through a cadherin switch from tumor suppressing E-cadherin to tumour promoting N- 
cadherin and cadherin-11. E-cadherin loss disrupts the cell-cell adhesion contacts allowing 
cells to move away from one another and causing tissue disorganization and N-cadherin 
and cadherin-11 gain allows cells to better interact with their surroundings so that they can
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invade. Cadherins also participate with the actin cytoskeleton to inhibit cell migration and 
proliferation through the inhibition of RhoA. E-cadherin loss relieves this inhibition and 
many invasive cancers may use this strategy.
The fundamental requirements of cell migration: cytoskeletal reorganization, protease 
matrix degradation and cellular adhesion molecule-mediated cell adhesion and signaling, 
can be generally described in terms of two different and yet overlapping arms of cell 
migration, protease dependent and protease independent.
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Figure 1.2.4: Loss of E-cadherin and cell migration
Loss of E-cadherin is associated with cancer cell migration. Cadherins bind to the same subtype on 
neighboring cells at cell adherence junctions and mediate cell-cell adhesion by signal transduction through 
catenins. The cytoplasmic tail of the cadherin molecule binds P-catenin, which connects the cadherin signal 
from the neighboring cell to the actin cytoskeleton through a-catenin. a-catenin binds both P-catenin and the 
actin cytoskeleton by directly binding to a-actinin (actin bundling protein). The E-cadherin subtype can play 
a role in both tissue organization and controlling cell migration through its interaction with Rho GTPases. A. 
Intact E-cadherin can signal to pl90GAP to inactivate RhoA and keep migration in check. B. Destabilization 
of E-cadherin is commonly observed in cancer and can facilitate migration through multiple pathways 
including loss of RhoA regulation by pl90GAP.
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1.2.2 Types of Cancer Cell Migration Machinery
Cancer cell migration has been loosely categorized on the basis of two proposed 
mechanisms: protease dependent or protease independent. Furthermore, the same cell can 
employ these distinct mechanisms at different times by preferentially switching between 
the two. Protease dependent migration is also termed ‘mesenchymal’ migration and 
depends on the release of proteases to create a space in the ECM to move through (Rowe 
and Weiss 2008 and Hanahan and Weinberg 2011). Protease dependent, mesenchymal- 
elongated cell migration is mediated by Rac stimulated actin protrusions and does not have 
a requirement for Rho or ROCK (Sahai and Marshall 2003). Protease independent 
migration also called ‘ameboid’ migration is a type of migration that occurs in the absence 
of proteases and relies on the cell’s capacity to ‘squeeze’ itself through the ECM (Rowe 
and Weiss 2008 and Hanahan and Weinberg 2011). Rho/ROCK signaling mediates this 
form of cell migration without the need for proteases (Sahai and Marshall 2003 and 
Wyckoff 2006). Wyckoff et al. demonstrated that metastatic breast tumour cells (MTLn) 
migrate through a complex ECM without proteolysis (Wyckoff 2006). Although the 
pharmacological inhibition of proteases does not prevent the ‘deformation’ of collagen, 
pharmacological inhibition of myosin ATPase or ROCK does. These results clearly 
implicate a protease-independent form of migration, related to actomyosin contraction, in 
order to contort through substrata. E. Sahai and C. Marshall elegantly point out the ability 
of cancer cells to switch during metastasis by demonstrating that cells with ‘rounded’ 
ameboid-like morphology invade using the protease-independent form of migration and 
inhibitors against Rho GTPases or ROCK or both synergistically, deplete invasion (Sahai 
and Marshall 2003). Conversely, elongated-mesenchymal type cells do not show the same 
decrease in invasion upon addition of these inhibitors alone or in combination, and 
invasion was even enhanced in one cell type. Subjection of both rounded and elongated 
cells to protease inhibitors does not lead to decreased invasion, but surprisingly, the 
combination of protease inhibitors and a ROCK inhibitor reduces their migration in all 
cases. From this data, Sahai and Marshall suggest that blocking the ability of cells to 
switch between the two forms of migration ultimately ceases cell invasion, a necessary 
component of migration.
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1.2.2.1 Cortactin and RhoA, Examples of Proteins Involved in the 
Two Arms of Migration Machinery
RhoA and Cortactin are examples of proteins involved in the two different mechanisms 
used in cell migration. RhoA is involved in protease-independent cell migration machinery 
such as: formation of focal adhesions, cell contraction and pushing the cell forward from 
the rear. Conversely, cortactin is involved in protease-dependent migration machinery such 
as: actin polymerization in the formation of invadopodia used for matrix degradation and 
assists in pulling the cell forward at the leading edge. RhoA and cortactin are also 
frequently over-expressed or amplified, respectively, in many human cancers, conferring 
poor patient prognosis (Fritz, Just and Kaina 1999; Horiuchi 2003; Schuuring 1995; and 
Cai 2010). Elucidation of the roles rhoA and cortactin have on conferring metastatic 
potential to cancer cells in vivo, would help in the indication of the type of migration 
machinery critical for fully metastasized cells, and would assist in further defining the 
steps in metastasis where migration is rate limiting.
R o le  o f  R h o A  in C e ll u la r  M ig ra tio n
RhoA, a member of the Ras homology super family of small guanosine triphosphatases 
(RhoGTPases), acts as a molecular switch to turn on protease-independent, amoeboid cell 
migration machinery such as: formation of focal contacts at the leading edge of the cell, 
actin polymerization and stabilization, actomyosin mediated contraction and cell-cell 
contact destabilization.
RhoA mediated formation offocal adhesion contacts at the leading edge
RhoA activation has been described in numerous publications to promote the formation of 
nascent focal contacts during the initiation of migration. Focal contacts, as discussed in the 
previous section, are clusters of integrin cell- adhesion molecules that allow the cell to 
come into contact with the ECM. It is hypothesized by many that focal adhesion contacts 
are necessary to provide traction for the cell at the leading edge so that the cell can grab 
hold of the ECM to push itself forward using RhoA mediated actomyosin contraction, 
discussed below.
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R ho A mediated actin polymerization and actomyosin contraction at the rear
To initiate cell motility, RhoA-GTP binds and activates its effector, Rho-associated coiled- 
coil forming kinase (ROCKl,2) (Narumiya, Tanji and Ishizaki 2009). ROCK 1 and 2 
show sequence-similarity and both act to increase actomyosin contraction by 
phosphorylation of the myosin II light chain (MLC), rendering it in a conformation that 
associates with nearby F- actin filaments (Somlyo and Somlyo 2000). When multimeric 
myosin interacts with F-actin, myosin uses ATP to walk towards either end of two 
opposing growing ends of actin filaments and creates contractile force necessary for cell 
motility (Olsen and Sahai 2009). ROCK also antagonizes myosin light chain phosphatase 
(MLCP) to render myosin in an active state during contraction (Somlyo and Somlyo 2000). 
The RhoA-ROCK mediated cell migration drives the amoeboid arm of migration whereby 
tumor cells generate sufficient actomyosin contraction to push through the extracellular 
matrix (ECM) independent of degradation enzymes or cell protrusions. For example, 
treatment with a ROCK inhibitor in cells that rely on amoeboid migration increases cell 
protrusions yet these cells are unable to invade (Wyckoff 2006). Conversely, the same 
cells, when treated with ECM protease inhibitors, have fewer protrusions and still invade 
as the control cells (Wyckoff 2006).
R o le  o f  C o r t a c t in  in  C e l l u l a r  M ig ratio n
During metastasis, cells can form specialized, peripheral protrusions, called invadopodia, 
that assist with invasion into the ECM or endothelium during protease-dependent 
mesenchymal migration. Cortactin acts as a master switch, and upon phosphorylation, 
forms functional and mature invadopodia structures through the activation of actin 
polymerization in the direction of cell migration.
The role o f Cortactin in mature invadopodia formation
Invadopodia formation can be broken down into stages from initiation of small 
invadopodium precursors to mature structures. Precursors contain actin, and actin 
polymerization regulators such as cortactin, N-WASP and cofilin (Yamaguchi 2005 and 
Artym 2006). Although cortactin is not a requirement for precursors, phosphorylation of
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cortactin is absolutely necessary to stabilize and allow formation of mature invadopodia 
(Yamaguchi 2005 and Artym 2006). Cortactin relies on precise interactions at each of its 
distinct binding domains to complete the invadopodia maturation process. The acidic 
region at the N-terminus of cortactin harbors a binding site for the actin-polymerizing 
Arp2/3 complex. Upon phosphorylation of cortactin, the Arp2/3 complex actively begins 
to polymerize actin, forming branched networks extending the cell membrane outward 
(Mader 2011 and Pollard 2007). Following this domain is the site for F-actin binding, 
which allows for the actin fiber to come into close proximity to the Arp2/3 nucleating 
complex. At the C-terminus of the molecule is the location of Src-homology 3 (SH3) 
domain, which recruits additional components that are also necessary for initiation of 
invadopodia formation and provides additional Arp2/3 mediated actin polymerization, such 
as N-WASP (Neural Wiskott-Aldrich syndrome protein) family proteins (Yamaguchi 
2005). Finally, there is a proline rich region that contains phosphorylation sites for Src 
family kinases which kick starts the aforementioned maturation and stabilization of 
invadopodia but also allows for progression of mature invadopodia to functional 
invadopodia.
The role of Cortactin in functional invadopodia formation
The final stage of invadopodia maturation confers functionality to these structures. This 
function is delivery, followed by secretion, of extracellular matrix-degrading enzymes such 
as typel matrix metalloprotease (MT1-MMP) (Yamaguchi 2005 and Artym 2006). For 
example, when cortactin was depleted from MD-MBA-231 cells, gelatin matrix- 
degradation was blocked due to failure of cells to form invadopodia. Conversely when 
MT1-MMP was inhibited, invadopodial structures were only slightly decreased but cells 
were unable to degrade the matrix (Artym 2006). These findings indicate that cortactin is 
required to stabilize mature invadopodia, but cannot deform the ECM alone, and therefore 
requires MMPs for functional invasion. Cortactin has been shown to orchestrate 
invadopodia formation and ECM degradation events following stimulation with epidermal 
growth factor (EGF), via signaling through Arg and Src kinase (Mader 2011). This EGFR- 
Arg-Src-cortactin mediated pathway triggers actin polymerization by Arp2/3 complex and 
matrix proteolysis-dependent tumor cell invasion and provides a link between the external
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matrix conditions and functional invadopodia formation (Mader 2011).
A side by side study, where both the protease-independent or protease-dependent arms of 
migration are inhibited, would allow for the question of whether one is more important 
than the other, for cell migration and metastasis, to be asked. Knockdown of genes such as 
rhoA or cortactin would represent both arms of the migration machinery and is a quick 
way to begin looking at this question. Migration machinery of both arms, however, can be 
overlapping, and additional validation would be required to tease out these overlapping 
functions. Gene knockdown can be mediated by short-interfering or short-hairpin RNA 
molecules that target mRNA transcripts in a sequence specific manner, depleting mRNA 
expression and protein expression of the gene of interest.
1.3 RNA Interference
RNA interference, or RNAi, is a conserved response to double-stranded RNA (dsRNA) 
utilized by most, if not all, eukaryotic organisms (Cullen 2004). This form of post- 
transcriptional gene silencing was originally discovered in Caenorhabditis elegans after 
the administration of dsRNA resulted in an increase in sequence-specific gene knockdown 
that was 10-fold more potent then single stranded RNA alone (Fire 1998). A hallmark of 
the dsRNA silencing machinery is the production of 21-25 base pair dsRNAs called small 
interfering RNAs (siRNAs) by Dicer, an enzyme that essentially ‘chops up’ long dsRNAs 
(Hannon 2002). In this form, siRNAs specifically and efficiently target transcribed genes 
using exact Watson-Crick base pairing to mRNA transcripts, by association with RISC 
(Hannon 2002). Targeted mRNAs experience degradation or inhibited translation, 
ultimately silencing the gene associated with the transcript. Endogenous dsRNA, called 
microRNA, can also be processed in the RNAi pathway as a method of gene regulation 
(Lochmatter and Mullis 2011). MicroRNAs, like exogenous dsRNA, also trigger formation 
of siRNA, however due to incomplete Watson-Crick base pairing to the targeted mRNA, 
the translation is stalled rather than degraded, as is normally encountered with long dsRNA 
processing (Lochmatter and Mullis 2011). This section summarizes the RNAi response 
used by mammalian cells to process both long dsRNA for resistance to exogenous 
pathogenic nucleic acids, and endogenous microRNAs to regulate expression of their own
coding genes. The application to which the RNAi response has been applied in research 
and the types of synthetic molecules used in this process is also highlighted.
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1.3.1 Function of RNAi in Nature
M e d ia t io n  o f  R e sist a n c e  to  pa th o g e n ic  d sR N A s b y  th e  R N A i r espo n se
The RNAi pathway can be initiated by long pieces of dsRNA that can arise exogenously, 
as in the case of pathogenic virus infection or by injection of long dsRNA into the cell 
cytoplasm, as shown previously with murine oocytes (Lochmatter and Mullis 2011 and 
Wianny, and Zemicka-Goetz 2000). The antiviral response includes processing dsRNA 
into siRNA through the RNAi pathway and ultimately targeting viral gene products for 
destruction-halting viral propagation. Degradation of dsRNA is facilitated by Dicer, an 
RNase III endoribonucease enzyme, that is located in the cytoplasm. Dicer cleaves dsRNA 
into hallmark 21-25 nucleotide RNA duplexes, or siRNAs, each with a 2-nucleotide 
overhang at the 3’ end (Lochmatter and Mullis 2011). The cleavage is thought to be cyclic 
so that Dicer binds dsRNA and repeatedly cleaves 22 bp until the entire dsRNA is 
obliterated (Lochmatter and Mullis 2011). Following cleavage, the ~22bp siRNA duplex 
remains associated with Dicer and one strand of the duplex is loaded into the RNA induced 
silencing complex (RISC) (Cullen 2004).
RISCs are ribonucleoprotein complexes made up of Argonaute proteins and contain the 
siRNAs for targeting of mRNA transcripts with complimentary sequences. The Argonaute 
protein family members all contain a PAZ domain that can bind siRNA and a PIWI 
domain to provide ‘sheer’ or nuclease activity (Valencia-Sanchez 2006). The main enzyme 
that confers RISC with its endonuclease or ‘sheer’ activity for target mRNA is Ago2 (Liu 
2004). Ago2 coexpression also substantially increases sequence specificity of siRNA to its 
target as demonstrated by increased EGF receptor knockdown upon addition of Ago2 
except for in the case where the EGFR mRNA has been mutated (Diederichs 2008).
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M ed ia tio n  o f  G e n e  E x pr e ssio n  u sin g  R N A i r espo n se  a n d  m ic r o R N A s
The discovery that small, noncoding RNAs (20-30 nucleotides) can regulate the 
expression of genes was first made in C. elegans. Researchers found that a small, 21 -nt 
RNA molecule, called I in-4, regulated lin-14, a developmental gene in C. elegans (Lee, 
Feinbaum and Ambros 1993). More intriguing to these researchers, was that the lin-4 
molecule did not code for a protein, and instead, contained complementary sequences to 
the lin-14 mRNA, targeting lin-14 for translational inhibition through the RNAi pathway 
(Lee, Feinbaum and Ambros 1993). These RNA regulatory molecules, termed microRNAs, 
are now known to be abundant in the human genome where at least 1000 of these 
microRNAs (miRNAs) are hypothesized to have a key role in regulating many biological 
processes, including 30% of coding genes (Lochmatter and Mullis 2011).
The biogenesis of miRNA differs from siRNA because siRNA is cleaved from long 
dsRNA in the cytoplasm by Dicer, and does not require any prior processing. Conversely, 
miRNAs are transcribed from genes, introns or separate transcription units, all of which are 
located in the nucleus, and to facilitate Dicer cleavage in the cytoplasm, additional 
processing of miRNAs is necessary. The miRNA biogenesis pathway is comprised of RNA 
intermediates: primary-miRNA, pre-miRNA hairpin and the miRNA duplex (Figure 1.3.1). 
To initiate the biogenesis of mature miRNA, RNA polymerase II transcribes a several 
hundred-nucleotide primary-miRNAs (pri-miRNAs) from the genome (Lochmatter and 
Mullis 2011). Pri-miRNAs have a hairpin-shaped stem-loop that lacks perfect base pairing 
and can lead to ‘bulges’ in the initial secondary structure, which are often earned into the 
mature miRNA (Lochmatter and Mullis 2011). Within the nucleus, pri-miRNA hairpin 
associates with a large nuclear microprocessor complex composed of Drosha (RNase III 
endonuclease) and an essential cofactor, DiGeorge syndrome critical region gene 8 
(DGCR8) (Lochmatter and Mullis 2011). DGCR8 binds the stem-loop structures of pri- 
miRNA and Drosha, like Dicer, cleaves the pri-miRNA about 70 nucleotides away from 
the hairpin loop leaving a 2-nucleotide 3’ overhang (Lochmatter and Mullis 2011). The 60- 
80 nucleotide hairpin-RNA duplex that is released from Drosha is termed the pre-miRNA 
and is further processed in the cytoplasm, however since pre-miRNA resides in the 
nucleus, it must associate with Exportin-5 nuclear exporter protein, to be translocated out
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of nucleus (Cullen 2004). Similar to the fate of dsRNA, once pre-miRNA is in the 
cytoplasm, the molecule is subjected to Dicer cleavage. Dissimilar to dsRNA, however, 
pre-miRNA cleavage serves in the removal of the hairpin loop to liberate the mature 
miRNA, a 22 nucleotide RNA duplex with 2-nt 3’ overhangs (Cullen 2004). Once cleaved 
by Dicer, the rest of the RNAi pathway is similar to that of dsRNA whereby miRNAs are 
unwound and one strand is incorporated into the RISC complex to induce gene silencing 
(Lochmatter and Mullis 2011). Since siRNAs are almost perfectly complementary to target 
mRNA, siRNA gene silencing is usually facilitated by endonucleolytic cleavage of the 
mRNA transcript. However, if mismatches and bulges are present during base pairing, as 
observed in most naturally occurring miRNA, translational repression generally occurs 













Figure 1.3.1: The RNAi pathway
A. RNA Polymerase II (Pol II, yellow) transcribes the several hundred-nucleotide long pri-miRNA from the 
endogenous genes in the nucleus. DROSHA (RNase III endoribonuclease), in association with an essential 
co-factor, DGCR8, cleaves the pri-miRNA about 70 nt from the hairpin, liberating a pre-miRNA. Pre- 
mi RN As are transported out of the nucleus and into the cytoplasm by the nuclear export factor, Exportin ‘5’. 
In the cytoplasm, the hairpin-loop is excised by DICER (RNase III endoribonucease), and this yields a 22-nt 
mature miRNA duplex. One of the strands from miRNA can be incorporated into RISC for translational 
inhibition of the mRNA (green) possibly by preventing the ribosome from entering. B. The exogenous entry 
of dsRNA into the cytoplasm triggers the RNAi pathway. Long dsRNA is recognized by DICER and cleaved 
into 22-nt siRNA duplexes. One strand of the duplex is loaded into RISC and the target mRNA (green) is 
degraded.
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1.3.2 RNAi and Genomics
Sy n t h e t ic  RNAi M o le c u l e s  a n d  D eliv er y  M e t h o d s : B en efits  a n d  D r a w b a ck s
Synthetic siRNA, shRNA, or shRNA-microRNA molecules can be artificially expressed in 
cells and enter the RNAi pathway for RISC-associated mRNA degradation or translational 
suppression. This section provides the benefits and drawbacks for using these synthetic 
molecules in experiments requiring gene knockdown.
Synthetic small interfering RNA (siRNA) molecules
A. Fire et al, demonstrated that the introduction of long dsRNA (>500 nt) can induce 
specific gene silencing in C. elegans (Fire 1998). In mammals, however, introduction of 
such large RNA molecules activates an interferon response normally used in viral 
infections, and ultimately results in cell apoptosis (Lee and Esteban 1994). At first, this led 
to a roadblock in RNAi-mediated gene silencing in mammalian cells, however, a 
breakthrough was made upon the discovery that short (<30 nt) synthetic dsRNAs, termed 
siRNAs, could initiate RNAi-induced gene knockdown without eliciting the interferon 
response (Elbashir 2001). Several studies have since used synthetic siRNA, or similar 
versions, to elicit specific gene knockdown through the RNAi pathway, proving this 
genetic tool to be a powerful means of studying mammalian gene function (Simpson 2008; 
Brie 2009; Smolen 2010 and Lara 2011).
One advantage of siRNA molecules is that due their small size (~22nt) requirement, the 
chemical synthesis of synthetic siRNA is quick and easy for manufacturers (Sandy,
Ventura and Jacks 2005). This is a major bonus when utilizing these molecules in gene 
knockdown experiments because the turn around time is quick and the costs are low. 
Another bonus of siRNA is that these molecules generate quick and robust knockdown in 
cells in vitro, because they can immediately associate with the RISC complex in the cell 
cytoplasm following delivery, negating Dicer (Lochmatter and Mullis 2011). Despite their 
rapid trigger of gene knockdown, siRNA molecules are diluted out in rapidly dividing cells 
and gene knockdown is only transient (maximum 1 week) in this context and costs could 
increase if the knockdown is needed over a longer time course, presenting major 
drawbacks to these molecules (Sandy, Ventura and Jacks 2005). Another potential
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drawback is that siRNA must be delivered in a liposomal carrier, such as a transfection 
reagent, that will interact with the cell membrane and be taken up by the cell. While 
liposomal transfection agents can be user friendly, they often come at a high cost and 
further drive up the price of gene silencing in experiments where prolonged gene 
knockdown is necessary. Furthermore, not all cells are permissive or ‘easy to transfect’ and 
so gene knockdown in this fashion would not be feasible (Sandy, Ventura and Jacks 2005). 
These drawbacks of siRNA can be overcome by the introduction of short-hairpin RNAs 
(shRNAs) and viral transduction methods.
Plasmid short-hairpin RNA (shRNA) molecules
Short-hairpin RNAs are produced from single-stranded molecules of 50-70 nts that form a 
stem-loop, or hairpin, when the single strand folds back onto itself. A loop is formed 
because the molecule is designed to have two complementary 19-29 nt RNA fragments 
(the stem), leaving 5 to 10 nucleotides to form a loop from a lack of complementary base 
pairing in this region. The shRNA-encoding DNA fragment is almost always ligated into a 
DNA plasmid for ease of delivery. Once inside the nucleus, the shRNA-encoding DNA is 
transcribed into RNA, with the hairpin secondary structure intact, using RNA polymerase 
III promotors (for example; tRNA-val , U6 and HI) (Sandy, Ventura and Jacks 2005). A 
benefit to transcription using Pol III promotors is that they are active in all cell types 
providing continuous expression of the shRNA (Sandy, Ventura and Jacks 2005). 
Following transcription, the shRNA is transported to the cytoplasm and recognized by 
Dicer. Dicer essentially cleaves off the loop portion of the hairpin and the resulting product 
is identical to siRNAs (made of ~22nt and with 2-nt 3’ overhangs) and is subsequently 
incorporated into RISC (Lochmatter and Mullis 2011). One huge advantage of using 
shRNAs incorporated into plasmid vectors is that gene knockdown can persist over time 
from stably transfected plasmids carrying an antibiotic resistance gene. Also, the 
introduction of an shRNA into a retro-or lentiviral vector allows for the stable integration 
of shRNA and antibiotic resistant genes into the genome for indefinite expression under 
antibiotic pressure (Dickins 2005). The use of viral vectors to carry shRNAs into the cell 
also circumvents the issue of the transfection-resistant cells since virus particles can infect 
many cell types including non-dividing, primary cells. A potential fallback of the viral
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vector shRNA delivery system is that there is more start-up time for experiments because 
the shRNA must first be cloned into the viral vector, which could also introduce shRNA 
sequence errors, followed by ‘packaging’ of the vectors into virus particles for cellular 
transduction. Another fallback of the viral vector delivery system is the risk of shRNA 
integration into the host genome at undesirable locations. Retroviruses prefer to integrate 
near transcriptional start sites and this enhances the possibility for gene perturbation in host 
cells (Liu and Berkhout 2011). Self-inactivating (SIN) vectors have been developed to 
rectify this problem by removing regions on the viral vector that may interfere with cellular 
gene expression (Liu and Berkhout 2011). Also, lentiviruses have been used for shRNA 
delivery more frequently due to their preference to integrate within introns of active 
transcriptional units, which limits their ability to interfere with coding genes (Liu and 
Berkhout 2011).
Plasmid short-hairpin RNA-microRNA (shRNA-mir) based molecules
This new class of synthetic RNAi triggering molecules improves upon previous shRNA 
designs by taking into account the expanded knowledge of the RNAi pathway in 
mammalian cells. Initially, shRNA constructs were based upon a somewhat simple hairpin 
RNA, identical to the pre-miRNA intermediate (Silva 2005). When these constructs were 
made, understanding of the miRNA maturation process was still incomplete, in particular, 
the involvement of primary or pri-miRNA and the interaction it has with Drosha. In light 
of the advances made in our understanding of miRNA maturation, a new generation of 
shRNA constructs (shRNA-miR) have been developed and are modeled after more 
naturally occurring miRNAs, specifically, the primary miR-30 backbone. The actual 
design of the microRNA-30 based hairpin design evolved from the fact that endogenous 
primary miRNAs require a long flanking sequence (Silva 2005). MicroRNA-30 based 
hairpin design, therefore, incorporates a 125 nt flanking sequence on both the 5' and 3’ 
ends of the hairpin that was derived from the human miR-30 primary transcript sequence 
(Silva 2005). The hairpin stem consists of 22 nt of dsRNA, complementary to the gene 
target of interest, and a 19nt loop from human miR30 (Silva 2005). This design adds a 
Drosha processing site to the hairpin construct and results in 12-fold increase in Drosha 
and Dicer processing of the expressed hairpins when compared with conventional shRNAs
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(Silva 2005). Furthermore, gene suppression is more effective in this new ‘natural’ 
redesigned molecule in comparison to the simple hairpin design, possibly because miR-30 
based design is more effective in producing mature synthetic miRNAs (Boden 2004 and 
Silva 2005). For example, in mammalian cells infected with laboratory strain of HIV-1, 
the miR-30 design was 80% more effective in knocking down the HIV tat protein than 
conventional shRNAs (Boden 2004). The majority of primary miRNAs are transcribed by 
RNAse II polymerase at Pol II promotors (CMV, MSCV) (Silva 2005). A comparison of 
the knockdown efficiency of shRNA-miRs, driven by various promoters, demonstrated that 
shRNA-miRs are more highly expressed by the pol II promotor CMV or, interestingly, the 
U6 pol III promotor (Silva 2005). Therefore, the incorporation of either a U6 or CMV 
promoter is often used in the design of shRNA-miR vectors to give the most consistent 
repression.
These second generation shRNA molecules, shRNA-miRs, can be delivered either by 
transfection or transduction, both of which introduce the stable expression of shRNA and 
mediate long term gene knockdown in many cell types. The same drawbacks of 
conventional shRNA are applied to the new design, since the effect of genome integration 
following viral infection is not guaranteed to provide insertion into inert locations and 
spare host cell gene expression. However, as mentioned above, precautions have been 
taken to avoid such events. Some added benefits of the newly designed molecules, aside 
from the obvious enhanced gene knockdown, are that many companies are offering viral 
particles with pre-packaged constructs, at an added cost, but allowing for less start up time 
for experiments. Also, since mir-30 shRNA designs are more naturally occurring in the 
cell, they are less likely to interfere with endogenous gene regulation unlike shRNAs and 
siRNAs that skip Drosha processing, and siRNAs that also skip Dicer processing, and can 
effectively ‘monopolize’ the RISC complexes and halt endogenous gene regulation by 
microRNA (Lochmatter and Mullis 2011).
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G e n o m e - w id e  g en e  k n o c k d o w n  u sin g  shRNA L ibra ries
Since the phenomenon of RNAi was first discovered 13 years ago, progress has been made 
in understanding the biosynthesis of molecules within the pathway, and this knowledge has 
been used to generate effective gene silencing. Today, RNAi is a useful genetic tool to 
study the function of individual genes in the context of many experimental conditions. In 
addition, collections of RNAi effector molecules, whether siRNA, shRNA or shRNA-miR, 
have been pooled together to represent almost all annotated genes in both the human and 
mouse genomes. In this manner, an abundance of screens for loss-of-function phenotypes 
have been reported, many using one of the commercially available ‘libraries’ in 
mammalian cells. All of the RNAi screens to date are based on the method of integrating 
one shRNA expression vector per target cell, subsequently leading to knockdown of one 
gene per clone, and reducing confounding results of multiple gene silencing (Boettcher and 
Hoheisel 2010; Lara 2011; Simpson 2008 and Smolen 2010). Identification of the shRNA 
template sequence in each cell, by means of a molecular tag, can then be easily performed 
in smaller screens by PCR amplification of the molecular tag, followed by sequencing or in 
larger screens by microarray hybridization techniques. The published RNAi screens to date 
are representative of the feasibility of these shRNA libraries and have contributed to major 
improvements and rigorous quality control measures made on these commercially 
available libraries over the last 6 years. Pooled shRNA libraries have proven to be effective 
tools for performing high-quality, high-throughput screens both in cell culture end point 
assays and when applied to screening for phenotypic attributes of cells in vivo.
Commercially available shRNA libraries
Due to the demand for RNAi technology, at least three shRNA-based libraries have been 
made commercially available. These libraries differ with respect to the amount of human 
genes they can target, the amount of shRNAs covered each gene, the means by which 
shRNAs are identified, the type of shRNA molecule and even the vector backbone used to 
carry the shRNA cassette.
Two of the commercially available libraries were selected to compare in this discussion as 
they were used to carry out two distinct aspects of the thesis project: 1) the Hannon and
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Elledge library (H&E) and 2) The RNAi Consortium (TRC). A substantial portion of the 
H&E library was used to carry out a screen for mediators of migration in a cancer cell line, 
while individual constructs from the TRC library were used to establish a proof of 
principle for the migration screen.
Hannon and Elledge
The Hannon and Elledge (H&E) library has gone through considerable changes over the 
past 6 years beginning with the construction of their first generation library to the creation 
of a second-generation library covering 32,216 human genes (as of June 2006) (Chang, 
Elledge and Hannon 2006). H&E first generation libraries are composed of 29 nt shRNAs, 
made to mimic pre-miRNAs. Conversely, second-generation shRNA expression libraries 
consist of >125 nt shRNA-miRs, modeled after the naturally occurring primary miR-30 
transcript (Silva 2005). The new libraries are substantially improved over their first- 
generation counterpart and are 12 times more effective in producing siRNA molecules 
(Silva 2005).
For construction of the second generation library, ‘Ink Jet’ synthesis (Agilent 
Technologies, Inc.) was used to make 22-24 thousand oligonucleotides per microarray, 
each containing a different shRNA-miR construct (Cleary 2006). In this manner, >195 000 
oligonucleotides, representing more than 32, 000 known and predicted genes in humans, 
was generated (Silva 2005). The shRNA inserts were eluted from the glass array and 
amplified by polymerase chain reaction (PCR) so that they could be inserted into the pSM2 
retroviral vector in pools (Cleary 2006 and Silva 2005). Altogether, 87,283 shRNAs 
targeting 32,216 human genes and 76,896 shRNAs targeting 30,629 mouse genes have 
been created using inkjet synthesis for the second generation library (Chang, Elledge and 
Hannon 2006). While 34% of the human genes represented in the library are covered by 3 
shRNAs, the goal is to generate at least three shRNAs for each target gene (Chang, Elledge 
and Hannon 2006). The full collection of mouse and human shRNAs can be accessed at 
RNAi Codex (http://codex.cshl.edu/).
A U6 promoter drives expression of the shRNA-miR, however shRNA inserts can be 
easily moved into different vectors with alternative promoters, such as CMV, via a
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recombination strategy (Silva 2005). This modification has been performed by Open 
Biosystems to create the lentiviral pGIPZ construct, and uses the CMV promoter to drive 
shRNA-miR expression.
Immediately following each miR-30 cassette is a RNA polymerase III termination signal 
and a randomly generated 60-nt ‘barcode’ region to identify individual shRNAs in large 
populations (Silva 2005). In general, molecular tags such as the H&E ‘barcodes’ work by 
PCR amplification of sequences unique to the shRNA construct but using primers common 
to all constructs (Boettcher and Hoheisel 2010). In this manner, all genomic DNA is 
collected, following infection of a population of cells, and the PCR product amplified from 
the genomic DNA contains multiple tags, representative of many different shRNAs 
introduced into the population. The PCR products are ubiquitously labeled with a 
fluorescent dye and each labeled tag will hybridize to complementary sequences spotted on 
the oligonucleotide microarray (Boettcher and Hoheisel 2010). Each spot is of a known 
sequence and so identifies the shRNA linked to the fluorescent tag. In this way, the 
abundance of given shRNAs in a cell population are indirectly analyzed by signal intensity 
as a complementary tag binds. This is a quick technique to detect the gain and loss of 
signal for shRNAs, and thus the genes with positive and negative effects on a cell 
population.
The molecular tag used by the H&E libraries are external 60 nt barcode, present in every 
shRNA-miR expression vector, and are an exclusive feature of the H&E library (Boettcher 
and Hoheisel 2010). Although other libraries have molecular tags to identify the encoded 
shRNA inserts, the H&E barcode is unique because it is located downstream from the 
shRNA template and was sequence validated, linking each barcode to a given shRNA 
expression construct (Boettcher and Hoheisel 2010). In contrast, the H&E libraries that are 
used to perform smaller scale screens can, like other commercially available libraries, use 
the actual shRNA hairpin sequence, with the forward primer upstream of the hairpin, and 
the reverse primer downstream, so that the actual shRNA is sequenced for gene 
identification (Boettcher and Hoheisel 2010).
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The RNAi Consortium (TRC)
The RNAi Consortium (TRC) library was in production at the same time as the H&E 
library, however, this library has taken a different approach: resulting in far less genome 
coverage than the H&E library, but double the number of shRNAs covering each 
individual gene. Specifically, the TRC library covers 14, 538 human genes, however, the 
amount of shRNAs created between the two groups are almost the same: 77,301 shRNAs 
for TRC (July, 2006) and 87,283 for H&E (June 2006) (Root 2006 and Chang, Elledge and 
Hannon 2006). The significance of taking such an approach is to increase the confidence 
in positive hits by avoiding ‘off-target effects’, or occasions where shRNAs will bind 
unintended sequences, thereby knocking down the wrong gene. In this respect, the H&E 
library falls short with half the number of shRNAs/gene target compared to the TRC 
library.
To the dismay of the scientists involved in the design of the TRC library, their library was 
constructed using the pre-miRNA model, containing 21-nt stems and a 6 nt loop, as an 
RNAi trigger. Although engineers of the H&E library showed a significant increase in 
siRNA production using more ‘natural’ shRNA-miR-30 constructs, the TRC library does 
not contain this technology and the scientists involved explain that it is “important to 
determine whether improved knockdown is due to the miRNA context, or whether other 
shRNA design and vector attributes are more important for enhanced gene suppression” 
(Silva 2005 and Root 2006). TRC library shRNAs were originally produced using 
conventional oligonucleotides synthesis, but have since been produced in a similar manner 
to H&E library using chip synthesis of oligomers to reduce cost. Harvested shRNA 
oligomers were then amplified and cloned into the pLKO.l vector (Root 2006).
The TRC library is composed of a simple vector design, containing the shRNA cassette in 
the pLKO.l vector. pLKO.l, like the pGIPZ vector, is a third generation, self-inactivating 
lentiviral based vector. Self inactivating (SIN) vectors are designed so that the viral 
particles can package the shRNA containing vector for delivery to cells, however once 
inside the cell, the viral particles do not have the capacity to replicate and so the cell will 
not harbor a viral infection and user safety is enhanced (Root 2006). Furthermore, third 
generation lentiviral vectors are generated using a three-plasmid packaging system that
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separates essential viral assembly genes: gag, pol and rev and the gene encoding VSV-G 
envelope or viral coat protein into separate vectors (Root 2006). This minimizes the 
possibility of these sequences recombining into viruses that have the capacity to replicate. 
Also, as mentioned previously, SIN vectors are designed to insert into non-coding regions 
of the genome, to reduce the risk of interfering with endogenous gene expression (Liu and 
Berkhout 2011). In both H&E and TRC libraries, the U6 promoter is used to drive 
expression of the shRNA cassette, and the PKG promoter is responsible for expression of 
the puromycin resistance gene to allow selection of transduced cells. An exception is the 
pGIPZ version of the H&E library, which relies on the CMV promoter to drive expression 
of both the shRNA-miR and the puromycin resistance gene, however there is an internal 
ribosomal entry site or IRES before the puromycin resistance gene to help ensure its 
expression. The TRC library uses half-hairpin tags as a method to identify shRNA 
constructs. Half-hairpin tags are made useful by PCR amplification of the antisense strand 
of the shRNA sequence itself.
Finally, it should be noted that in both libraries 1 out of 3 shRNA expression constructs, 
targeting a given gene have been verified to knockdown gene expression by at least 70% 
(Boettcher and Hoheisel 2010). However, this information must be taken with a grain of 
salt, as not all cell lines will behave in a similar manner to the cell lines used for validation 
by the commercial suppliers.
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Table 1: Comparison of Key Features of Hannon and Elledge (H&E) and The RNAi
Consortium (TRC) Commercially Available shRNA Libraries
Hannon and Elledge (H&E) The RNAi Consortium (TRC)




Partnered with Ontario Institute 
of Cancer Research (OICR)
Retroviral Vector pSM 1 (1st generation) 
pSM2 (2nd generation) None
Self-inactivating





Number of Genes Covered As of June 2006: 
32,216 human genes 
87,283 shRNAs
As of July 2006: 
14,538 human genes 
77, 301 shRNAs





shRNA insert shRNA-miR-30 shRNA
(primary-miRNA RNAi trigger): (pre-miRNA RNAi trigger):
22 nt stem,
19 nt loop,
flanked by 125 nt of miR-30 
sequence on both 5’ and 3’ end of 
stem
21 nt stem, 
6 nt loop
Molecular Tag 60 nt external barcode or hairpin Half -hairpin
Adapted from Boettcher, M. and Hoheisel, J.D. Current Genomics (2010),! 1:162-167
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Screening for mediators o f migration using sltRNA libraries
Genetic screens to identify genes involved in a phenotypic outcome are becoming 
increasingly popular ever since the introduction of highly efficient, commercially available 
RNAi libraries for mammalian cells. Many of the screens in the literature are aimed at 
understanding molecular pathways involved in human cancer cells. These screens have 
focused on the hallmarks of cancer including, but not limited to: cell proliferation 
pathways, tumor suppressor genes, genes involved in metastasis and genes required for cell 
migration. These screens have greatly increased our understanding of the progression of 
cancer and identified novel markers of cancer for further study. RNAi screens for cell 
migration in human cancer constitute a relatively small subset of cancer related genetic 
screens and 100% of RNAi screens for cancer cell migration are performed in vitro. In this 
section I will introduce a few key genetic screens that have been performed in human 
cancer cells, to identify mediators of migration, with a focus on the methods used to 
measure cellular migration, and one genetic screen that has been performed in vivo, 
however, not directly looking at cancer cell migration.
Screening for mediators of migration in vitro
Wound healing
One of the early cell migration-based RNAi screens published, was performed in MCF- 
10A cells, an immortalized, yet non-tumorigenic, breast epithelial cells using a ‘scratch 
wound’ or wound healing assay (Simpson 2008). The scratch wound assay involves plating 
cells to confluence, after which a wound is made in the layer of cells. The cells are imaged 
at time zero, and a given time after the wound is made, and the rate at which the wound 
closes is related to the migration capacity of cells as they move towards the center. One 
parameter that must be normalized, or at least taken into account when performing this 
assay, is the cell proliferation status between the cells containing various siRNA 
constructs. An siRNA that causes cell proliferation or decreases cell proliferation could 
influence the number of cells breaching the wound area, therefore, the assay would 
represent a measurement of proliferation rather than migration. To accommodate for this, 
some groups have characterized the rate of proliferation for cells prior to experimental
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testing using chemical based assays such as MTT. MTT or 3-(4,5-Dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide, is a yellow tetrazole that, when in living cells, is reduced 
to purple formazan by mitochondrial enzymes (Scudiero 1988). The intensity of the purple 
is read by a spectrophotometer and corresponds to the amount of live cells per well. 
However, another method was employed by J.A Brugge's group and includes the use of 
another chemical reagent, Alamar Blue to test the cytotoxicity, or reduction in cell 
numbers upon addition of each siRNA on the MCF-10A cells just prior to wounding the 
cells (Simpson 2008). Alamar blue is a membrane permeable, non-toxic dye that upon 
reduction by living cellular enzymes, produces a measurable fluorescent signal and is, 
therefore, a measure of cell viability, proliferation and metabolism (Simpson 2008). Two 
siRNA libraries, targeting a total of 1,081 human genes, were used to perform the screen 
for migratory genes in MCF-10A cells. One library of siRNAs covered the human 
phosphatase and kinases and the other was a migration and adhesion related (MAR) 
library, targeting known or predicted genes involved with migration (Simpson 2008). 
Transient knockdown of siRNAs that reduced or accelerated migration were then validated 
using a second trial of scratch wound assays, however with individual shRNAs from TRC 
targeting the same genes. In this respect, knockdown of genes identified as being important 
to migration from the first scratch wound assay, were confirmed by stable gene knockdown 
in a second scratch wound assay.
This 2008 screen, performed by J.S. Brugge’s group, paved the way for future screening 
for cell migration mediators, identifying 66 validated and high confidence genes involved 
in migration, 42 of which were not previously associated with motility or adhesion. 
However, this screen is still lacking a measure of physiological cell migration since the 
screen is performed as cells randomly migrate across a rigid substratum, without a matrix 
to recapitulate cell movement in vivo. As discussed in the cell migration section, cell 
adhesion molecules (CAMs) signal to internal regulators of migration based on their 
interactions with the ECM and environmental cues such as chemoattractants, resulting in 
the release of proteases, invasive structures, and exhibiting directional cell migration in 
realistic 3D environments. In a plastic dish, the invasive structures, such as invadopodia, 
may not form due to the lack of substratum to ‘burrow’ into. In addition, proteases may not 
exert their normal functions in a plastic dish or their secretion may be downregulated due
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to the lack of invadopodia formation. In addition, CAMs, such as integrins, initiate 
signaling upon binding to collagen or fibronectin and receive signals from neighboring 
receptors associated with growth factor ligands. Without such matrices and external 
stimuli, the cell migration witnessed in this initial screen may not reflect true mediators in 
an in vivo context, whereby cells move with directionality towards a stimulus using 
structures necessary to manipulate 3D environments.
Boyden Chamber
In the two years following the scratch wound-based screen for migration-associated genes, 
at least two additional screens for cell migration emerged, however they were both based 
upon migration through a boyden chamber. Boyden chamber assays measure the ability of 
cells to move across a perforated plastic membrane, usually with pores about 8.0 um in 
size. Cells are suspended in serum free, chemoattractant-free media in the upper chamber, 
above the membrane. Over a time course of about 18-48 hours, cells that have the capacity 
to migrate will move through to the opposite side of the membrane, thus the membrane 
acts as a physical barrier between the less migratory and more motile cells. Furthermore, 
the cells travel towards a lower chamber containing a chemoattractant, such as serum, so 
that the migration is directional. The physical separation between the migratory vs non- 
migratory cells is an attractive feature for RNAi screening because cells that make it across 
the membrane can be harvested, and the hairpins identified by conventional PCR 
(Finlayson and Freeman 2009 and Smolen 2010). Individual shRNAs can also be 
introduced into separate cell populations that are then placed in their respective chambers 
followed by a quick staining of the bottom of the membrane for a direct comparison of 
migration between cells infected with various shRNAs (Smolen 2010). In their study, G.A 
Smolen et al. performed an RNAi screen using 55, 000 pooled lentiviral shRNAs from the 
TRC library targeting ~11,000 genes using MCF-10A cells (Smolen 2010). They 
performed a primary screen, allowing cells to migrate through the transwell of a boyden 
chamber, towards a chemotactic stimulus, following infection with the shRNA library 
(Smolen 2010). Cells that migrated were considered 'highly migratory’ and they were 
harvested for shRNA identification (Smolen 2010). shRNAs identified through this 
primary screen could then be individually infected into MCF-10A cells so that
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confirmation of the increased migratory capacity could be re-examined by staining the 
bottom of transwell membranes for direct comparison between various shRNAs (Smolen 
2010). A.E. Finlayson and K.W. Freeman also performed a cell motility screen using 
boyden chambers, however in these chambers, the membranes were overlaid with 
Matrigel ™ to select for pro-invasive genes (Finlayson and Freeman 2009). Matrigel ™ is 
a proprietary basement membrane extract composed of extracellular matrix proteins and 
thus acts as an in vitro 3D-model of cell migration, recapitulating the in vivo phenotype to 
a higher degree than the membrane-only boyden chamber and the scratch wound assay.
Screening for mediators of migration in vivo
Although the boyden chambers, with Matrigel™ inserts, are a better representation of the 
3D environment cells normally migrate in and provide matrix proteins to facilitate 
downstream signaling by CAMs, they are still lacking a true in vivo setting. An in vivo 
setting includes interactions between not just the migrating cells in question, but also the 
surrounding stroma cells, immune cells, blood vessels and the multitude of components in 
the ECM including ligands acting as triggers of downstream signaling. An elegant study 
for the identification of tumor suppressors in a spontaneous lymphoma mouse model 
highlights the ability to perform large RNAi screens in vivo (Brie 2009). In their study, A. 
Brie et al. took fetal mouse liver hematopoietic stem cells (HSCs) with a Eu-Myc 
background, so as to facilitate lymphoma progression, and infected them with the ‘Cancer’ 
1000 set (collection of shRNA-miR-30 molecules targeting 1000 cancer related genes from 
the H&E library) (Brie 2009). To establish a phenotype for screening, irradiated, syngenic 
recipients were injected by tail vein with the shRNA-miR-30 containing stem cells and 
onset of lymphoma was monitored in the animals receiving shRNA-containing cells versus 
control shRNA-containing cells (Brie 2009). In this study, the phenotype was 
tumourogenesis instead of cell migration, however this screen invites others to try an in 
vivo screen where the phenotype is cell migration. The caveat is that mouse models are not 
transparent and so witnessing a phenotype for cell migration is not straightforward. 
Furthermore, to perform a representative screen of a large portion of the human genome, 
not only would an exorbitant amount of animals need to be used, but also the animals 
would need to be tolerant to human cancer cells. In the next section, I will introduce an
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animal model that is conducive to witnessing cell migration phenotypes using intravital 
imaging, is cost effective when performing large-scale RNAi screens and can tolerate 
human cells: the ex-ovo chicken embryo model.
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1.4 A Model of Human Cancer Cell Migration: The Ex-Ovo 
Chicken Embryo
The chicken embryo model offers many advantages for performing cell migration and 
metastasis assays including: (1) an immunodeficient host that is permissive to 
transplantation of foreign tissues, including human cancer cells, (2) a platform for analysis 
of the different stages of metastasis using either an experimental or a spontaneous mode of 
cancer dissemination, (3) accessible membranes that are external to the embryo and 
contain vasculature, stroma cells and extracellular matrix components to recapitulate the 
tumour microenvironment and provide a ‘window’ into visualizing cancer cell movement, 
and (4) is inexpensive and establishes tumorogenesis and metastasis within 7 days, saving 
time and labor.
At the heart of the chicken embryo model is the chorioallantoic membrane or CAM. This 
specialized tissue is attached to the eggshell and can be liberated by removal of a ‘window’ 
of shell for experimental manipulation and observation. The ex-ovo chicken embryo model 
provides even easier access to the CAM by allowing the embryo to develop outside of the 
egg. In this manner, the CAM is fully exposed and can be utilized for cancer cell growth, 
invasion and migration studies.
1.4.1 Anatomy of the Chicken Embryo Used to Study Cell Migration
The chorioallantoic membrane (CAM) is a versatile organ for studying cancer cell 
migration and invasion due to its capacity to support human tumour cells and the ease at 
which cancer cells can be monitored. The CAM is formed between days 5 and 6 of embryo 
development by the fusion of the chorion and allantois for the purpose of gas exchange 
between the blood vessels within the CAM and the porous eggshell (Ribatti 2010). The 
CAM is an extremely thin organ (lOOum thick) and is composed of three, distinct layers 
(Figure 1.4.1) (Deryugina and Quigley 2008). The ectoderm is a one or two-cell epithelial 
layer that attaches to the shell membrane or at the air interface in ex-ovo models 
(Deryugina and Quigley 2008). At day 10 of development, the ectoderm is fully developed 
and contains a capillary plexus (network of capillaries), which serves as one of the most 
important features of the CAM in regards to invasion and metastasis (Ribatti 2010). The
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ectoderm capillary plexus supports transplantation of human cancer cells and promotes 
tumour progression through the formation of new blood vessels (neoangiogenesis) that 
feed the growing tumor (Deryugina and Quigley 2008). Underlying the ectoderm is the 
mesoderm that contains blood vessels, terminal capillaries, fibronectin, laminin and type 
IV collagen fibers, and stromal cells (Deryugina and Quigley 2008). Finally, the endoderm, 
composed of a monolayer of cells, along with the ectoderm effectively ‘sandwiches’ the 
mesoderm. (Deryugina and Quigley 2008). Since the CAM is thin, transparent, and is the 
outermost layer of the embryo, experimental injection of fluorescently labeled human 
cancer cells into the vasculature of the embryo permits cancer cell visualization using a 
standard upright fluorescent microscope. Following injection, cancer cells are seen first 
within vessels, and later, post-extravasation, the cells can be observed within the stroma. 
Alternatively, cancer cells can be inoculated directly onto the ectoderm of the CAM and in 
this spontaneous model of invasion; cancer cells can be directly visualized at the tumour 
cell border invading into the stroma.
1.4.2 Methods Used to Study Cell Migration and Metastasis in the 
Chicken Embryo
Experimental Metastasis Model
The experimental model of metastasis in the ex-ovo chicken embryo involves the injection 
of human cancer cells directly into the vasculature, after which, the cells will circulate 
throughout the embryo and transmigrate into tissues at the site of extravasation. The tissues 
that tumour cells arrest in post-extravasation include not only the CAM, but also organs 
such as the lung, liver, and brain. When cells arrest in the ectoderm of the CAM, however, 
they have extravasated out of the capillary plexus and migrated through the stroma, 
oftentimes towards arterioles in which they wrap themselves around before proliferating 
into micrometastases (Chambers 1995). In the experimental model of metastasis, the 
formation of micrometastases begins within hours of injection and although growth of 
micrometastases are dependent on the proliferation rate of the cell line, most aggressive 
cancers achieve sizable colonies within 7 days. The downside to the experimental model is 
that the early steps of metastasis, such as invasion and intravasation into the blood vessels
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are eliminated, however, local invasion of cells from progressing micrometastases can still 
be observed as well as the capacity for these cells to colonize different tissues.
Spontaneous Metastasis Model
Topical administration of cancer cells
The CAM model for spontaneous metastasis takes into account the early steps of 
metastasis, tumor cell invasion from the primary tumour and intravasation into the 
vasculature. This model involves the topical inoculation of 20-30ul of human cancer cells 
onto the surface of the ectoderm following the abrasion of this membrane to promote local 
angiogenesis. Depending on the number of cells inoculated and their rate of proliferation, 
most primary CAM tumours are in the range of 200-600 mg after 7 days post 
transplantation. Simultaneous to tumour growth, aggressive tumour cells can invade the 
surrounding stroma and intravasate into blood vessels, causing their dissemination to 
distant organs. At these organs, cancer cells can grow into micrometastases that are visible 
by fluorescence microscopy of fluorescently labeled cells or by histological analysis. In 
this manner, all of the steps of the metastatic cascade are performed, however, this process 
is over 6-7 days rather than the typical 4-10 weeks for murine models (Ribatti 2010).
Bolus administration of cancer cells
The spontaneous model of metastasis can also be accelerated by the inoculation of tumour 
cells directly into the mesoderm. This procedure is reminiscent of the subcutaneous 
injection of tumor cells in murine models and introduces a ‘bolus’ of cancer cells that 
generate an immediate mass of cells mimicking the primary tumour. Cells that have been 
inoculated into the CAM by ‘bolus’ injection can be imaged immediately, however after 3 
days, most boli resemble similar sized tumour to topically administered cells and are more 
appropriate for study (Deryugina and Quigley 2008).
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Figure 1.4.1: The ex-ovo chicken embryo model
The chorioallantoic membrane (CAM) is utilized by the embryo for gas exchange between blood vessels and 
the porous eggshell. The ex-ovo chicken embryo model allows for the embryo to develop outside of the egg, 
providing full exposure of the CAM for cancer cell growth, invasion and migration studies. The CAM is 
composed of three layers as depicted by a cross-sectional view: the ectoderm, a one or two-cell epithelial 
layer that contains a capillary plexus (network of capillaries), the mesoderm that contains blood vessels, 
terminal capillaries, fibronectin, laminin and type IV collagen fibers, and stromal cells and finally, the 
endoderm, composed of a monolayer of cells. Experimental injection of fluorescently labeled human cancer 
cells into the vasculature of the embryo (Experimental metastasis assay) permits cancer cell visualization 
following injection, first within vessels, and later, post-extravasation, the cells can be observed within the 
stroma. Alternatively, cancer cells can be inoculated directly onto the ectoderm of the CAM (Spontaneous 
metastasis assay) and can be directly visualized at the tumour cell border invading into the stroma. Another 
means to perform the spontaneous assay is injection of a ‘bolus’ of cells directly into the mesoderm of the 
CAM, forming primary tumours (Spontaneous metastasis assay (Bolus)).
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Intravital Imaging of Cancer Cell Migration
In addition to evaluating the capacity for cells to metastasize to distant organs by tissue 
harvesting, the experimental mode of metastasis can be used to visualize cancer cells 
within the stroma, post-extravasation, to monitor their motility. Similarly, the spontaneous 
mode of metastasis can also be used to monitor early events of metastasis, such as invasion 
and migration, by intravital microscopy of cells at the transplanted tumor border 
(Deryugina and Quigley 2008 and Wyckoff 2000). A. Chambers et al. explain that 
intravital video microscopy (IVVM) allows cancer cells to be ‘watched’, in vivo, thus 
proving inferences about cancer cell migration and metastasis that were previously inferred 
from histological samples or end-point animal assays (Chambers 1995). Intravital video 
microscopy uses a camera attached to an epifluorescent or light microscope to visualize 
and record cell movement whether it be within the CAM or another animal model. The 
drawback of intravital video microscopy is that tissues have to be inherently thin and 
remain immobilized in order to transilluminate them as well as keep the cells within them 
in focus. The chicken embryo ex-ovo model, is the ideal model for witnessing cancer cell 
migration using intravital imaging because of how thin and accessible the CAM is. Using a 
modified immobilizing-incubation chamber, fitted with a coverslip that is placed over the 
area of interest, the CAM, and the cancer cells within it, are easily immobilized for the 
production of focused videos. A fluorescent microscope can be used to illuminate the 
CAM and excite fluorescently labeled cancer cells within the tissue without any 
background signal.
In other animal models, imaging cancer cell movement is not as straightforward because 
the organs to be imaged are not transparent, or the animal must undergo surgery, 
anesthetization or both. Although intravital imaging of cancer cell migration has been 
demonstrated in murine models, the technique involved is invasive and laborious (Morris 
1993 and Wyckoff 2000). In mouse models, the labeled cancer cells are either injected into 
the blood circulation, which may require surgery to reach a vessel of interest, or injected 
subcutaneously. Tumour progression then occurs to the desired stage: immediately, if 
capturing extravasation events from cells injected into the vasculature, and up to 3 weeks if 
capturing invasion events from cells implanted subcutaneously (Morris 1993 and Wyckoff
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2000). In either event, the mouse must be anesthetized and undergo surgery to reveal the 
cancer cells underneath the skin (skin flap surgery) or in the desired organ. Most 
concerning is the possibility of disrupting the vasculature, which could have profound 
influences on cell migration and metastasis during these surgeries. Also, the organs and 
tissues must be perfused with saline to maintain hydration, which is not only time 
consuming, but without careful manipulation, may influence the pressure in the 
surrounding tissues containing the cancer cells. Oftentimes, these murine intravital 
experiments can only be performed in limited occasions, and this not only increases the 
amount of animals used, but also contributes to variation amongst animals.
Another model used to capture cell migration using intravital, real-time imaging is the 
zebrafish embryo model (Stoletov 2010). The zebraflsh is immunodeficient, transparent 
and can be transgenic to express fluorescent protein throughout the entire embryo. These 
qualities make the zebrafish an excellent candidate to image cancer cell migration in 
action, however, there are still drawbacks to using this model. For instance, animals must 
still be anesthetized prior to imaging and cancer cells may not be located near the exterior 
of the fish, resulting in the requirement for confocal microscopy to acquire a high 
resolution image, which is more complex and not as ubiquitously found in laboratories.
A lu  Polymerase Chain Reaction (PCR): A quantitative measure o f metastasis
In both spontaneous and experimental metastasis models, inoculation of cancer cells would 
normally not occur any earlier than day 9 of development. Since the embryos ‘hatch’ on 
day 21 of development, this leaves at the very most 12 days to complete a metastasis assay, 
whereby the organs are harvested and analyzed for micrometastases. Even the most 
aggressive cells do not usually form macroscopically visible colonies in the secondary 
organs in this short amount of time, making the detection of micrometastases the most 
difficult part of the assay. To remedy this situation, investigators have modified and tested 
the alu Polymerase Chain Reaction (alu PCR) method to detect very small populations of 
human cancer cells in secondary organs (Zijlstra 2002).
This extremely sensitive and quantitative method of analysis is based on the PCR 
amplification of human-specific-a/w sequences in a background of chicken embryo cells.
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The organs are harvested following a metastasis assay, and the mixed populations of 
human cancer cell DNA and chicken embryo cell DNA (from the particular organ) is 
extracted directly. Utilizing real-time PCR, the amount of human alu events are recorded 
per sample and permits comparison between highly metastatic cell populations inoculated 
into one embryo and low metastatic cell populations inoculated into another embryo 
(Zijlstra 2002). Creation of a standard curve, or known amount of human cancer cells 
mixed with the naive organ of interest, facilitates in the quantification of alu signal release 
from the samples by comparison to the standard curve.
This method of quantification has been shown to detect as low as 25 cells/lung in the 
chicken embryo model of metastasis demonstrating the sensitivity of the technique (Zijlstra 
2002). In addition, this method requires no processing past the PCR step, handles a large 
number of replicates, does not require the specialized microscopy seen with IVVM, and 
can be applied to both the spontaneous and experimental models of metastasis.
1.4.3 Screening for Mediators of Cell Migration in the CAM
Ra t io n a l e
Metastasis is the cause of 90% of cancer related mortalities (Hanahan and Weinberg 2000). 
Therefore, the primary motivation behind this project is to halt the metastatic cascade 
through the discovery of targets for anti-metastasis therapies. Compelling evidence that 
migration is a key player in metastasis was demonstrated by previous studies performed by 
our group whereby the inhibition of migration with a monoclonal antibody against human 
tetraspanin CD151, a transmembrane protein previously published to be involved in cell 
motility and metastasis, abolished metastasis (Johnson 2009 and Ke 2009). In this study, 
the systemic treatment of anti-CD151 mAb decreased in rear detachment of human 
adenocarcinoma and fibrosarcoma cells at the invasive tumor border, halting migration and 
metastasis for both cell lines in spontaneous models of metastasis for both the chicken 
embryo and the SCID mouse (Zijlstra 2008). These results highlight migration as an 
important step to focus on out of the various steps in metastasis.
In the same study, the human cancer cells were introduced into the chicken embryo via 
experimental metastasis assay. In this context, the tumour cells still proliferated to form
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micrometastasis in the stroma of the CAM, however, when treated by systemic 
administration of anti-CD151 antibody, the cells failed to invade into the CAM and 
remained tightly clustered (Zijlstra 2008). In other words, compared to ‘diffuse’ tumour 
colonies seen in the CAM with control cells, the tumor colonies seen upon treatment with 
the migration-blocking antibody established a ‘compact’ tumour phenotype in the CAM. 
consistent with a loss in cell migration.
Based on these findings, I propose that an experimental metastasis approach can be taken 
to perform an in vivo shRNA screen for targets that inhibit tumour cell migration in the 
CAM. Injection of fluorescently tagged, human epidermoid adenocarcinoma (HEp3) cells, 
harboring shRNAs against migration, can be screened using fluorescent microscopy and 
visually searching the CAM for the compact, migration-inhibited tumor phenotype. Since 
the CAM is transparent and exposed, it is straightforward to identify and retrieve non- 
migratory tumour cell colonies under a fluorescence stereomicroscope. Compact colonies 
or ‘hits’ will be cultured for PCR analysis of the shRNA hairpins corresponding to genes 
required for migration (Figure 1.4.2).
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Figure 1.4.2: Screening Strategy.
1. pGIPZ lentiviral vector containing shRNA-miR cassette. Contains puromycin selection marker and 
turboGFP for ease of detection upon infection. 2. Transfection of the helper cell with pGIPZ and accessory 
plasmids permits packaging of the pGIPZ construct into lentivirus particles. 3. A library of virus particles 
containing 10,000 shRNAs are purchased from Open Biosystems and are ready-to-infect into the cell of 
interest, HEp3. 4. The transduced cells are injected as a pool into the vasculature of the ex-ovo chicken 
embryo model (a) where they will extravasate into the stroma of the CAM and form many micrometastases 
(b). 5. Individual compact colonies are extracted from the CAM and sub-cultured in separate dishes under the 
selection of puromycin. 6. The genomic DNA is extracted from the each dish that pertains to an individual 
extracted colony. 7. PCR-mediated amplification of the shRNA, followed by sequencing, identifies the 
shRNA responsible for the compact colony phenotype.
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H y po t h e sis
1) Genes that are required for the migration of HEp3 cancer cells can be identified 
using a random, shRNA library screen for compact tumour phenotypes, using an in 
vivo chicken embryo metastasis assay
2) The inhibition of cortactin or rhoA, which are associated with poor prognosis and 
metastasis in many human cancers, will result in decreased cell migration and lead 
to abrogation of metastasis in the chicken embryo model and serve as positive 
controls for the RNAi screen
O b je c t iv e s
1) Establish optimal screening parameters in vitro and in vivo:
a. Calculate the functional multiplicity of infection (MOI) of human HEp3 
epidermoid adenocarcinoma cells for the Open Biosystems Decode RNAi 
viruses
b. Determine the amount of cells to inject per animal for maximal arrest of 
shRNA-containing cells in the CAM
c. Estimate the number of animals to provide 3X representation of the 5000 
genes covered in the screen (1 gene represented per tumour colony)
2) Establish a proof of principle using positive control shRNAs that target known 
mediators of cell migration, RhoA and Cortactin:
a. Knockdown of rhoA and cortactin mRNA transcripts using individual 
shRNAs in HEp3 cells
b. Assess the level of RhoA and Cortactin protein levels following RNAi- 
mediated knockdown in HEp3 cells
c. Determine the impact of rhoA and cortactin knockdown on cell migration 
for HEp3 cells in vitro
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d. Determine the impact of rhoA and cortactin knockdown on cell migration 
for HEp3 cells in vivo using intravital imaging
e. Characterize the proliferation rate of cortactin and rhoa knockdown cells in 
comparison to control cells
f. Measure the presence of liver métastasés using a spontaneous model of 
metastasis in the chicken embryo model using cortactin or rhoA inhibited 
HEp3 cells
3) Perform the RNAi screen for compact tumour colonies in vivo using HEp3 cells 
and a pool of 10 000 shRNAs covering 5000 distinct genes in the human genome
4) Identify targets of migration by performing polymerase chain reaction on sub­
colonies of extracted ‘hits’, using primers unique to the shRNA, followed by 
sequence analysis.
The preliminary results from the RNAi screen performed in this study indicate the 
feasibility of this screen, in particular, the ability to locate compact tumour colonies in the 
CAM following gene inhibition. Although the data is ongoing, it provides a basis for a 
larger scale screen, covering more genes in the human genome. The efforts made here 
ultimately contribute to the overall goal to identify targets whose loss-of-function 





2.1 Objective 1: Establish Optimal Screening Parameters In 
vitro  and In vivo
C a lc u l a t io n  o f  th e  fu n c t io n a l  m u l t ipl ic it y  o f  in fec tio n  (MOI) of HEp3 c ells  in  
vitro
A titration assay o f pGIPZ-empty lentivirusparticles reveals the ‘cell counting method’ 
to be comparable to flow cytometry as a measure ofpercent GFP and demonstrates an 
increase in transduction efficiency upon increasing amounts of virus
The pGIPZ containing lentivirus particles provided in the Open Biosystems Decode ™ 
RNAi viral screening libraries have been titered using a highly permissible version of 
human embryonic kidney cells (HEK293T) and are verified to contain at least 5x10  
transducing units/milliliter (TU/mL). Transducing units are not virus particles per se and 
instead, represent the only virus particles that are successful in producing a phenotype, 
whether it be puromycin resistance, GFP expression, or capacity to clear a cell monolayer 
in the case of lytic viruses. The concentration of effective virus particles (TU) is necessary 
to calculate the multiplicity of infection (MOI) and achieve a desired number of pGIPZ- 
shRNA-miR integrations per cell. MOI is calculated by the following equation:
MOI = number of effective virus particles (TU/ml) 
number of cells to be infected
For RNAi screening, only one shRNA-miR construct should be integrated per cell and 
according to Poission’s distribution (Table 2), the predicted probability of multiple 
integrants is almost 10% of the cell population over an MOI of 0.4. To minimize the 
percentage of cells with more than one shRNA-miR, cells should not be infected with an 
MOI greater than 0.4 in RNAi screening studies to avoid additional screening of 
confounding results. For example, identification of a compact tumour phenotype with more 
than one shRNA contributing to that phenotype would require additional testing to 
determine if the multiple gene knockdown is synergistic in decreasing cell migration or if
only one of the genes is an effector. At the same time, viral infections should be 
maximized to obtain a high number of cells that harbour a pGIPZ-shRNA-miR construct. 
Taking these principles into consideration, the optimal MOI would theoretically be 0.4 as 
the percentage of cells with multiple integrants is within an acceptable range, yet 33% of 
cells will become infected with pGIPZ-shRNA-miR.
The MOI is a vital ratio to take into consideration when performing RNAi screens to 
prevent confounding results, however, the MOI is an inherent property of the cell line used 
for viral infection. Determination of an appropriate MOI using the viral titer obtained from 
using HEK293T cells, as in the case of the Open Biosystems Decode™ library, therefore, 
may not necessary represent the same outcome in another cell line. To account for the 
differences, the calculation of a functional MOI will need to be calculated for HEp3 cells.
A functional MOI is calculated based on the number of transduced cells as reported by a 
phenotype in the cell line of interest and can be compared to a non-functional MOI which 
is calculated based on the MOI that is derived from the titer value reported by the supplier 
(as calculated in HEK293T cells).
Calculation of the functional MOI necessary transduce cells and elicit a phenotype such as 
GFP expression, has been performed by flow cytometry and microscopic analysis of GFP 
positive cell counts (Sastry 2002 and Lyva 2011). Since the pGIPZ lentiviral construct 
contains turbo GFP as a marker of cell infection (Figure 2.1.1 A), the percentage of GFP 
positive cells is proportional to the ratio of virus particles that successfully produce GFP 
phenotype in cells (MOI). Taking advantage of these properties, the functional MOI for 
HEp3 cells was calculated by a microscopic ‘cell counting method’ whereby the number of 
GFP positive cells are counted and divided by the total cell number, yielding the 
percentage GFP. Alternatively, flow cytometry was used as an automated method to 
calculate the percentage of GFP positive cells within in the infected population.
To test the accuracy between the two methods for calculating the functional MOI, both 
flow cytometry and cell counting were performed on HT1080 cells and the percent GFP 
positive cells were compared between each method. To provide a range of viral 
concentrations to test, HT1080 cells were infected with serially diluted amounts of non­
silencing control virus (pGIPZ-empty). This construct is identical to the pGIPZ-shRNA-
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miR vectors used for the RNAi lentiviral screening libraries, however, the non-silencing 
control is ‘empty' and does not contain the shRNA-miR cassette (Figure 2.1.1A). 
Following infection, HT1080 cells were allowed to express turbo GFP so that the 
percentage of GFP positive cells could be quantified using the cell counting method. 
Immediately after cell counting, cells were fixed and subjected to flow cytometry. 
Comparison of the cell counting method versus flow cytometry revealed no significant 
difference between the two methods of analysis (Figure 2.1.1A, p=0.1477 as determined 
using a matched, 2-way ANOVA with Bonferroni Post test, of the mean ±SEM, N=2, 6 
Fields of view (FOV)Avell (microscopy) or 10,000 events (flow)). Details regarding 
materials and methods used in each experiment performed in the results section can be 
obtained in ‘Chapter 4: Materials and Methods’. The change in percent GFP between 
dilutions, however, was statistically significant (Figure 2.1.1 A, p<0.0001 as determined by 
a matched, 2-way ANOVA of the mean ± SEM, N=2, 6 FOV/dilution). These results 
conclude that either method is conducive to calculating the percentage of GFP positive 
pGIPZ-empty containing cells, and that increasing amounts of virus leads to an increase in 
transduction efficiency for HT1080 cells (Figure 2.1.1AB). Due to limited amount of 
occasions requiring the calculation of the functional MOI, the counting method was 
employed so that MOI calculations for any cell line could be quickly performed in house, 
without formal flow cytometry training.
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T a b le  2: P o isso n 's  D is tr ib u tio n  o f  M u ltip le  In teg ra n ts .
Distribution of the percentage of cells expected to contain multiple shRNA integrants per 
cell in response to increasing Multiplicity of Infection (MOI). The shRNA construct 
confers GFP expression upon integration and is therefore an indirect measurement of MOI.
Integrants 0 >1 >2 >3 >4
MOI




0.1 90 9 0 0 0 9
0.2 82 16 2 0 0 18
0.3 74 22 3 0 0 25
0.4 67 27 5 1 0 33
0.5 61 30 8 1 0 39
0.6 55 33 10 2 0 45
0.7 50 35 12 3 0 50
0.8 45 36 14 5 0.01 55
0.9 41 37 16 5 0.01 58
1.0 37 37 18 6 0.02 61
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Figure 2.1.1: Quantification of percent GFP using ‘cell counting’ method is comparable to flow 
cytometry.
A. Quantification of the percentage of HT1080 cells infected with pGIPZ -empty (inset) as measured by GPF 
signal, either by the ‘counting’ method (% GFP count HT1080) or flow cytometry (% GFP flow HT1080), 
reveals there is no difference between the two methods. B. Representative images of HT 1080- pGIPZ-empty 
cells, 48 hours following infection with various dilutions of virus taken with 100X magnification. As the 
dilution factor decreases (625X-25X), providing more transducing units (TU) per cell, the transduction 
efficiency, as measured by GFP signal, increases. Columns, represent the mean from duplicate experiments 
as determined by both counting and flow cytometry and bars represent the SEM.
The fu n c tio n a l MOI is lower in HEp3 cells in comparison to the n o n -fu n c tio n a l MOI 
reported by Open Biosystems, as measured by percent GFP expression
67
The functional MOI for HEp3 cells was calculated using the cell counting method in order 
to determine the amount of virus necessary to obtain an optimal number of integrants per 
cell and maximize the transduction efficiency. To perform functional MOI calculations, 
HEp3 cells were infected with the pGIPZ-empty lentivirus using three different MOIs (1,
5, andlO), each calculated using the titer obtained by Open Biosystems in HEK293T cells 
and are referred to as non-functional MOIs. Read-out of the percentage GFP positive cells 
for each of the non-functional MOIs (1,5, and 10) represents the functional MOI in the cell 
lines of interest when cross-referenced to the Poisson distribution curve (Table 2). 
Interestingly, the functional MOI for HEp3 cells was lower than the corresponding non­
functional MOI (Figure 2.1.2 AB). This suggests that the HEp3 cell line is less permissive 
to the vesticular-somatis virus G protein (VSV G)-pseudotyped lentiviral particles than the 
highly permissive HEK293T cells, however without testing the virus on HEK293T cells in 
house, it can only be concluded that the functional MOI is less than the titer reported by 
Open Biosystems. At non-functional MOIs of 1, 5 and 10, the corresponding percentage 
of GFP positive HEp3 cells is: 8%, 30% and 46% which represent functional MOIs of 0.1, 
0.4 and 0.6 respectively (Figure 2.1.2 AB). Furthermore, the percentage of GFP positive 
cells increased with increasing MOIs, similar to what was seen in HT1080 cells (Figure 
2.1.1 AB) and by other groups, and this was statistically significant (p< 0.0001, as 
determined by 1-way ANOVA, and Tukey’s post test, of the mean ±SEM, N=3, 6 
FOV/MOI) (Lyva 2011). This data demonstrates that the calculation of a functional MOI is 
possible for HEp3 cells using the counting method and the functional MOI is at less for 
HEp3 cells than the non-functional MOI, as quoted by Open Biosystems in HEK293T 
cells. Furthermore, increases in MOI are able to illicit increases in transduction efficiency, 
however this increase is not linear as GFP signal appears to increase by a smaller 
percentage at higher MOIs. From these experiments, it was determined that a non­
functional MOI of 5 would be used for future experiments as this corresponds to a 
functional MOI of 0.4 in the cell line of interest and will not only keep the number of cells 
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Figure 2.1.2: The F unctional MOI of HEp3 cells is less than the non-functional MOI reported in 
HEK293T cells
A. HEp3 cells were infected with pGIPZ-empty lentivirus at various non-functional MOIs (1,5, and 10) that 
were calculated using the titer quoted by the supplier. 48 hours post-infection, cells expressing GFP were 
counted and divided by the total number of cells in a field of view to achieve a percent GFP per MOI. B. The 
percent GFP for each non-functional MOI was compared to the Poisson distribution curve in order to 
evaluate the functional MOI. The functional MOI is up to 10-fold less than expected in comparison to the 
quoted MOI calculations. C. Representative images of one field of view used to calculate the percent GFP in 
HEp3 cells at 100X magnification. As the MOI increases (1-10 or 0.1-0.6), more virus is used to infect HEp3 
cells resulting in increased transduction efficiency, as measured by GFP signal. Columns, represent the mean 
from triplicate experiments and bars represent the SEM, ***p<0.001.
O pt im iza t io n  o f  sh R N A -c o n t a in in g  c o l o n ie s  in th e  CAM a n d  E stim a tio n  of the
NUMBER OF ANIMALS TO PROVIDE 3X GENE REPRESENTATION FOR RNAI SCREENING
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Administration o f 100, 000 HEp3-pGlPZ cells into the vasculature of the chicken 
embryo yields an optimal number of colonies within the CAM and allows for 3X 
coverage o f the 5000 genes in the RNAi screen using 168 animals
The discrete number of HEp3-pGIPZ colonies the CAM can sustain is an important 
question to address since this will ultimately determine the total number of animals needed 
to perform the screen. A single tumour colony within the CAM represents the outgrowth of 
an individual cell that has been optimized to harbour only one shRNA or gene knockdown. 
This relationship dictates that a total of 5000 colonies must be present in the cumulative 
number of CAMs across ‘X’ number of animals to represent the 5000 genes in the library. 
The total number of colonies that arise in the CAM, in response to a given concentration of 
cells, must be known in order to determine ‘X’. To answer this question, two different 
concentrations of HEp3-pGIPZ-empy cells were injected into the vasculature of day 9 
embryos. Before day 12, the basal lamina of endothelial cells, pericytes and smooth muscle 
cells are discontinuous, allowing for greater vessel permeability (Ribatti 2010). The 
percentage of cancer cells that undergo extravasation and arrest in the stroma of the CAM 
is, therefore, lower when injected into the vasculature of older embryos (day 13) in 
comparison to cells injected into younger animals (day 9) due to these decreases in vessel 
permeability. To prevent the possibility of inhibiting cell extravasation by knocking down 
a gene important to this function when performing an RNAi screen, day 9 animals should 
be used when administering cancer cells into the bloodstream since the extravasation 
barriers are limited. Using day 9 animals, therefore, is ideal for the purpose of witnessing 
cell migration post-extravasation since even cells whose migration machinery has been 
inhibited, can still extravasate into the stroma with high efficiency (Figure 2.2.5-2.2.6).
Upon i.v injection of two different concentrations of HEp3-pGIPZ-empty cells into day 9 
animals, tumour cells arrested in the stroma of the CAM (Figure 2.1.3 B, day 0) and 
tumour colonies were allowed to form (Figure 2.1.3B, day 8) prior to manually counting 
the number of colonies per animal. The first concentration of 100,000 HEp3-pGIPZ-empty 
cells per animal (50ul injection) yielded a total mean of 192 ± 34 colonies per animal
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(N=4), when quantified 8 days post injection (Figure 2.1.3A). Colonies were quantified by 
scanning the entire surface of the CAM using a fluorescent microscope and ‘stitching’ 
individual fields together to form one complete image of the CAM and the Turbo GFP 
colonies within the CAM (Figure 2.1.3B). Some of the colonies, however, did not have a 
sufficient amount of spacing between them, which is a requirement for their extraction and 
further processing (Figure 2.1.3B, inset). The total number o f ‘extractable’, or distinct 
colonies that could be removed, was 91±10 colonies (N=4 animals). This means that upon 
injection of 100,000 HEp3-pGIPZ-shRNA-miR cells, -192 genes will be represented by 
the colonies within the CAM but only 48% of the total colonies in the CAM are relevant 
for the screen, and only -  90 genes will be represented per CAM. In an attempt to increase 
the number o f ‘extractable’ colonies per CAM, injection of a lower concentration of 
HEp3-pGIPZ-empty cells, 50,000 cells per 50ul injection, was administered, also on day 9 
embryos. This concentration achieved a total mean of 59± 8 colonies per animal (N=4 
animals), 8 days post-injection. Although there was greater spacing between colonies when
50.000 HEp3-pGIPZ cells were administered per injection, only 68% of the total number 
of colonies (38±8 colonies, N=4 animals) were extractable, yielding less usable colonies 
per CAM than the 100,000 cells/injection group.
Since the total number of extractable colonies was greater per animal in the 100,000 cells 
per injection group, it was determined that this would be an optimal number of HEp3- 
pGIPZ cells to inject per animal for the screen. Understanding that 100,000 cells yields 
-90 extractable colonies in the CAM, allows for the number of animals needed to cover all 
5000 genes in the screen to be estimated:
100.000 HEp3-pGIPZ cells/animal= 90 extractable colonies/animal 
1 colony=l shRNA=l gene knockdown
10, 000 shRNAs 2 shRNAs/gene= 5000 genes 
5000 genes 90 extractable colonies/animal=~56 animals
56 animals x 3= -168 animals for a 3X representation of the screen
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It is estimated above that 56 animals will be needed to cover the 5000 genes represented in 
the library if 100,000 HEp3-pGIPZ-shRNA-miR cells are injected per animal. In order to 
increase the confidence of the screen, it is necessary to perform a 3X representation of the 
total genes in the library. The total number of animals needed for a 3X representation of 
the screen is, therefore, 168 animals.
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50K HEp3 cells/CAM 100K HEp3 cells/CAM
Figure 2.1.3: Total and ’extractable* number of HEp3-pGIPZ-empty colonies in the CAM
A. Quantification of the total number of HEp3-pGIPZ colonies seen in the CAM 8 days post injection of 
either 50,000 or 100,000 cells per animal (green bars) versus the number of colonies that can be ‘extracted’ 
for further processing (red bars). B. ‘Stitched’ images of a section of CAM immediately following injection 
with either 50,000 or 100,000 HEp3-pGIPZ-empty cells at 25X magnification (DAY 0). Stitched images of 
the entire CAM 8 days post injection of either concentration of cells at 25X (DAY 8). Zoomed in image of 
colonies from the white box in DAY 8 (Inset) detail the spacing between colonies that is necessary for proper 
extraction.
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2.2 Objective 2: Establish a Proof of Principle Using Positive 
Control shRNAs Targeting Known Mediators of Cell 
Migration: RhoAand Cortactin
Prior to performing an RNAi screen to identify novel migratory genes, it was first 
necessary to demonstrate the behavior of cancer cells when known mediators of migration 
are inhibited both in vitro and in the chicken embryo model. Individual shRNAs against 
the cortactin and rhoA genes, shCTTN and shRhoA respectively, were infected into HEp3- 
GFP cells using a lentiviral delivery system to test if RNAi-mediated knockdown of known 
migratory genes cause decreased migration, invasion and metastasis.
K n o c k d o w n  of th e  r h o A  a n d  c o r t a c t in  m R N A  t r a n sc r ipt s  a nd  P rotein  u sing  
in d iv id u a l  sh R N A s in H E p3 c ells
The RNAi Consortium lentiviral shRNA delivery system can be used to deliver individual 
shRNAs against cortactin and rhoA mRNA transcripts and quality control measures to 
test for recombination confirmed the correct shRNA-containing plasmid orientation 
prior to virus production
To establish the chicken embryo model as a predictable model to measure cell migration, a 
proof-of-principle was established using two known mediators of migration: RhoA and 
Cortactin. In another in vivo screen, A. Brie et al. demonstrated the feasibility of providing 
a positive control while screening to demonstrate the phenotype they were screening for 
(Brie 2009). To inhibit RhoA and Cortactin, RNAi was utilized to further emulate the 
actual screening parameters. The shRNA constructs used were designed by The RNAi 
Consortium, and unlike the Open Biosystems RNAi library, virus particles, harboring 
either shCTTN or shRhoA hairpins are made in house. Construction of virus particles 
involves transfer of the pLKO.l -hairpin plasmid, contained in glycerol bacterial stocks, to 
Luria broth supplemented with carbenicillin to ensure amplification of the hairpin-pLKO 
plasmid. As lentiviral plasmids have a high frequency of recombination in bacteria, quality 
control measures must be taken in house to ensure the correct plasmid sequence is 
replicated. Although the pLKO.l vector has been shown to have a rate of recombination 
below 0.05% following growth from bacterial glycerol stocks, it is necessary to retest the
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vectors in house for recombination events (Root 2006). Restriction enzyme-mediated DNA 
digestion was performed on various pLKO. 1 plasmids containing shRNAs against genes of 
interest: green fluorescent protein (shGFP) and luciferase (shLUC) as negative controls 
and cortactin (shCTTN) and rhoA (shRhoA) as positive controls for migration, prior to 
production of viral particles, to ensure the successful transduction of shRNA into HEp3 
cells. The restriction enzymes EcoRl and Kpnl, specifically, were used to digest each 
pLKO. 1 plasmid and yield the predicted DNA fragments of 7 Kb and 1.4 Kb if the shRNA 
is contained within the plasmid and recombination has not occurred (Figure 2.2.1 A). 
Digestion of the pLKO. 1 plasmids, isolated from more than one bacterial clone for each 
shRNA, all yielded the appropriate size bands when subjected to DNA electrophoresis, 
suggesting that these plasmids are in the correct orientation and have not undergone 
recombination events, as predicted by D.E Root et al (Figure 2.2.IB). More than one 
shRNA construct was tested for each gene and are represented by individual numbers 77- 
145. Clones 145, 146 (shGFP), 77, 78 (shLUC), 134, 135, 136, 137, 138 (shCTTN), 45,












(77)(78)(145)(146)(134)(136) (45) (46) (47) (48) (49) (135)(137)(138)
shRNA Target Sequences
shGFP (145) : CGACCACATGAAGCAGCACGA 
shLUC (78) : ACGCTGAGTACTTCGAAATGT 
shCTTN (136) : CACGAATATCAGTCGAAACTT 
shRhoA (49) : GAAAGCAGGTAGAGTTGGCTT
Figure 2.2.1: pLKO.l construct and the mRNA target sequences of shRNA clones.
A. pLKO.l construct, designed by The RNAi Consortium, contains a 1.9Kb stuffer sequence that can be 
excised in exchange for a shRNA (22-mer hairpin) using the Agel and EcoRI restriction enzyme sites. B. 
Restriction enzymes EcoRI and Kpnl were used to digest the shRNA containing pLKO.l plasmid to check 
for recombination events. The DNA was run on 0.7% agarose gel containing ethidium bromide and 
visualized for the appearance of the correct size bands (7Kb (top band) and 1.4Kb (lower band)). Target 
sequences contained in the mRNA for the given genes are listed next to the corresponding shRNA clone used 
in the study.
Quantification o f the mRNA expression level for rhoA and cortactin following RNAi- 
mediated knockdown revealed that the mRNA transcripts were depleted for both genes 
by more than 80%
To test the efficacy of shRNA constructs for specific gene knockdown, HEp3-GFP cells 
were stably transduced with individual shRNA clones targeting either the cortactin or rhoA 
mRNA transcripts, followed by quantification of the mRNA levels of each gene using real 
time quantitative polymerase chain reaction (RT-PCR). Gene-specific primers were 
utilized for amplification of rhoA or cortactin mRNA transcripts and were normalized to 
the ‘house-keeping’ gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA 
transcript levels (Figure 2.2.2A). mRNA expression levels in HEp3-GFP-shRhoA 
(shRhoA) and HEp3-GFP-shCTTN (shCTTN) cells were compared to control HEp3-GFP 
cells that harbor an shRNA for either GFP (shGFP) or luciferase (shLUC) genes, both of 
which are not normally expressed by human cancer cells and thus have no natural, 
endogenous mRNA target. RT-PCR analysis of mRNA transcript levels revealed that the 
shRNA constructs: 48, 49 and the combination of both 45 and 49, all had significantly 
reduced rhoA mRNA transcript expression in comparison to the control HEp3-GFP cells.
In particular, the rhoA mRNA expression was reduced by > 80% in comparison to shLUC 
cells for these shRNA constructs (p<0.05 for constructs 48 and 49 and p<0.001 for 
combination of constructs 45+49, N=3, as determined by a 1-way ANOVA and Tukey’s 
post test and reported mean ±SEM). shRhoA cells harboring constructs 45 and 47 
demonstrated a reduction in the mean rhoA mRNA expression level, however this was not 
significant, while rhoA shRNA construct 46 did not reduce the rhoA mRNA levels (Figure 
2.2.2C). The combination of constructs 45+49 did not have a significant synergistic effect 
on rhoA mRNA transcript level, as there is no significance between construct 49 and 
45+49. Cells containing the combination of shRNA constructs, although they provided 
good knockdown of rhoA mRNA, were not used for further study as the control cells do 
not harbor two different shRNA constructs. Due to the excellent rhoA mRNA repression 
seen upon addition of shRNA constructs 48 and 49, cells harboring construct 49 were 
selected for further study.
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In contrast to the shRhoA cells, only two constructs were tested for the shCTTN cells 
because the other shCTTN constructs were eliminated by a prior western blot analysis of 
the Cortactin protein levels (Appendix A). For the shCTTN constructs tested by RT-PCR, 
cortactin mRNA expression levels w'ere also reduced by greater than 80% when compared 
to shLUC cells (Figure 2.2.2C (inset), p<0.05 for construct 136, N=3, as determined by an 
unpaired, two-tailed, student’s T-test, reported the mean ±SEM). shCTTN cells harboring 
construct 134 also demonstrated a reduction in the mean CTTN mRNA expression level, 
however this was only performed in a single cursory experiment and significance cannot 
be determined (Figure 2.2.2B). In summary, knockdown of rhoA and cortactin gene 
expression through specific RNAi-mediated mRNA silencing resulted in significant, stable 
repression of mRNA transcripts by greater than 80% when either shRhoA constructs 48,49, 
and 45+49 or shCTTN construct 136 were introduced into HEp3-GFP cells. For 
subsequent studies, the HEp3-GFP cells containing shCTTN construct 136 or shRhoA 
construct 49 were used to test the loss-of-function phenotype in the context of cell 
migration and metastasis. Although mRNA transcript levels are specifically targeted and 
repressed, this finding does not always translate to a decrease in the protein. To test the 
impact of rhoA or cortactin mRNA repression on the level of RhoA and Cortactin protein 
expression, shRhoA (49) and shCTTN (136) cells were probed for protein expression using 
antibodies specific to both RhoA and Cortactin protein by western blotting.
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A Primer Sequences
Gene Forw ard Reverse
rhoA 5 VATGGCTGCC ATCCGG AAGAA-3 ’
CTTN 5 -GCXiTC AACCTTTG AGGATGT-3 * 
GAPDH 5 'CCTGGCCAAGGTCATCCAKiAC-?*
5 ‘ -TC AC AAG ACAAGGCACCCAGA-3 ' 
5'-CT('CTCCAGClTCCTCCTG-3 *
5 ’-TGTC ATACCAGGAAATGAGCTTG-3 *
References
(Simpson, K., ei al.. 2004) 
(Luo, M L. et al., 2006) 
(Lipscomb, E.A.:etal 2005)
Figure 2.2.2: Relative mRNA expression of rhoA and cortactin transcripts following knockdown
A. Primer sequences used to amplify specific mRNA transcripts from the total RNA extracted from HEp3- 
GFP-shRNA cells during simultaneous quantification of mRNA expression levels by RT-PCR. B. 
Representative images of amplified mRNA transcripts following RT-PCR processing that were run out on a 
1% agarose gel stained with ethidum bromide and visualized using UV light. C. Results of N=3 RT-PCR 
runs for rhoA mRNA expression levels for each shRhoA construct (left panel) and the quantification of 
cortactin mRNA expression level for shCTTN construct 136 (right panel) compared to controls. Inset is the 
quantification of cortactin mRNA levels for N=3 RT-PCR runs for shCTTN (136) as compared to shLUC 
(78). Columns represent the mean of triplicate experiments (C and B (inset)) and duplicate experiments (C, 
right panel). Bars represent the SEM, *p<0.05 and **p<0.01.
Quantification of protein expression levels for RhoA and Cortactin following RNAi- 
mediated inhibition revealed that RhoA was depleted by 80%, and Cortactin by more 
than 95%
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To directly test if the inhibition of rhoA and cortactin transcript repression translated to 
decreased RhoA and Cortactin protein levels, monoclonal antibodies specifically targeted 
to both proteins were utilized to visualize the amount of protein present by western blotting 
(Figure 2.2.3A). RhoA protein was probed for using anti-RhoA monoclonal antibody 
towards both shRhoA and shCTTN whole cell protein lysates, and the expression was 
measured relative to total protein by also probing for P-Tubulin. Analysis of the relative 
RhoA protein for both rhoA and cortactin knockdown cells revealed the RhoA protein was 
reduced by 80% in shRhoA cells, but there was no significant reduction of RhoA protein in 
shCTTN cells (Figure 2.2.3B. N=3, p<0.05, as determined by a 1-way ANOVA and 
Tukey’s post test of the mean ±SEM and compared to shLUC). Careful observation of the 
mean RhoA expression in shCTTN cells, however, revealed a decrease in mean expression 
of RhoA compared to shLUC cells, and although this is not significant, suggests that the 
inhibition of cortactin mRNA may influence the expression of RhoA protein. These 
western blotting experiments confirm that RNAi-mediated rhoA mRNA depletion 
translates to decreased RhoA protein in shRhoA cells. Furthermore, RhoA is not 
significantly decreased upon inhibition of cortactin mRNA in comparison to control.
To detect the expression of Cortactin protein, an anti-CTTN monoclonal antibody was 
used to probe shCTTN and shRhoA cells. Analysis of the relative Cortactin protein for 
both rhoA and cortactin knockdown cells revealed that in the cortactin inhibited cells, 
Cortactin protein was reduced by more than 95% in comparison to shLUC cells (Figure 
2.2.3C (inset), N=3, p<0.05, as determined by an unpaired, two-tailed student’s T-test, of 
the mean ±SEM). There was a large variation in the level of Cortactin protein across 
western blots for shRhoA cells and, therefore, the significance of Cortactin protein 
expression upon rhoA inhibition could not be determined. It can be speculated, however, 
that rhoA depletion may contribute to decreases in Cortactin protein expression since the 
mean expression of Cortactin in shRhoA cells is lower than control cells. This relationship 
between rhoA and cortactin was also seen in the opposite case where cortactin was
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inhibited and RhoA protein levels were decreased. Further analysis would need to be 
performed to test this hypothesis such as use of additional means to inhibit RhoA and 
Cortactin protein and mRNA by inhibitors or by employing different shRNA constructs for 
rhoA and cortactin mRNA, respectively. Understanding that both the rhoA and cortactin 
genes are inhibited through knockdown of mRNA transcript expression and moreover, 
RhoA and Cortactin protein expression is repressed, allows for the comprehensive analysis 
of HEp3 cell migration both in vitro and in the chicken embryo model in the absence of 
these mediators of migration.
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Figure 2.2.3: RhoA and Cortactin protein expression is repressed following RNAi inhibition
A. Detection of the RhoA and Cortactin proteins using Western blotting. The Cortactin protein (top row) and 
the RhoA protein (second row from the bottom) were detected using specific monoclonal antibodies (left 
panel) and their fold protein expression relative to a-Tubulin was quantified using densitometry and 
normalized to relative expression in shLUC cells (N=3) in both shCTTN and shRhoA cells (right panel). B. 
RhoA protein expression is significantly decreased in shRhoA cells in comparison to shLUC, however, there 
is no significant decrease in expression of RhoA protein for shCTTN cells, although the mean RhoA 
expression is repressed. C. Cortactin protein expression is decreased in shCTTN cells, however, in a 1-way 
ANOVA statistical analysis, this is not significant compared to shRhoA cells. A student’s T-test reveals that 
the level of Cortactin is repressed by 95% in comparison to control cells (inset). Columns, represent the mean 
from triplicate experiments as determined by densitometry using ImageJ analysis tools and bars represent the 
SEM, *p<0.05.
A ffe c t  o f  R h o A  a n d  C o r t a c t in  In h ib it io n  on  C ell  M ig r a tio n  In  V itro  and  C ell  
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RhoA and Cortactin are required for cell migration and invasion in an in v itro  setting 
that resembles the tumour microenvironment
Prior to testing the migration capacity of rhoA and cortactin knockdown cells in the 
chicken embryo model, these cells were first subjected to an in vitro cell invasion and 
migration assay. This assay involved the use of a Boyden chamber and the invasion and 
migration of shRhoA and shCTTN cells through a Matrigel™ matrix and porus membrane 
is measured over time in comparison to shLUC control cells (Figure 2.2.4A). In these 
experiments, the Matrigel™ is composed of matrix proteins that are found in the tumour 
microenvironment and thus, this is a good in vitro measure of cell invasion and migration 
in comparison to cell movement across a rigid substratum such as a plastic dish.
Previously, cancer cell invasion through a 3D-matrix was used to identify an actin- 
polymerizing protein, mDial, as a positive mediator of cell migration after siRNA- 
mediated knockdown (Kitzing 2010). Similar to this experiment, HEp3-GFP cells, 
following RNAi knockdown of positive mediators of cell migration, should demonstrate 
decreased levels of invasion through the Matrigel™.
The results of the invasion and migration experiments revealed that both RhoA and 
Cortactin are important for cell movement in this context as measured by manual counting 
of the migrated cells after 22 hours of incubation (Figure 2.2.4B. N=3 
membranes/experimental condition, reported the mean number of cells that traversed the 
membrane for 5 FOV per membrane ±SEM, pO.OOOl as determined by 1-way ANOVA, 
Tukey’s post test). The mean percentage of invaded cells for shCTTN and shRhoA 
experimental groups were 52% and 61% of the average number of shLUC control cells that 
invaded. These experiments indicate a role for both Cortactin and Rho in cell migration 
and invasion, however there was no significant difference between cells inhibited for either 
rhoA or cortactin suggesting that both proteins are equally important for this process in 
HEp3 cells in vitro. The next question asked was whether or not inhibition of rhoA or 
cortactin by RNAi also contributes to decreased cell invasion, migration and metastasis in
the chicken embryo model to demonstrate that the model is conducive to both the 
monitoring of cell migration and detecting metastasis following gene knockdown.
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Figure 2.2.4: Cortactin and RhoA are required for cell migration and invasion in vitro
A. Cartoon of the Matrigel™ invasion chambers. The inner chamber (red) contains serum free media and 
cells on the surface of the Matrigel™. Cells are incubated for 22 hours and invasive cells that have migrated 
and invaded through both the Matrigel™ (black) and the PET membrane (green) are fixed and stained by 
removing the inner chamber. The outer chamber (blue) contains 5% serum so that the cells move in the 
direction of the chemoattractant. B. Counting the number of cells adhered to three PET membranes/group 
revealed that cortactin and rhoA are required for cell migration and invasion in vitro (***p<0.0001, 1 way 
ANOVA of the mean ±SEM, Tukey’s Post test.). C. Representative images of the PET membranes depicting 
the invasive cells for each group.
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R/ioA and Cortactin are required for cell migration in the chicken embryo model and the 
inhibition o f rhoA or cortactin by RNAi decreases cell migration by more than 50%
To test the affect of rhoA and cortactin knockdown on cell migration in the chicken 
embryo model, shRhoA or shCTTN cells were established in the CAM using an 
experimental metastasis approach. This model of metastasis involves the injection of cells 
directly into the bloodstream, effectively bypassing the initial steps of metastasis and 
allowing the cells to extravásate and arrest in the stroma of the CAM of day 9 embryos. 
Once cells have established a niche in the CAM stroma, they proliferate to form 
micrometastases composed of up to 100 cells per micrometastasis on average, after 3-5 
days post-injection. Micrometastases are useful for studying cell migration because single 
cells can be easily tracked following time-lapsed, live cell imaging, using tracking software 
(ImageJ). A single micrometastasis also allows many cells (-30 cells) to be tracked over 
long time courses, but since the CAM can harbor many micrometastases, more than one of 
these colonies can be imaged during a single experiment by programming the microscope 
to toggle over each colony per time point. These properties of the experimental metastasis 
model in the chicken embryo CAM allow for more aggressive statistical analysis of cell 
migration in a single experiment. To compare the migration of shRhoA and shCTTN cells 
versus the shLUC control cells in the chicken embryo model, individual animals were 
injected per experimental condition on day 9 animals and imaged over a 10-hour time 
course, 3-5 days post-injection. At least 5 micrometastases were imaged per animal, 
however only cells from the best 3 of these colonies were used for quantification. Manual 
tracking of cells for the 3 individual micrometastases were averaged together for each 
group tested and the average cell velocity was compared to shLUC control cells. Velocity 
was calculated by the change in the X and Y cell coordinates between time points over a 
time span of 10 hours.
These experiments revealed that either RhoA or Cortactin is required for cell migration in 
the stroma of the chicken embryo model because knockdown of each of these genes 
resulted in reduced migration by more than 50% compared to shLUC control cells (Figure 
2.2.5C, N=60 or more cells per animal, mean velocity is reported ±SEM, pO.001, as 
determined by a 1-way ANOVA and Tukey’s Post Test). These results are similar to the
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observations made in the in vitro invasion and migration assays, where either RhoA or 
Cortactin was required for migration and invasion through the ECM, however, in vivo, 
there is no significance between shRhoA and shCTTN cell migration. These observations 
suggest that HEp3 cells do not preferentially utilize one protein over the other in cell 
migration and invasion. The ability of Cortactin and RhoA to work together to orchestrate 
cell migration was not tested. A key experiment to test if both Cortactin and RhoA work in 
the same pathway to enhance cell migration would be to simultaneously knockdown both 
genes and observe if this results in a synergistic decrease in cell migration. Although this 
experiment would have been feasible to perform by the methods used to test one gene at a 
time, these experiments are outside the scope of this project. The purpose of the project is 
to inhibit one gene at a time using genome-spanning shRNAs and screen for individual 
mediators of migration in the chicken embryo model.
The results from both the in vitro and in vivo migration assays demonstrate that known 
mediators of migration can be inhibited by RNAi to decrease cell migration and provide a 
proof of principle for the shRNA screen. When performing the screen for novel mediators 
of cell migration using the RNAi libraries, compact tumor phenotypes will be the selection 
criteria for decreased migration upon gene knockdown, and not cell velocity. To make a 
connection between decreased cell velocity and the appearance of less diffuse cells at the 
tumour border and better recapitulate the selection criteria of the screen, the shRhoA and 
shCTTN cell velocities were studied at the invasive border of tumours. In theory, compact 
colonies would be less likely to have invasive, motile cells at the tumour colony borders. If 
the cell velocities are reduced at the tumour border for rhoA and cortactin knockdown 
cells, this data would not only support previous findings in the current study, but would 
also relate cell migration in terms of velocity to the more compact tumour phenotypes 
where cells are not as motile at the tumour periphery.
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Number of Tracks: 35 Number of Tracks: 37 Number of Tracks: 35
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Figure 2.2.5: Cortactin and RhoA are required for cell migration as individual cells in micrometastases
A. Wind-Rose plots of the X and Y co-ordinates for cell tracks at each time point over 10 hours and the 
corresponding frames for each track at time 0 and lOhrs (50X magnification). Bracketed numbers represent 
the individual micrometastasis used to generate X/Y plots and images out of the three micrometastases that 
were averaged together to calculate the average velocity for each group in B. B. Cell velocity in micrometers 
per hour (um/hour) for individual cells (N=3 micrometastases/group). Cell velocities in the cortactin and 
rhoA knockdown groups are significantly lower compared to the control knockdown group, shLuciferase 
(shLUC). ***p<0.0001 compared to shLUC, 1 way ANOVA of mean±SEM, Tukey’s Post Test.
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RltoA and Cortactin are required for cell migration at the tumour border in the chicken 
embryo model and the inhibition o f rhoA or cortactin by RNAi decreases cel! velocity at 
the tumour periphery by 50% for shCTTN cells and by 37% for sit RhoA cells
Previous studies performed by Zijlstra et al. have shown that decreased cell migration at 
the tumour border results in the formation of compact colonies and leads to decreased 
metastasis (Zijlstra 2008). To relate cell migration, in terms of cell velocity, to the 
appearance of compact colonies, shRhoA and shCTTN cell velocities were calculated at 
the invasive tumour border using a spontaneous model of metastasis in the chicken embryo 
model and intravital imaging. In contrast to previous studies performed by A. Zijlstra et al., 
instead of using an antibody to block cell migration, shRNA against known mediators of 
migration, rhoA and cortactin, were used by injecting shRhoA or shCTTN cells directly 
into the mesoderm of the CAM. Injection of this ‘bolus’ of cells effectively bypasses 
extravasation events of metastasis and instead, cancer cells immediately begin to establish 
a niche in the stroma of the CAM by invading into the surrounding tissues. Decreases in 
cell motility at the tumour border have been explained by J.B Wykoff et al for protease- 
independent, amoeboid cell migration and demonstrate that RhoA mediated cell 
contraction, through its effector, ROCK, is responsible for the cell pushing itself through 
the ECM (Wyckoff 2006). Invasion into the surrounding tissues, as detected by 
histopathology, compounded by increases in Cortactin expression, also suggest a role for 
protease dependent invasion into the stroma (Mader 2011). In light of the possibility of 
cells to utilize protease dependent and independent programs in cell invasion and migration 
at the tumour border, in the current study, the roles of both arms of the migration 
machinery were examined by studying either RhoA or Cortactin knockdown cells at the 
tumour-stroma interface. In this experiment, shRhoA or shCTTN cells at the invasive 
border were imaged over time and cell migration was tracked to illustrate: 1) that less 
invasive tumours have decreased motility at their borders and 2) to uncover the type of 
migration machinery necessary to achieve less invasive, compact colonies.
Quantification of the average cell velocity at the tumour border for shCTTN cells revealed 
that the velocity was 4 um/hr, representing a 50% reduction of cell velocity compared to 
shLUC control cells that traveled at 8 um/hr (Figure 2.2.6B, N=55 cells, velocity
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represents the mean cell velocity ±SEM of cells in 3 non-overlapping FOV per tumour, 
p<0.01, as determined by a 1-way ANOVA and Tukey’s Post test). These migration results 
are identical to those discovered from the in vitro study and also corroborate with the 
reduction of cell migration seen with cells in a micrometastasis in vivo. The reduction of 
cell velocity seen with shCTTN cells at the tumour border also support the findings of A. 
Zilstra et al. who show that reduced cell migration at the tumour border leads to compact 
tumor phenotypes, thus strengthening this proof-of-principle study for the RNAi screen for 
migration mediators. Also, the lack of significance between shRhoA and shCTTN cells, 
indicates that both arms of the migration are necessary for motility at the tumour border.
Quantification of the average cell velocity at the tumour border for shRhoA cells revealed 
that the velocity was 5 um/hr, representing a 37% reduction of cell velocity compared to 
shLUC control cells (Figure 2.2.6B, N=71 cells, velocity represents the mean cell velocity 
±SEM of cells in 3 non-overlapping FOV per tumour, p<0.05, as determined by a 1-way 
ANOVA and Tukey’s Post test). This reduction in cell velocity is not significantly 
different from the shCTTN cells, however the mean cell velocity is higher for rhoA 
inhibited cells at the tumour border than the cells in a micromet (Figure 2.2.5B). The data 
for shRhoA cell migration, taken together, suggests that rhoA may be more important for 
single cell migration in the CAM over invasive cell migration at the tumour border for 
HEp3 cells.
In summary, cell migration is inhibited upon the RNAi-mediated knockdown of both 
cortactin and rhoA mRNA transcripts and protein both in vitro and in the chicken embryo 
model. The average cell velocity is decreased in vivo upon inhibition of rhoA or cortactin 
in the context of single cells in a micrometastasis. These decreases in cell velocity are 
carried over to cell migration at the invasive tumour border, suggesting that cell migration 
is responsible for more invasive tumour phenotypes as previously demonstrated by A. 
Zijlstra et al. Also, in both cases of migration, either as a single cell in a micrometastasis, 
or as a cell at the tumour-stroma interface, both protease-dependent and protease-depended 
cell migration machinery are required for migration. These studies provide a proof of 
principle for conducting the shRNA screen for compact tumor phenotypes to identify
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mediators of migration, however, in this study, it has not yet been demonstrated how cells 
with inhibited mediators of migration will behave in the context of metastasis.
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Figure 2.2.6: Cortactin and RhoA are required for cell migration at the invasive tumour border
A. Wind-Rose plots of the X and Y co-ordinates for cell tracks at each time point over 8 hours and the 
corresponding frames for each track at time 0 and 8hrs (100X magnification). Bracketed numbers represent 
the individual FOV per tumour used to generate X/Y plots. B. Cell velocity in micrometers per hour 
(um/hour) for individual cells at the tumour border (N=3 FOV/group). Cell velocities in the cortactin and 
rhoA knockdown groups are significantly lower compared to shLUC .*p<0.05 and **p<0.01 compared to 
shLUC, 1 way ANOVA of mean±SEM, and Tukey’s Post Test.
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Inhibition of migration mediators, RhoA and Cortactin, results in diminished metastasis
Due to the overexpression of rhoA and amplification of cortactin in many human cancers, 
and the accumulating amount of evidence detailing their effects on enhancement of cell 
migration and metastatic potential, animal studies have been performed to look at their 
direct effect on metastasis (Fritz, Just and Kaina 1999; Gou 2011; Cai 2010; Lai 2009; 
Chan 2010 and Yansong 2001). Most of the studies to date, however, are generated using 
experimental metastasis models and use only semi-quantitative methods to read out 
metastasis such as presence or absence of microscopic nodules, histology and/or imaging 
techniques. Also, the crude analysis of métastasés does not take into account tumor cells 
that may lie dormant in organs and go undetected. Furthermore, these studies were done by 
manipulating either rhoA or cortactin in a cell line of interest, but never rhoA or cortactin 
in the same cell line and/or model. Due to the design of previous studies, rhoA and 
cortactin were not studied side by side, and therefore, the general mechanism of cancer cell 
migration, either protease-dependent or protease-independent, and whether RhoA or 
Cortactin is more important during invasion and intravasation, is still undefined. Execution 
of an experiment to look at the particular migration machinery important to all steps of 
metastasis, either protease-independent or protease-dependent, and whether these cells are 
addicted to one method over the other, is possible using a quantitative, spontaneous model 
of metastasis and would be a novel study to perform in vivo, in addition to providing a 
proof of concept for the RNAi screen.
Inhibition of migration has previously been shown to abolish metastasis in vivo using a 
spontaneous model of metastasis (Zijlstra 2008). To test if mediators of migration 
identified through an RNAi screen could possibly result in decreased metastasis upon 
inhibition, shRhoA and shCTTN cells were tested using the spontaneous metastasis model 
and the absolute number of cells present in the liver was quantified using the sensitive, alu 
RT-PCR technique (Zijlstra 2002). The spontaneous model of metastasis requires 
implantation of cancer cells directly onto the ectoderm of the CAM and incorporates all the 
steps in the metastatic cascade including invasion into the surrounding stroma and 
intravasation into nearby blood vessels, followed by extravasation into the secondary sites 
(Ribatti 2010).
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In the assay, chicken embryo livers were dissected 7 days following implantation of 
shCTTN or shRhoA cells and the genomic DNA was extracted from all cells in the liver. 
Utilization of primers specific for human alu repeats, in a chicken embryo background, 
allowed for both the amplification and detection of human cancer cells present in the liver. 
A standard curve was run side-by-side in the alu RT-PCR experiment, and was used to 
interpolate the precise number of human cancer cells per liver in unknown samples 
(Zijlstra 2002). Primary tumours were also collected and weighed at the time of sacrifice, 
and were used to normalize the amount of metastases.
When the spontaneous metastasis assay was performed on rhoA and cortactin knockdown 
cells, quantitative RT-PCR analysis revealed that the average number of cells found in the 
chicken embryo livers was reduced for both experimental groups when compared to the 
control cells, however this was not significant (Figure 2.2.7A, N=1 experiment, at least 4 
animals per experimental and control groups. Reported is the mean number of cells 
detected in the liver per milligram of primary tumour, relative to the amount of liver tissue 
present, as detected by chicken GAPDH specific primers. A 1-way ANOVA, and Tukey’s 
post-test tested for significance). This data suggests that both arms of cell migration, as 
observed in previous assays performed in the study, are also important in metastasis. Upon 
analysis of this assay, it was necessary to normalize the amount of cells in the liver to the 
primary tumour size as the primary tumours that develop for rhoA and cortactin inhibited 
cells have a smaller average size than those for control cells, although this finding is 
insignificant when compared to shLUC tumour weights (Figure 2.2.7C (left panel), N=5 
tumours, reported is the mean weight of tumours in milligrams, 7 days post-implantation 
±SEM. *p<0.05 compared to parental cells, as determined by a 1-way ANOVA, Tukey’s 
post test).
Cell proliferation assays have been performed by many groups to test the affect of a given 
treatment between experimental and control cells and have found that the knockdown of 
certain genes can lead to differential cell proliferation rates (Scudiero 1988and Simpson 
2008). To exclude the possibility that that tumours of rhoA and cortactin inhibited HEp3 
cells are proliferating at a slower rate than control cells, an MTT cell proliferation assay 
was performed to calculate the number of cells present for each group over 7 days. Results
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from this experiment conclude that the knockdown cells are not proliferating at 
significantly different rates compared to shLUC cells (Figure 2.2.7B. N=3 experiments, 
duplicate wells per experiment for each cell type, shCTTN: p=0.089 and shRhoA: p=0.124 
as determined by analysis of the differences between the slopes in a linear regression test 
and compared to shLUC). The fact that shRhoA and shCTTN cells do not proliferate 
slower than the control, suggests that the proliferation rate of rhoA and cortactin 
knockdown cells is not responsible for low tumour weights and instead, the inability of 
these cells to invade down into the mesoderm of the CAM, where blood vessels are 
located, is more likely. Evidence for this hypothesis comes from previous experiments in 
this study where the inhibition of rhoA and cortactin lead to decreased invasion through 
Matrigel™ (Figure 2.2.4).
To determine if increasing the number of rhoA or cortactin knockdown cells implanted 
onto the CAM would increase the tumour weight, 2 million cells per implant were used to 
form primary tumours with shRhoA or shCTTN cells, but only 1 million cells per implant 
were used to form primary tumours with parental and shLUC control cells. This 
experiment did not result in significantly larger tumours (See Appendix B), although the 
mean weight of the tumours for shRhoA cells did increase, bringing these tumours closer 
to the size of control and tumours (Figure 2.2.7C, right panel).
These results suggest that the knockdown of mediators of migration, rhoA and cortactin, 
decrease the motility and invasion of cells at the primary tumour, and contribute to an 
overall decrease in metastasis. Experimental evidence obtained from these known 
mediators of migration provide support for the execution of a genome-wide, RNAi screen 
for the compact tumour phenotype where novel mediators of migration can be identified 
and these genes may also be required for metastasis.
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Figure 2.2.7: Inhibiton of RhoA or Cortactin prevents tumour establishment in the ectoderm of the 
CAM and decreases metastasis
A. The number of cells that metastasized to the liver per milligram (mg) of primary tumour as quantified by 
alu RT-PCR, relative to total amount of liver per sample (chicken GAPDH). The results of this experiment 
are not significant as determined by a 1-way ANOVA analysis, N=4-6 animals per experimental condition.
B. Cell proliferation assay as measured by colourometric analysis of the conversion of MTT to formazan.
The slopes are not significantly different as determined by linear regression analysis between shRhoA or 
shCTTN and shLUC cells (N=3, duplicate wells per cell type). C. Left panel: tumour weight (mg) for 
primary tumours of animals analyzed by alu RT-PCR. shRhoA tumours are significantly smaller than the 
parental cells (N=5 animals, *p<0.05, as determined by a 1-way ANOVA, Tukey’s Post test). Right panel: 
tumour weight (mg) for primary tumours, 7 days post-administration of 2X cells onto the CAM for shRho 
and shCTTN cells (N=3-9 tumours/group *p<0.01, **p<0.001 as determined by 1-way ANOVA and Tukey’s 
Post test). Bottom: Representative livers 7 days post implantation of 1 million cells/animal for each 
experimental and control group at 10X and individual fluorescent HEp3-GFP cells in the liver at 20X.
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2.3 Objective 3: Perform an shRNA Screen for Novel 
Mediators of Cell Migration in the Chicken Embryo 
Model
Id en t ific a t io n  o f  c o m pa c t  t u m o u r  c o l o n ie s  in  vivo  u sin g  HEp3 c ells  and  a po o l  of 
10 000 sh R N A s , c o v e r in g  5000 d ist in c t  g en e s  in the  h u m a n  g en o m e  a n d  
Id en t ific a t io n  o f  sh R N A  t a r g et s  in  in d iv id u a l  c o m pa c t  co lo n ies
To perform the RNAi screen, HEp3-GFP cells were first infected with the optimized non­
functional MOI of 5 {functional MOI of 0.4) to reduce double integration events in vitro 
using the Open Biosystems Decode RNAi viral screening library. This library contains 
lentiviral particles that are packaged with 10, 000 individual shRNA containing pGIPZ 
vectors that target -5000 genes in the human genome for knockdown (Figure 2.2.8A).
Cells were selected in puromycin to eliminate non-infected HEp3-GFP cells and were 
subsequently expanded to provide a total of 20 million cells for the screen. Each animal 
was subjected to i.v injection of 100,000 HEp3-GFP-pGIPZ-shmiR cells and a total of 150 
animals were injected within an 8 hour period of time to accommodate 3X coverage of the 
5000 genes in the screen. The CAMs of chicken embryos were visualized using 
fluorescence microscopy for compact colonies beginning at 5 days post-injection. 
Discovery of compact tumour colonies were marked with filter paper and resected from the 
CAM (Figure 2.2.8B). Compact colonies continued to be identified, and resected up to day 
7 post-injection (day 17 embryos). Dissected colonies were expanded in tissue culture in 
puromycin to select out chicken embryo tissue and contaminants. In this iteration of the 
screen, 12 compact tumour colonies were extracted from the CAMs of chicken embryos 
(Figure 2.2.8B and Appendix.C-E). These colonies were ranked as highly compact (score 
of 1) to diffuse (score of 5), and out of the 12 colonies: 5 were highly compact (1), 3 were 
compact (2), 2 were medium compact (3), 1 was somewhat compact (4), and another was 
diffuse (5). Unfortunately, out of all 12 colonies resected, only 3 colonies survived 
expansion in tissue culture (Figure 2.2.8B: colonies C, D and F). From these three 
colonies, sub-colonies were picked to reduce the chance of expanding two cells with 
different shRNAs that may have formed one colony. This step is necessary since only one 
short hairpin can be sequenced per sample. Genomic DNA was extracted from 5 sub­
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colonies per tumour colony and using forward and reverse primers, unique to sequences 
flanking the shRNA, regions containing the shRNA were amplified using PCR (Figure 
2.2.8A). Sequencing of these amplicons revealed three gene targets: MESDC1, KIF3B and 
ARHGAP12 (Figure 2.2.8D). These targets arose from colonies C and F, but not colony D, 
as amplicons from D did not yield interpretable sequencing results. An explanation for this 
is that there is more than one short hairpin in the sample, contaminating the PCR result. 
The additional shRNA could be present either by the multiple-integration of unique pGIPZ 
plasmids, or by the contamination of more than one cell per well during the selection of 
sub-colonies in cases where more than one cell forms a compact tumour.
In summary, the optimization of an shRNA screen has been performed for a small-scale 
screen and these optimization parameters can also be applied to larger scale screens for cell 
migration. The efforts made in this study contribute not only to the optimization of such 
large scale screens but also provides a proof-of-principle by describing how positive hits 
can be identified in the chicken embryo model through RNAi inhibition. In this smaller 
scale screen, three gene targets were discovered to be important for cell migration in vivo, 
however, many potential targets were lost through the screening process and clearly, there 
are still areas of the screen that need further optimization. Such areas include maximizing 
the survival of hits post-extraction or subjecting these cells to more sensitive PCR 
techniques that require less cells. Another area of improvement would be to sub-clone the 
shRNAs into individual cloning vectors from the collection of cells from the primary 
tumour instead of colony picking. This would provide faster processing time and prevent 
drop out of hits from muddled sequencing results when more than one shRNA is PCR 
amplified. In addition, further validation of the gene targets found in this initial screen, 
using cell migration assays described in this study is still necessary to elucidate and 
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Figure 2.3.1: Identification of novel mediators of cell migration using an RNAi screen in vivo
A. Annotated pGIPZ construct and the region containing the shRNA-mir30 sequence (inset). The forward 
and reverse primers amplify the region containing the shRNA from compact colonies. B. Images of the 
compact colonies extracted for identification of the shRNA construct responsible for the loss of cell 
migration. Colonies C, D and F are ranked as highly compact and are a ‘1’ on a scale of 1-5. The diffuse 
colony in the bottom right panel represents a colony that would not be considered a hit in the screen and is 
given a score o f ‘5’. C. shRNA specific primers were used to amplify the short hairpin and flanking 
sequences (561 bp) in order to sequence the shRNA and identify the gene target. 5 sub-clones from each 
individual compact colony were PCR amplified and sent for sequencing. D. Target genes of the shRNAs 




Cell migration is a well-documented phenomenon in the human body and typically results 
in a beneficial outcome, such as in the event of immune surveillance, wound healing, and 
reproduction (Walzer and Vivier 2011; Wang 2011 and Chen 2011). In contrast, cell 
migration in the context of cancer enhances the invasiveness of tumour cells, and leads to 
increased instances of metastasis, ultimately contributing to poor patient prognosis (Zijlstra 
2008 and Shieh 1999). Many of the mediators of migration, including cytoskeletal 
reorganization proteins, matrix metalloproteases and cell adhesion molecules have been 
identified to be deregulated in cancer cells, and their aberrant expression is often found in 
advanced stage cancers (Horiuchi 2003; Toyoda 2009; Wang 2010; Cai 2010 and 
Alshenawy 2010). Although 1300 manuscripts linking migration to cancer were published 
as of 2010, the full repertoire of cell migration genes is incomplete and only a fraction of 
the mediators discovered have been tested clinically, and none are in clinical use (Palmer 
2011). There is always a question of whether or not it is feasible to target motility in the 
clinic as most patients arrive post development of the primary tumour and cancer cells may 
have already disseminated. In the review by T.D. Palmer et al., the authors make a strong 
case for why targeting motility could be a success in the clinic. They suggest that targeting 
motility could be a preventative measure taken while ‘watchful waiting’ so that the patient 
who presents biomarkers for metastasis or who has a higher grade tumour, may be treated 
less aggressively without putting them at risk for developing metastasis. Targeting 
migration in invasive cancers that cannot be resected, such as in the brain or pancreas, 
could also be another benefit for patients. Finally, the authors make the point that targeting 
migration in cancer early on may prevent more aggressive phenotypes from evolving, as 
invasive-programs are often associated with enhanced motility (Palmer 2011; Zuo 2011 
and Alshenawy 2010).
Clearly, the known players in cell migration to date have not resulted in a successful 
treatment for cell migration and metastasis, providing a rationale for the identification of 
novel mediators of migration as additional druggable targets for metastasis (Palmer 2011 
and Kessenbrock, Plaks and Werb 2010). Treating migration in the clinic requires targeting
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the molecular mediators of cancer cell migration only, and not the mediators of 
inflammation and wound healing. A genome-wide screen for mediators of migration, in 
vivo would be a beneficial means to identify a multitude of diverse genes involved in 
cancer cell migration so that exclusion of genes critical to normal physiological processes 
would not significantly impinge upon the number of druggable targets that could be taken 
to the clinic.
RNAi screens for cell migration in human cancer constitute a relatively small subset of 
cancer related genetic screens and 100% of RNAi screens for cancer cell migration are 
performed in vitro. Therefore, this study fulfills the need for a high throughput method to 
identify relevant migration mediators in vivo. The screen performed in this study is a 
modified H&E shRNA-miR-30 based library, purchased from Open Biosystems, and 
packaged in the form of lentiviral particles. Individual particles deliver single shRNA-miR- 
30 cassettes and integrate them into the host genome. To corroborate with other RNAi 
screens that are based on the method of integrating one shRNA expression vector per target 
cell, so that confounding results of multiple gene silencing are reduced, the RNAi screen in 
this study was optimized to introduce the bare minimum amount of double integration 
events (Boettcher and Hoheisel 2010; Lara 2011; Simpson 2008 and Smolen 2010). 
Optimizing the amount of virus particles delivered to each cell is an important measure to 
take in the cell line of interest (HEp3) to ensure only one shRNA is integrated per cell. 
Since Open Biosystems uses a different cell line to titer viral particles, the MOI would 
need to be calculated in the HEp3 cell line as HEK293 cells yield notoriously higher viral 
titers than most cell lines when tested by GFP expression or by quantifying the amount of 
DNA transcripts within the cell (Sastry 2002). P. Salmon et al. point out two independent 
reasons why different cell lines have varying amounts of permissibility. First, variation 
between cell lines could reflect changes in the expression levels of pro-viral genes, or 
genes necessary for the many steps required in the infection process from viral entry to 
genomic integration. Secondly, as viral titers are based on the expression of exogenous 
genes such as GFP or puromycin resistance, the assay used to determine cell infectivity 
would also rely on the capacity of the particular cell line to produce the protein being 
measured (Salmon and Trono 2006).
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To address the question of how HEp3 cells compare to HEK293 cells in terms of viral 
infectivity, a measure of the functional MOI had to be determined though a biological 
assay on HEp3 cells. Open Biosystems, as well as other groups, calculate viral titer using 
flow cytometry analysis for HEK293 cells, however it is suggested by the supplier and 
other groups that manual cell counting of GFP signal can be used to obtain titer and MOI 
values for the cell line of interest (Sastry 2002 and Lyva 2011). To test if manual counting 
is accurate compared to flow cytometry analysis, in house, the percentage of GFP positive 
cells was counted using both methods. Comparison of the two methods of analysis showed 
no statistical difference in the way cells are titered for MOI determination. However, as the 
dilution of virus becomes greater, the titers begin to diverge between the two methods, 
lending to the fact that dim cells are not detected by flow cytometry and are therefore gated 
out of the calculations (Sastry 2002). As the two methods are identical at the low dilutions, 
which most closely resemble the amount of virus that was be used in the actual study, the 
cell counting method was implemented for MOI calculations on HEp3 cells. Another 
observation taken from this study was the significant decrease in GFP positive cells 
calculated by both the cell counting and flow cytometry methods as the dilution of virus 
increases. Other groups using different cell lines have also made this observation, and so 
the data obtained in this study corroborates with current literature on lentiviral infectivity 
(Lyva 2011).
Calculation of thefunctional MOI for HEp3 cells was performed using the counting 
method for GFP positive cells since this was determined to be comparable to flow 
cytometry. Results from this experiment demonstrate that HEp3 cells have a lower 
functional MOI than the expected MOI based on the viral titers calculated by the supplier 
in HEK293T cells. The low transduction efficiency of HEp3 cells could be a result of their 
capacity to express proteins necessary for viral gene delivery or could be a reflection of 
their ability to express Turbo GFP. Large differences in cell permissively have been 
reported for the same cell type when infected with the same MOI when different methods 
are used for cell differentiation, and thus gene expression profiles may be altered between 
the two cell types. In these reports, however, infectivity was measured by GFP or EGFP 
(flow cytometry) and although this demonstrates how gene alterations could account for 
the lower MOI values in HEp3 cells than expected, it still does not uncover whether or not
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these changes in gene expression result in less viral permissively or less fluorescent protein 
production (Lyva 2011). Differences in cell permissiveness between cell types, however, 
has been reported when directly measuring viral infectivity without relying on expression 
of an exogenous genes such as GFP, supporting the need for pro-viral genes that support 
the virus life cycle (Cooi 1988). Although HEp3 cells demonstrate a lower infectivity for 
the VSV-G peudotyped lentivirus particles, they still exhibit the same kinetics seen in HT- 
1080 cells and by other groups and the increase in virus particles (MOI) causes increases in 
transduction (Cooi 1988; Lyva 2011 and Sastry 2002). Surprisingly, this increase in 
transduction was not a linear relationship in accordance with MOI, as seen by L. Sastry et 
al. and instead, appeared to have ‘decreasing amounts of increase’ as moving from non­
functional MOIs of 1 to 5 had a greater increase in GFP expression than moving from 5 to 
10. The method used to detect increases in viral infection by L. Sastry et al. however 
involved a more sensitive technique using PCR amplification of viral DNA vectors present 
within cells, that gives 10-fold higher transduction efficiency readings than GFP 
measurement and therefore the could be an artifact of the assay used (Sastry 2002). Finally, 
it cannot be discounted that the virus received from Open Biosystems may have exhibited a 
lower titer on HEK293T cells, had they been tested for viral infectivity in house. The 
permissibility of HEp3 cells, therefore, cannot be concluded to be lower HEK293T cells, 
however there is evidence to prove that HEK293 cells are a highly permissive cell type in 
comparison to most cells (Sastry 2002).
Discovering how the cell line of interest behaves in terms of viral infectivity is a necessary 
first step to performing RNAi based screen. The next step in this process is to ensure that 
all genes represented by the RNAi library are represented in the model of interest whether 
in vitro or in vivo. The RNAi screen performed in this study was initially infected into cells 
in vitro and the cell population used for infection was enough to accommodate all genes 
within the library. An MOI of 5 was discovered to be effective for transductions and 
renders 30% of cells infected. Since 300, 000 cells were used for RNAi infection, this 
means 90,000 shRNAs will be represented in vitro. These figures allow for the 10,000 
shRNAs in the library to be represented 9X and the genes in the screen to be represented 
18X. Moving in vivo, however, this representation needs to be maintained to a level of at 
least 3X. Expanding cells from in vitro RNAi infections in cell culture allows for any
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number of cells to be administered to animals for maintenance of gene representation in 
vivo. The in vivo model system employed, however, cannot be oversaturated with cells as 
this would interfere with both screening for compact tumour phenotypes as well as 
extraction of hits. To obtain a desirable number of cells in the CAM, that represents genes 
in the library at 3X, and more importantly, represents genes that can be properly extracted 
without contaminating colonies, the number of cells administered to each animal must be 
optimized. Optimization parameters included: 1) maximization of the amount of colonies 
in the CAM, to reduce the number of animals needed, for more high-throughput screening 
and 2) minimization of the amount of colony overlap for a clean isolation of hits. The 
results from this study describe that upon administration of 50,000 HEp3 cells, the number 
of colonies that are also easily extracted, without contaminating colonies, is still less than 
the number of colonies that can be cleanly isolated by the administration of 100, 000 cells. 
This observation led to the selection of 100,000 HEp3 cells to use for the screen and also 
allowed for a broad estimation of the number of animals the screen would need to be 
performed on in order to represent the genes in the screen three times over. In other model 
systems used for in vivo RNAi screening, there can be up to a 20-week end point for 
tumour development to occur and so screening in this manner can be arduous and does not 
facilitate entire genome screening (Brie 2009). The feasibility of entire genome screening 
within the chicken embryo CAM, demonstrated by the high number of tumour colonies 
and the short time course for tumour development seen within the CAM, is an exciting 
opportunity to explore the entire genome for cell migration, in vivo, which has never been 
done before.
Others have used positive controls when conducting RNAi screen in vivo and have 
demonstrated the importance of these controls, not only to prove that phenotypes can be 
measured by the system, but also to set a baseline to which RNAi knock down can illicit a 
particular phenotype in vivo (Brie 2009). In this study, known mediators of migration and 
metastasis, RhoA and Cortactin, were selected to serve as positive controls in an RNAi 
screen for novel mediators of migration in vivo. These proof-of-principle studies have laid 
the ground work for not only a small scale RNAi screen in the chicken embryo model, but 
have also contributed to the overall goal of screening the entire human genome to create a 
comprehensive library of potentially therapeutic targets of cell migration. RhoA and
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Cortactin were chosen as positive controls because in addition to their association with cell 
migration, metastasis and poor patient outcome, these proteins also encompass all 
requirements of cell migration through the two distinct arms of cell migration, protease- 
independent and protease-dependent, respectively (Gou 2011; Cai 2010; Wyckoff 2006 
and Artym 2006). In addition to providing a proof of principle for the screen, testing the 
cell migration patterns in either cortactin or rhoA knockdown cells, could provide insight 
into the types of cell migration machinery most often used by HEp3 cells for migration and 
predict the type of genes that might be identified in the screen. In this respect, inhibition of 
cortactin, would depress protease-dependent cell migration through a decrease in mature, 
invadopodia structures that assist in locating collagen IV proteases to the site of cell 
invasion and ‘pave the way’ for migration into the ECM (Artym 2006 and Rowe and 
Weiss 2008). Inhibition of RhoA, on the other hand, would depress protease-independent 
movement through the ECM through ROCK-myosin II actomyosin contractility (Wyckoff 
2006 and Row and Weiss 2008). The results from this study show that there is no 
preference for the use of protease-independent versus protease-dependent migration 
machinery in HEp3 cells since inhibition of either rhoA or cortactin led to similar 
decreases in cell migration both in vitro and in vivo. Furthermore, this depression of 
migration contributes to obliteration of metastasis as reported by other groups (Palmer 
2011 and Zijlstra 2008). These positive controls, therefore, demonstrate that knockdown of 
migratory genes should demonstrate the less invasive phenotype seen by less motile cells, 
and that the baseline decrease in cell migration in HEp3 cells upon inhibition could be as 
low as 50% (Zijlstra 2008). These results also conclude that the type of cell migration 
mediators uncovered by the screen could involve players of either arm of migration 
machinery. One hypothesis for why both arms of cell migration might be important to 
establishing migration, invasion and metastasis, has been suggested in the literature. This 
hypothesis emphasizes that since events in metastasis-cascade require many barriers to 
cells, cancer cells may preferentially switch between the two arms of cell migration to 
accommodate for any situation they may encounter (Sahai, and Marshall 2003). Results 
from this study show that knockdown of either rhoA or cortactin inhibits metastasis and 
this could be accounted for by the inability of HEp3 cells to switch between the two 
mechanisms when one is inhibited. Another explanation for the similar requirements for
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both RhoA and Cortactin in all of the steps in the migration cascade including migration, 
invasion, intravasation, and extravasation could be that rhoA and cortactin function in the 
same pathway. Evidence for this hypothesis comes from discovery that cortactin modulates 
rhoA activation in 1 lql3-amplified head and neck cancer cells, where 11 q 13 represents the 
chromosome on which the cortactin (EMS1) gene is located, to promote cell cycle 
progression and enhanced cell proliferation (Croucher 2010). This observation could 
explain why knockdown of cortactin behaves similarly to knockdown of rhoA since, in this 
hypothesis; rhoA could be a downstream effector of cortactin. The amplification status of 
EMS1 is unknown for HEp3 cells, however, because the proliferation rate of cortactin 
knockdown cells is not significantly different from the control, it is not likely that cortactin 
is amplified in HEp3 cells lines, as a decrease in cortactin expression in 11 ql 3 amplified 
cells should show a decrease in proliferation. Furthermore, Cortactin has been shown to 
signal through Cdc42, but not RhoA, to potentiate migration in mouse embryonic 
fibroblasts suggesting that the connection between Cortactin and RhoA may only be 
applicable for proliferation and not migration (Lai 2009).
One drawback to the experiments performed with RhoA and Cortactin is that the RNAi 
mechanism by which these genes were silenced is, in theory, specific for the cortactin and 
rhoA transcripts only, however, since only a few nucleotides, or seed region, on the 
shRNA need to match the mRNA, there is a chance for off-target or unwanted gene 
knockdown, confounding the results (Dua 2011). To add confidence to these experiments, 
additional shRNA constructs targeting these genes could be used to confirm the results; 
alternatively, inhibitors of these proteins could also be used to treat these cells prior to 
experimentation. These results are strengthened, however, by the fact that not only one, but 
two mediators of migration were knocked down independently, and each resulted in 
decreased invasion, migration and metastasis, and in an indirect way this is similar to the 
addition of two shRNAs per one migratory gene. Furthermore, knockdown of each of these 
genes exhibited a decrease in migration, invasion and metastasis in a number of different 
experiments testing for migration, emphasizing that the decrease in migration is not an 
artifact of one particular testing method.
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Taken together, the knockdown of cortactin and rhoA, as tested by measuring both mRNA 
transcript levels and protein, demonstrates that inhibition of migration mediators will 
exhibit a decreased migratory phenotype in multiple experiments, including experiments in 
the chicken embryo model. These experiments look at genes responsible for both arms of 
migration machinery, and thus, allude to the type of genes that could be uncovered for 
HEp3 cells. These genes could represent both arms of the migration machinery, either 
because HEp3 cells ‘switch’ between the two types of migration, or use both protease- 
independent and dependent genes in the same pathway at once. Understanding and 
predicting the type of hits could be found in large-scale screening allows for the 
rationalization of such gene targets and the planning of appropriate validation experiments.
Performing an iteration of the Open Biosystems, H&E pGIPZ-shRNA-miR-30 RNAi 
library, containing 10,000 hairpins covering -5000 genes, led to the discovery of three 
mediators of migration: MESDC1, KIF3B, and ARHGAP12. MESDC1 or mesoderm 
development candidate 1, recovers two PubMed articles when input into the database: the 
first describes the identification of MESDC1 as an embryonic lethal deletion in mice, 
located on mouse chromosome 7, and has a highly conserved sequence from humans to 
Xenopus to Drosophila (Wines 2001). M. Wines et al. also identifies the mouse Talin 
protein to have similar sequence identity to the protein encoded by MESDC1 (Wines 
2001). Talin is responsible for connecting the ECM to the actin cytoskeleton through 
integrins and is, therefore, a key component to cytoskeletal reorganization and cell 
adhesion molecules, both of which are requirements of cell migration (Aplin 1998). The 
second publication identifies MESDC1 as a novel F-actin binding protein that has 
homologous residues to a portion of Talin, and binds actin to a higher extent than Talin. 
The authors suggest that MESDC1 is a novel F-actin binding protein and that it may play 
an important role in the function of Talin (Gingras 2010). The lack of publications directly 
looking at the role of MESDC1 in cell migration provides an open opportunity to explore 
this protein for potential drug targeting to potentially block migration and metastasis.
KIF3B yields 45 publications when searched for in PubMed and while most demonstrate 
this protein as a kinesin II motor, used for microtubule motility and intracellular 
trafficking, KIF3B has recently been identified as a player in transport of MT1-MMP
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(MMP-14) along microtubules to the cell surface for both adhesion protein shedding and 
ECM degradation (Zang and Hancock 2004; Wiesner 2010). Furthermore, knockdown of 
KIF3B and KIF5B led to decrease in migration for MTl-MMPs along microtubules and 
more importantly, the siRNA-mediated knockdown of KIF3B led to less matrix 
degradation by these macrophages (Wiesner 2010). The suggestion of KIF3B as an 
important mediator of ECM degradation through MTl-MMPs could provide an upstream 
target of MTl-MMPs for the reduction of cell migration and improve upon previous failed 
clinical trials using MMP inhibitors (Kessenbrock, Plaks and Werb 2010). The implication 
of the immune system requirements for KIF3B however, would have to be addressed in 
further detail to risk detrimental impairment of the immune system using KIF3B blocking 
drugs.
The final gene identified through the screen was ARHGAP12, and while there are many 
publications in PubMed regarding ARHGAPs, only 3 are specifically addressed to 
ARHGAP12. One of these publications identifies ARHGAP12 as a Rho-inactivating 
protein expressed at high levels in many tissues including tumour cell lines, while another 
investigated further to discover that the ARHGAP12 interacts with Racl to decrease it’s 
activity, but not RhoA (Zhang 2002 and Gentile 2008) In this study by A. Gentile, et al., 
the silencing of ARHGAP12 and simultaneous hepatocyte growth factor stimulation, led to 
an increase in cell migration through a Matrigel™ transwell chamber, increased cell 
spreading on fibronectin and increased cell adhesion (Gentile 2008). This study contrasts 
with the findings of the current screen, which show ARHGAP12 as a requirement for cell 
migration and the invasive tumour phenotype and upon shRNA-mediated inhibition, cell 
migration is blocked. The discrepancy between the study by A. Gentile, et al., and the 
current study could be accounted for by the fact that ARHGAP12, while inactivating Racl, 
may allow for the expression of other pro-migratory proteins in the cell. Evidence for this 
comes from the fact that pl90RhoGAP, while inactivating RhoA, allows FAK to activate 
Racl to proceed with migration (Tomar and Schlaepfer 2009). In order to definitively 
conclude the role of ARHGAP12 in the context of cell migration in vivo follow up assays 
of migration will need to be performed.
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Although the RNAi screening technique allows for high throughput analysis of genes 
involved in many processes including cell migration, there are drawbacks associated with 
this technique that are important to take into consideration when interpreting the results of 
RNAi based screens. One point of concern is that although the RNAi library has been 
validated so that 1 out of 3 shRNA knockdown gene expression by at least 70%, not all cell 
lines will behave in a similar manner to the ones used for these validation studies 
(Boettcher and Hoheisel 2010). In fact, there are even discrepancies between the cell lines 
tested by the commercial suppliers for knockdown of the same gene (Boettcher and 
Hoheisel 2010). Since HEp3 cells have not been validated for >70% knock down for each 
of the 5000 genes represented in the library, it is plausible that a portion of the migration 
genes may not be knocked down to a level that would result in a compact tumour 
phenotype. In this respect, migration mediators may be missed in this cell line. One means 
to remedy this situation would be to apply the same screening parameters on another 
cancer cell line that thrives in the chicken embryo model, such as HT-1080 fibrosarcoma, 
to observe if additional migration mediators are identified.
Another parameter that must be taken into account when performing the screen, is the cell 
proliferation status between cells containing various shRNA constructs (Simpson 2008).
An shRNA that causes decreases in cell proliferation could influence the number of cells 
that form colonies in the CAM. Although genes directly related to proliferation is not the 
goal of the screen, some genes that influence proliferation, may also influence cell 
migration (Croucher 2010). To account for this, extraction of colonies from the embryos is 
spread over 3 days, and since the genes are represented 3X, these slower growing colonies 
may be caught at later extraction dates, however, the cells that cannot proliferate at all 
could have already dropped out prior to in vivo administration because cells are expanded 
in culture for a week prior to administration. Alternatively, these slow-proliferating cells 
could be eliminated from the screen following colony extraction where the colonies must 
be expanded to facilitate PCR processing. This could have been the reason why many hits 
were identified in the screen, however after transfer to cell culture, they did not thrive and 
therefore could not be identified by PCR and sequencing. Another reason, other than cell 
proliferation, for lack of cell survival when moved from the in vivo setting to an in vitro 
setting could be that the cell migration genes lost in these cells may also be important for
109
cell adhesion. Cell adhesion is a requirement for migration and genes associated with 
adhesion could be identified as hits in the screen. If cell adhesion genes are lost, the cells 
may not be able to establish contact with the cell culture dish and experience anoikis, or 
cell death due to loss of anchorage to the ECM. To remedy the loss of hits post extraction, 
moving forward, an all-in-one DNA PCR extraction kit could be used to extract genomic 
DNA out of as many as 10 cells immediately following extraction (Applied 
Biosystems®Arcturus®PicoPure® DNA Extraction Kit). Due to the possibility that the 
screen may cause the dropout of cell migration genes related to proliferation, the screen at 
hand will only identify mediators of that influence migration, and not both migration and 
proliferation.
A technical consideration that was relevant in the single shRNA studies using pLKO. 1 
TRC library clones for cortactin and rhoA, also applies to the pGIPZ, H&E shRNA-mir30 
based library. The issue is that of off-target effects, or knockdown of unintended genes. 
Although the new generation of self inactivating lentiviral vectors like pLKO.l and pGIPZ 
have been designed to preferentially integrate into the intronic sequences of the human 
genome, and therefore endogenous gene expression deregulation is spared, unwanted 
mRNA sequences that are similar to the intended mRNA, could still bind to an shRNA- 
miR, silencing gene expression (Liu and Berkhout 2011 and Lochmatter and Mullis 2011). 
In this scenario, genes that actually cause the compact tumour phenotype may not be 
identified through PCR amplification of the shRNA, because the shRNA target sequence 
belongs to another gene. Although true mediators of migration may be recovered by their 
direct match shRNAs throughout the screen, the hits recovered that belong to the wrong 
shRNA target sequence will only be discovered after additional validation using either: 1) 
individual shRNAs designed to target the supposed gene associated with migration or 2) 
use of multiple shRNAs targeting different areas of the supposed mRNA transcript, in 
combination with inhibitors and additional assays for cell migration, some of which have 
been used in this study for validation of the positive control.
F u tu r e  d ir ec t io n s
In summary, the results of the current study have contributed to the development of an 
RNAi based screen for mediators of cell migration using the chicken embryo model. These
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results have demonstrated that HEp3 cells are transducible by two different shRNA 
lentiviral vectors, the TRC, pLKO.l -shRNA and the H&E, pGIPZ-shRNA-miR-30 and 
achieve a high level of knockdown for cortactin and rhoA using the TRC shRNA 
constructs. RNAi mediated inhibition of rhoA and cortactin have served to successfully 
demonstrate the feasibility of screening for migration mediators through in vivo assays, 
wherein knockdown of these genes resulted in marked decreases in cell migration and 
metastasis. Optimization of screening parameters allowed for the transition of an idea to 
reality by allowing the smooth execution of the first iteration of the RNAi library, 
screening for 5000 genes. In this screen, three migration mediators were identified: 
MESDC1, KIF3B, and ARHGAP12. The next steps in this project are to 1) complete 
further iterations of the screen, covering another set of 5000 genes until all genes in the 
genome (32,000) are represented and hits are identified and 2) validate hits using migration 
assays and individual shRNAs targeting multiple sites on the mRNA transcripts of target 
genes. To complete the screen and identify all hits, it is projected to take 6 months, as 
preparation of cells, animal turnover, screening, PCR and sequencing all add up to about a 
month’s worth of work and there are 6 more iterations of 5000 genes to test. Validation of 
hits is dependent on the amount identified through screening, but if there are even two hits, 
the validation process could be upwards of a year, as this was the length of time taken to 
validate both cortactin and rhoA. In total it is projected that the entire genome could be 
screened and validated in 1-2 years, and again this is dependent on the amount of hits and 
the number of personnel assisting with the project. In the bigger picture, validation of such 
hits as successful could then be carried over to mouse models of metastasis to test how 
cells behave upon knockdown of migration target genes in another animal model. This 
model would also be used to administer alternative methods of inhibition, such as 
pharmacological inhibitors and could also test combination therapy such as the gold 
standard, chemotherapeutics. Altogether, the study at hand is the tip of the iceberg and 




4 Materials and Methods
C ells  a n d  C e ll C u ltu re  R ea g en ts
Cell incubation conditions: 37°C with a 5% CO2 humidified atmosphere. Cell culture 
media: G ro w th  m ed ia : DMEM (GIBCO)+ 10% iFBS (GIBCO), 10,000 IU/mL penicillin 
(Invitrogen), 10,000 IU/mL streptomycin (Invitrogen), L o w  a n tib io tic  g ro w th  m ed ia: 
DMEM (GIBCO) + 10% iFBS (GIBCO), 10 IU/mL penicillin (Invitrogen), 10 IU/mL 
streptomycin (Invitrogen), H ig h  seru m  h a rv est m ed ia : DMEM (GIBCO)+ 40% iFBS 
(GIBCO), 10,000 IU/mL penicillin (Invitrogen), 10,000 IU/mL streptomycin (Invitrogen), 
p .L K O l In fec tio n  m ed ia : DMEM (GIBCO) + 16ug Hexadimethrine bromide (Sigma- 
Aldrich), 10% iFBS (GIBCO), 10 IU/mL penicillin (Invitrogen), 10 IU/mL streptomycin 
(Invitrogen), p G IP Z  In fec to n  m ed ia : DMEM (GIBCO), In v a s io n  ch a m b er  m ed ia: Top 
chamber, DMEM (GIBCO), 10,000 IU/mL penicillin (Invitrogen), 10,000 IU/mL 
streptomycin (Invitrogen). Cells: Fibrosarcoma (HT-1080) (ATCC CCL-121™), and 
human epidermoid cells (HEp3 and HEp3-GFP) (a gift from collaborator Dr. A. Zijlstra 
(Vanderbilt University, Nashville, Tennessee)) and were maintained in growth media 
under cell incubation conditions.
C ell C o u n tin g  a n d  F lo w  c y to m etry  a n a ly s is
HT-1080 cells were seeded at 5xl04 cells per well in a 24-well plate in growth media and 
incubated for 4 hours. Growth media was replaced with 0.225 mL of pGIPZ infection 
media prior to viral transduction. 6, 5-fold serially diluted amounts (25X-78125X) of 
pGIPZ-empty non-silencing control viral stock (Open Biosystems) were created in pGIPZ 
infection media and 0.025 mL of each dilution was added to duplicate wells of the plated 
HT-1080 cells in 0.225 mL media. Cells were incubated for 4 hours and 1 mL growth 
media was added back to each well. Cells were incubated for 48 hours post-infection, after 
which cells were counted for GFP positive cells. 6 fields of view per dilution for duplicate 
wells were captured using a fluorescent inverted microscope (Olympus), attached to a
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monitor and camera (Hamamatsu), and Image-Pro Analysis Software (Media Cybernetics 
®). Images were captured at 100X in both the FITC and DIC channels to capture GFP 
positive cells and total cells in brightfield respectively. Images were counted using a tally 
clicker (VWR). Percent GFP positive cells were reported as:
Percent GFP positive cells = number of cells with GFP signal in FITC channel * 100
number of cells in the DIC channel
Following image acquisition, cells from each well were trypsinized with 0.25% Trypsin- 
EDTA (GIBCO) and washed with IX PBS (GIBCO). Cells were centrifuged at 1200 rpm 
for 5 minutes (Thermo Scientific) and re-suspended in 1% formaldehyde (Sigma-Aldrich) 
in IX PBS for flow cytometry analysis of the percent GFP positive cells for 10,000 events 
(Beckman Coulter).
Functional M O I c a lc u la tio n  fo r  p G IP Z  len tiv iru s  p a r tic les
HEp3 cells were plated at lxlO5 cells in 12-well plates in growth media and incubated for 
4 hours. Media was replaced with pGIPZ infection media (lmL) immediately prior to 
infection. HEp3 cells were infected with pGIPZ-empty (non-silencing control lentivirus 
particles, Open Biosytems) using three different non-functional MOIs (1,5, and 10) in 
triplicate wells. Amount of stock virus used for infection of HEp3 cells with each non­
functional MOI was calculated by:
Amount of stock virus (ul) = Non-functional MOI (1. 5. or 101 * cells plated fl 00.000 cells')
Virus Titer (TU/ul) as determined by supplier in HEK293T cells
Corresponding volumes of stock virus were added to appropriate wells and cells were 
incubated for 4 hours post-infection followed by the addition of 1 mL growth media to 
each well. Cells were incubated for 48 hours post-infection after which, cell counting for 
GFP positive cells was performed. 6 FOV per MOI for triplicate wells were captured using 
a fluorescent inverted microscope (Olympus), attached to a monitor and camera 
(Hamamatsu), and Image-Pro Analysis Software (Media Cybernetics ®). Images were 
captured at 100X in both the FITC and DIC channels to capture GFP positive cells and 
total cells in brightfield respectively. Images were counted using a tally clicker (VWR). 
Percent GFP positive cells were reported as:
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Percent GFP positive cells= number of cells with GFP signal in FITC channel *100
number of cells in the DIC channel
In vivo C o lo n y  fo rm in g  assa y
lxl 05 or 5xl04 HEp3-GFP-pGIPZ-empty cells suspended in 50ul of serum-free DMEM 
were injected i.v into animals that were day 9 of embryonic development. Representative 
images were taken at 25X magnification immediately following injection and at 8 days 
post-injection using the upright, epifluorescence microscope (Axio Examiner, Carl Zeiss, 
Thomwood, NY) attached to a camera (Hamamatsu) and computer monitor. Whole CAM 
surfaces were imaged using the Velocity™ (Improvision, Lexington, MA) software by 
creating a ‘well overlay’ the same dimensions of the CAM and calibrating the motorized 
stage to effectively scan the entire overlay, stitching each image together in a montage. 
Montage images of animals 8 days post-injection were used to count the total number of 
colonies per image using a tally clicker (VWR) for 4 animals in each group (lxlO5 or 
5xl04 cells). To calculate the amount of ‘extractable’ colonies, the number of colonies that 
were overlapping was subtracted from the total colony count.
P rep a ra tio n  o f  h a ir p in -p L K O .l len tiv ira l v ec to rs
Individual hairpin-pLKO.l lentiviral vectors were shipped as Ecoli- glycerol stocks in a 
96-well plate format. Plates were stored at -80°C until use, and during use, they were 
maintained on dry ice. Clones of interest were selected by stabbing the frozen stock and 
placing it in 5mL of LB broth, supplemented with 100 ug/mL of carbenicillin (Sigma- 
Aldrich). Bacterial cultures were shaken at 37°C for 12 hours. Purification of DNA from 
the bacterial cultures was performed using the EX-10 Spin Column Plasmid DNA 
Minipreps Kit (Bio Basic Inc.), according to the manufacturer’s protocol. DNA quantity 
was measured using the NanoDrop (Thermo Scientific) and DNA yields were between 
100-200 ng/uL. DNA digests were performed using separate reaction tubes for lOOng of 
each hairpin-pLKO.l vector and the unique restriction enzymes Kpnl (New England 
Biolabs) and EcoRl (New England Biolabs). Digests were allowed to proceed for 40 
minutes at 37°C, after which they were run on a 0.7% agarose gel (Sigma), stained with 
Ethidium Bromide (run at 125 Volts for 1 hour alongside 1Kb DNA ladders (New England 
Biolabs)). Gels were visualized using UV light from a Gel Doc™XR (BioRad) and
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Quantity One Analysis Software (BioRad). Colonies in the proper orientation (presence of 
2 DNA bands: 7Kb and 1.4 Kb) were used for preparation of lentivirus particles.
P rep a ra tio n  o f  h a ir p in -p L K O .l len tiv iru s  p a r tic les
HEK293T cells were plated at 1x10s cells/mL in 6 mL of low antibiotic growth media in 6 
cm dishes and incubated for 24 hours prior to transfection. Co-transfection of the three 
plasmid system was carried out using hairpin-pLKO.l vector (lug), envelope plasmid 
(VSVG/pMD2.G,100ng) and packaging plasmid (pCMV-R8.74psPAX2, 900ng) as 
described previously (Moffat 2006). Transfections were carried out in Opti-MEM 
(GIBCO) using Fugene6® Transfection Reagent (Roche) according to the manufacturer’s 
protocol. Cells were incubated for 18 hours and transfection reagent was replaced with 
6mL high serum harvest media. 40 hours post-transfection, the viral supernatant (6 mL) 
was collected, passed through a 0.22 um filter, and stored at 4°C. HEK293 high serum 
harvest media (6 mL) was replenished, and viral harvesting was repeated a second time, 
pooled with previous harvest, aliquoted, and stored at -80°C until further use. HEK293T 
cells, pLKO.l-shRNA clones, pMD2.G and pCMV-R8.74psPAX2 plasmids were all gifts 
from Dr. Jason Moffat, in collaboration with the Ontario Institute for Cancer Research 
(OICR), Terrence Donnelly Center for Cellular and Biomolecular Research, University of 
Toronto, Toronto, Canada.
Functional M O I ca lcu la tio n  a n d  In fec tio n  o f  H E p 3  ce lls  w ith  h a ir p in -p L K O .l  
len tiv iru s
HEp3-GFP cells were plated at 5xl04cells per 0.5mL of p.KLO.l infection media in 12- 
well plates. Representative lentiviral stocks, obtained from the production of virus from 
two hairpin-pLKO.l clones, were used to calculate the functional MOI of hairpin-pLKO.l 
virus particles for HEp3-GFP cells using a modified method (Morris 1993). Briefly, HEp3- 
GFP cells were infected with 1 mL of 8, 2-fold serial dilutions (1-256X) of stock virus 
from each clone and the percentage of infected cells was counted and compared to growth 
control after puromycin (Sigma-Aldrich) selection (2ug/mL) using a hemocytometer:
Total cells/mL=
cell count * 10,000 (cells/mL in an area of hemocytometer grid) * 40 (dilution factor prior to counting) 
Percent Growth=
Total cells/mL for each virus dilution (1X-256X) - Total cells/mL for background control * 100
Total cells/mL for growth control
Background control: cells with no virus and puromycin selection 
Growth control: cells with no virus and no puromycin selection
Results from the titering assay demonstrate that the percentage of efficiently transduced 
cells (percent growth) was 40% and 60 % for each clone at the first dilution of lmL (neat). 
When cross-reference to Poission’s distribution table (Table 2), this translates to MOI 
values of 0.5 and 1. Therefore, 1 mL of hairpin-pLKO. 1 lentiviruses, produced in the 
exact manner as these representative clones, will equal an MOI in the range of 0.5-1 when 
transduced into 5x104 HEp3-GFP cells. To infect lentiviral stocks containing hairpin- 
pLKO.l constructs of interest, 1 mL (neat) of lentivirus stocks from clones: 77 and 78 
(shLUC), 145 and 146 (shGFP), 134, 135, 136, 137 and 138 (shCTTN), and 45, 46, 47, 48, 
and 49 (shRhoA) were added to 5 x 104HEp3-GFP cells in 0.5 mL pLKO.l infection 
media in 12-well plates to achieve similar MOI ranging between 0.5 and 1. 24 hours later 
post-infection, hairpin-pLKO. l-HEp3 cells were selected for puromycin resistance 
(2ug/mL) for 7 days, without clonal propagation.
Q u a n tita tiv e  rea l tim e  P C R  (R T -P C R )
Total RNA was isolated using TRIZOL (Invitrogen) 14 days following retroviral 
transduction and puromycin selection. Amounts of RNA were quantified using a 
NanoDrop and lug of RNA for each sample was DNase I (Invitrogen) treated prior to 
reverse transcription to cDNA using Superscript III Reverse Transcriptase (Invitrogen), as 
per the manufacturer’s protocol. RT-PCR was performed on cDNA samples, ‘reverse 
transcription negative’ controls, and ‘water-primer set only’ controls using Platinum 
SYBER Green qPCR SuperMix (Invitrogen) and primer sets described as per Figure 2.2.2. 
Reactions were carried out in a 96-well plate format and were spun for 2500 rpm for 30 
seconds prior to placing the plate in the Thermo Cycler (BioRad). HEp3-GFP-shRNA 
samples amplified with either rhoA or cortactin specific primers were reported relative to 
GAPDH as fold expression normalized to HEp3-GFP-shLUC samples.
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W estern  B lo ttin g
For analysis of Cortactin and RhoA expression, 80% confluent cultures of HEp3-GFP 
knockdown cells (shRhoA (45), (46), (47), (48), (49) and shCTTN (134), (135), (136), 
(137), (138), shLUC (78), shGFP (145) and HEp3-GFP (Parental) cells in 10 cm plates 
were lysed in cold lysis buffer (0.5% NP-40, lOOmM NaCl, 50mMM Tris-HCL, pH 7.5 
containing a protease inhibitor cocktail (Roche)) and scraped off the plates using a sterile 
cell scraper. Samples were collected into microcentrifuge tubes and centrifuged at 13 000 
rpm for 10 minutes at 4°C. Protein concentration of supernatants were analyzed using a 
Bradford assay using Quick Start Bradford IX Dye Reagent (BioRad) using the microplate 
method, and 1 OX bovine serum albumin (New England Biolabs) as the standard, according 
to the manufacturer’s protocol (http://www.bio-
rad.com/LifeScience/pdf/Bulletin 9004.pdf). 15ug of total protein was denatured in DL- 
Dithiothreitol (DTT) (Sigma-Aldrich) at 95°C for 5 minutes and was loaded into SDS- 
plyacrylamide gels (8% when blotting for Cortactin and 15% when blotting for RhoA). 
SDS-electrophoresis was carried out using the vertical blotting apparatus (mini-PROTEAN 
Tetra cell, BioRad) and proteins were transferred using a semi-dry unit (NuPage® Novex® 
Gel System, Invitrogen™) to hydrophobic polyvinylidene difluoride (PVDF) membranes 
(Amersham Hybond™-P, GE Healthcare). Membranes were cut in half to blot for either 
RhoA and Tubulin or Cortactin and Tubulin and blocked over-night in 5% skim milk 
(BioShop) in TBST (50mM Tris, 150mM NaCl and 0.05% Tween-20). To probe for either 
RhoA, Cortactin or Tubulin, a 1:2000 dilution of rabbit anti-RhoA monoclonal antibody 
(that does not detect the related RhoB or RhoC proteins, clone 67B9, Cell Signalling 
Technology ®, Danvers, MA) was added to the strips of membrane containing 20-25 KDa 
proteins, a 1:4000 dilution of mouse anti-Cortactin (p80/85) monoclonal antibody (clone 
4F11, Upstate, Lake Placid, NY) was added to the membrane strips with proteins at 75-80 
KDa, and a 1:1000 dilution of mouse anti-P-Tubulin monoclonal antibody (cone 2-28-33, 
Invitrogen™, Camarillo, CA) was added to membrane strips containing the 50 KDa 
proteins. All of these primary antibodies were incubated overnight in 5% Skim milk in 
TBST. A streptavidin-horseradish peroxidase conjugated secondary antibody, either anti­
rabbit or anti-mouse (both from Amersham, GE Healthcare, Piscataway, NJ), was 
incubated for 1 hour following multiple washes of primary antibodies. Chemilumescence
was detected using ECL-Plus Western Blotting Detection Reagent and Hyperfilm ECL 
(both from Amersham, GE Healthcare).
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All bands were a quantified by densitometry using ImageJ gel analysis tool and expression 
was reported relative to Tubulin expression and normalized to shLUC expression.
H u m a n  tu m o u r  cell m o tility  a n d  In v a sio n
In vitro invasion and migration assay
HEp3-GFP invasion for individual shRNA clones was tested using a BD Bioscience 
Matrigel ™ boyden chamber system as previously described using Matrigel™ without 
growth factors (Sahai, and Marshall 2003). Growth media was placed in the bottom 
chambers (0.5 mL) and HEp3-GFP-shRNA cells were plated in the upper chambers of a 
12-well format, in triplicate, with 5 xlO4 cells per chamber in 0.5 mL of invasion assay 
media. Invasive, migratory cells were recovered from the underside of the 8um pore PET 
membranes located under the Matrigel ™ (Figure 2.2.4) after 22 hours of incubation.
Inner chambers were removed and fixed/stained/washed using the Diff-Quick reagents 
(modified Wright Giemsa stain, Sigma) according to manufacturer’s protocol. Insert wells 
were allowed to dry and images of 5 non-overlapping fields of view were imaged using the 
inverted microscope (Olympus), attached to a monitor and camera (Hamamatsu), and 
Image-Pro Analysis Software (Media Cybernetics ®). Images were captured at 100X in the 
DIC channel to capture total cells in brightfield. Images were counted using a tally clicker 
(VWR) and were reported as the number of invasive or migratory cells normalized to 
shLUC.
Intravital real-time imaging o f tumor cell motility in the chicken embryo
Intravital imaging in the chicken embryo CAM was performed by both the imaging of 
single cells in micrometastases following an experimental metastasis model described by 
(Zijlstra 2002) or by the imaging of cells at the invasive tumour border using a 
spontaneous metastasis model by bolus injection as described by (Zijlstra 2008). For the 
experimental metastasis model. the motility of HEp3-GFP-shRNA (shCTTN, shRhoA, 
shLUC) were compared following the i.v injection of lx l0 5 cells on embryonic day 9 and
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allowing the cells to form micrometastases in the CAM for 3-5 days, post- injection, prior 
to imaging. For the spontaneous metastasis model. the motility of HEp3-GFP-shRNAs 
were compared following the injection of a primary tumor bolus into the mesenchyme of 
the CAM on embryonic day 9 animals that were allowed to form larger tumours for 2-4 
days prior to imaging.
To achieve imaging of the CAM on live chicken embryos, in real-time, an imaging unit 
was used to house the animals for both enhanced focus and for temperature and humidity 
control (Zijlstra 2008). Imaging of single cells in micrometeastases and cells at the tumour 
border was performed using an upright, epifluorescent microscope with a motorized stage 
(Axio Examiner, Carl Zeiss, Thomwood, NY) controlled by Velocity™ (Improvision, 
Lexington, MA). For micrometastases, the stage was calibrated to toggle over three 
independent micrometastases per animal for each of the HEp3-GFP- shRNA groups and 
images were acquired every 10 minutes for 10 hours (60 frames) at 50X. Focus was 
adjusted manually every 9 minutes for the first 12 frames and every 120 minutes for the 
remaining frames. For tumours, the stage was calibrated to toggle over three non­
overlapping edges of the tumour per animal for each of the HEp3-GFP-shRNA groups and 
images were acquired every 15 minutes for 8 hours (32 frames) at 100X. Focus was 
adjusted manually every 12 minutes for the first 15 frames and every 30 minutes for the 
remaining frames. Image drift and rotation were corrected for all image sequences or 
‘movies’ using the Stack_Reg plugin (Biomedical Imaging Group http://bigwww.epfl.ch/) 
running in the open-source software ImageJ (NUT). Cell tracking of individual cells was 
quantified using the Manual_Tracking plugin from ImageJ, which requires manually 
‘clicking’ on individual cells as they advance at every 10 minute interval 
(micrometastases) or 15 minute intervals (cells at invasive tumour border). These tracks 
were used to calculate the velocity of each cell by taking the total distance travelled 
(change in X and Y coordinates between frames) and dividing it by the frame interval, 
which was input into the ‘properties’ box in the ImageJ taskbar. The pixel width ‘X’ and 
height ‘ Y’ was calibrated to match the objective used and this allowed the pixels to be 
represented in um. For the 5X objective used in the micrometastases, the calibration unit 
used was 0.8 and for the 10X objective used in the tumour bob, the calibration unit used
was 1. Wind-rose plots were created using the Chemotaxis and Migration plugin for 
ImageJ (Ibidi®, www.ibidi.de/applications/ap_chemo.html).
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Q u a n tita tiv e  S p o n ta n eo u s  M eta sta s is  A ssa y
The quantitative spontaneous metastasis assay was performed as previously described 
(Zijlstra 2002). HEp3-GFP knockdown cells were placed directly on the CAM of day 10 
animals forming a primary tumor in 7 days. Tumours were then extracted, weighed and 
stored at -20 for record. Livers were also extracted and frozen at -20 until further 
processing. Human DNA was detected by alu PCR after homogenization and extraction of 
DNA from 50mg of liver sample from each experimental and control groups using the 
SYBER® Green Extract-N-Amp Tissue PCR Kit (Sigma-Aldrich) according to 
manufacturer’s protocol. As previously detailed by (Zijlstra 2002), primers against human 
alu sequences were used to amplify HEp3-GFP cell DNA out of a chicken embryo 
background, and using primers specific to chicken GAPDH, and the signal (as reported by 
CT value) for human DNA was normalized to total sample. To calculate the actual number 
of cells that are in each sample, a standard curve was run alongside the unknown samples 
to interpolate the number of cells in unknown samples to known concentrations of cells. To 
prepare the standard curve, 4-fold serial dilutions of HEp3-GFP (7-lxl05 cells) in equal 
volumes were added to individual microcentrifuge tubes containing 50mg of homogenized 
naïve liver. The standard curve samples were processed identically to the experimental 
samples from this point. Normalized alu CT values were compared to the standard curve to 
calculate the number of HEp3-GFP cells per 50mg liver tissue and the unit calculation of 
HEp3-GFP cells in the liver per ug of tumor was reported. Representative livers from 
animals harboring primary tumours from each of the knockdown cells were taken using the 
fluorescent steromicroscope (Lumar, Carl Zeiss, Thomwood, NY) in both brightfield and 
FITC channels using a canon digital camera attachment or the 1.5X Objective respectively. 
The fluorescent images were acquired using the Velocity™ software and were zoomed up 
20X and the brightfield images were zoomed in 10X.
120
sh R N A  screen
Use of a pooled lentiviral library has been described previously (Gazin 2007). In this study, 
3xl05 HEp3-GFP cells were infected at a functional MOI of ~0.4 (;non-functional MOI of 
5) in a 10 cm dish with pooled pGIPZ-shmiR constructs in virus particle format. 
Transduced cells were selected using 2ug/mL puromycin and allowed to expand to -20 
million cells in 5, 15cm dishes (about 10 days). 1x10s cells were administered i.v to 
animals of embryonic development day 9 in 50ul aliquoits for 150 animals. Colonies were 
allowed to form over 5-7 days post-injections and during this time, screening for compact 
colonies using the Axio Examiner upright epifluorescent microscope, attached to a camera, 
computer monitor and controlled by Velocity™, was used in the FITC channel at 25X for 
cursory screening and at 100X for more detailed identification. Compact colonies were 
marked by placement of pieces of cut, sterilized filter paper (Whatman, GE Healthcare) 
and were either resected on the day of identification or in the following days up to 7 days 
post-injection. Compact colonies were recorded by capturing an image in the FITC channel 
at both 50X and 100X magnification (for future reference) and were named and scored on 
the basis of ‘compactness’ 1-5, 1 being the most compact and 5 being the least. Compact 
colonies and close scoring relatives were extracted using dissecting equipment (tweezers 
and scissors) and were transferred to 96-well dishes with growth media supplemented with 
2 ug/mL puromycin. Colonies were further homogenized in a tissue culture hood within 
the 96-well plate using microdissection scissors and were incubated until confluent (about 
7 days). Confluent colonies were transferred to a 12-well plate and then a 10cm dish so 
that sub-colonies could be picked as described in the technical manual 
(http://www.openbiosystems.com/collateral/rnai/pi/Decode_GIPZ_manual.pdf).
Genomic DNA was extracted from 5 sub-colonies per compact colony using the Rapid 
Animal Genomic DNA Extraction Kit (Bio Basic) according to the manufacturer’s 
guidelines. Extracted DNA quantity was measured using a NanoDrop and used in the PCR 
reaction for amplification of the short-hairpin-miR. PCR reactions were set up using 1 OOng 
of DNA, 0.1 uM final primer concentration for each of the forward and reverse primers 
supplied by Open Biosystems (pGIPZF-5284- 5’ CGG TGC CTG AGT TTG TTT GAA 
TG 3' and pGIPZR-5824- 5’ GGC ATT AAA GCA GCG TAT CCA 3’) and Platinum Taq 
Polymerase (Invitrogen) according to manufacturer’s protocol. The PCR was carried out in
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the thermo cycler according to the following program: (Hotstart at 94°C for 2 minutes) x 1 
cycle, (Melt at 94°C, 15 seconds, Anneal at 55°C, 30 seconds, Extend at 68°C, 1 minute) x 
30 cycles, hold at 4°C.
A sample of PCR amplicons were run out on a 1% agarose gel stained with ethidium 
bromide and visualized using UV gel docking station (BioRad). PCR amplicons of the 
correct size, 561 nt, were cleaned using the EZ-10 Spin Column DNA Gel Extraction Kit 
(BioBasic) and samples were sent for sequencing with the sequencing primer provided by 
Open Biosystems (5’GCATTAAAGCAGCGTATC-3’) at the DNA sequencing facility at 
Robarts Research Institute (University of Western Ontario, London, Ont.).
S ta tis tica l A n a ly s is
Statistical analysis was performed in GraphPad Prism® 5 (GraphPad Software, La Jolla, 
CA). For grouped analysis, 2-way matched or unmatched ANOVA was performed, with a 
Bonferroni post-test. For three or more groups, 1-way ANOVA was performed with a 
Tukey’s post-test. For comparison of two groups, a student’s, unpaired, two-tailed T-test 
was performed. For proliferation curves, the data was baseline-corrected and subjected to a 
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Appendix A: Detection of Cortactin or RhoA protein in HEp3-GFP cell lysates
Western blots probed with either anti-cortactin (left panel) or anti-RhoA (right panel) for HEp3-GFP control 
(Parental, shLUC and shGFP) and the various constructs of HEp3-GFP knockdown cells (shCTTN, shRhoA) 
(Top blots), relative to the loading control, anti-Tubulin (Bottom blots). The Cortactin blot results promoted 
the selection of shCTTN constructs 134 and 136 for further RT-PCR analysis.
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Appendix B: Comparison of tumour weights for shRhoA or shCTTN cells upon administration of 
different tumour cell amounts onto the CAM
Administration of 1 million shRhoA or shCTTN cells (white bars) or 2 million shRhoA or shCTTN cells 
(black bars) onto the ectoderm of the CAM did not result in a significant increase in tumour weight (mg) 
when harvested 7 days post-administration (as determined by a 2-way, unmatched ANOVA, and Tukey’s 
post test).
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Appendix C: Compact colonies extracted from the CAM and scored as 1 (highly compact)
Images of the compact colonies within the CAM that were extracted for identification of the shRNA 
construct responsible for the loss of cell migration. Colonies O, P and F are ranked as highly compact and are 
a ‘l ’ ona  scale of 1-5. Only colony F survived tissue culture post-extraction and was subsequently 
sequenced. Images were taken on tumour colonies between days 5 and 7 post-injection using either the 5 or 
10X objective and the Axio Examiner upright epifluorescent microscope in the FITC channel on live chicken 
embryos.
134
Appendix D: Compact colonies extracted from the CAM and scored as 2 (compact)
Images of the compact colonies within the CAM that were extracted for identification of the shRNA 
construct responsible for the loss of cell migration. Colonies Q, N and M are ranked as compact and are a ‘2’ 
on a scale of 1-5. None of these colonies survived in tissue culture post-extraction. Images were taken on 
tumour colonies 5 days post-injection using either the 5 or 1 OX objective and the Axio Examiner upright 
epifluorescent microscope in the FITC channel on live chicken embryos.
D a y s  P o s t-in je c tio n 7 7 7 7
Appendix E: Colonies extracted from the CAM and scored as 3 (medium compact), 4 (somewhat 
compact) and 5 (diffuse)
Images of the compact colonies within the CAM that were extracted for identification of the shRNA 
construct responsible for the loss of cell migration. Colonies H and K are ranked as medium compact and are 
a ‘3’ on a scale of 1-5. J and G are ranked as somewhat compact and diffuse, respectively, and are a ‘4’ or 
‘5’ on a scale of 1-5, respectively. None of these colonies survived in tissue culture post-extraction. Images 
were taken on tumour colonies 7 days post-injection using either the 5 or 1 OX objective and the Axio 
Examiner upright epifluorescent microscope in the FITC channel on live chicken embryos.
A p p e n d i x  F: E t h ic s  A p p r o v a l  n u m b e r  f o r  w o r k in g  w ith  t h e  c h ic k e n  e m b r y o  m o d e l
AUS# 2007-087-10
Entitled: "Migration-mediated intravasation and tumour cell metastasis in cancer"
October 10, 2007
“This Is the Original Approval for this protocol*
“A Full Protocol submission will be required in 2011*
Dear Dr. Lewis:
Your Animal Use Protocol form entitled:
Migration-mediated Intravasation and Tumor Cell Metastasis in the Dissemination of Cancer 
Funding Agency NCIC - Grant #018178
has been approved by the University Council on Animal Care. This approval is valid from October 10, 2007 to 
October 31, 2010. The protocol number for this project is 2007-087-10.
1. This number must be indicated when ordering animals for this project
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received.
If the application for funding is not successful and you wish to proceed with the project, request that an internal 
scientific peer review be performed by the Animal Use Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the ACVS office. Health 
certificates will be required.
ANIMALS APPROVED FOR 1 YR.
Species Strain Other Detail PainLevel
Animal # Total 
for 1 Year
Bird-Domestic Chick embryos B 250
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar 
with the contents of this document.
1. Please let Trish Kirkpatrick know the number of eggs/embryos used in this project on a monthly basis for CCAC 
documentation.
c.c. Approved Protocol 
Approval Letter
H i e  University o f  Western Ontario 
Animal Use Subcommittee/University Council on Animal Care 
Health Sciences Centre • London, Ontario • CANADA - N6A 5CI 
Phone: 519-661-2111 ext. 86770 * Fax: 519-661-2028 • www.uwo.ca/animal
